

INDEX

Note: Page numbers followed by "f" indicate figures; those followed by "t" indicate tables. Drugs are listed under the generic name.

- A**
- AAS. *See* Androgen(s)
- Abacavir, 345
- Abarelix acetate, 699t, 700-701, 700f
- Abokinase. *See* Urokinase
- Abciximab, 149, 629
- Abilify. *See* Aripiprazole
- Abitrexate. *See* Methotrexate
- Abmoclolin. *See* Chlorambucil
- Absolute ethanol, 182
- Absolute specificity, 885
- Absorption, distribution, metabolism, and elimination (ADME) models, for computer-aided drug design, 25
- Acarbose, 662-663, 687-688, 687f-688f
- Accuretic. *See* Quinapril hydrochloride
- ACE. *See* Angiotensin-converting enzyme
- Acebutolol, 552-553, 553f-554f
- Acetaldehyde, in alcohol metabolism, 182
- Acetaminophen
as antipyretic, 803-806, 804f-806f
conjugation of, 89-90, 92, 97, 99
metabolism of, 8, 73-74
toxicity in, 805-806, 806f
- Acetanilide, 803-804
- Acetohexamide, 660, 671f, 673t, 676, 677f, 680
metabolism of, 59, 61, 80, 82
- Acetophenone, metabolism of, 80-82
- (+)-*trans*-(1S,2S)-acetoxycyclopropyltrimethylammonium, 565, 566f
- Acetoxyethyl onium salts, 567t
- 2-Acetylaminofluorene, metabolism of, 73-74
- Acetylation, 97-102
- Acetylation polymorphism, 101
- Acetylcholine (ACh), 24, 558
conformational flexibility of, 29-30, 29f
conformation of, 564-565, 565f
ganglionic stimulation by, 596-597, 597f
hydrolysis of, 570-571, 572f
neuromuscular junction transmission and, 599-600
as neurotransmitter, 558-559, 563-564, 563f-564f, 596-597, 597f
nicotinic effect of, 597-598
pharmaceutical, 568
release of, 563-564, 563f
storage of, 563, 563f
structure-activity relationships of, 566-567, 566f-567f, 567t
structure of, 558
synthesis of, 563-564, 563f-564f
- Acetylcholine chloride, 568
- Acetylcholine receptors, 559-563
activation of, 562-563, 562f
muscarinic, 560-563, 561f-562f, 566-567, 566f
nicotinic, 559-560, 559f-560f, 559t
- Acetylcholinesterase (AChE), 558, 563-564, 563f
action of, 570-572, 572f
inhibition of, 570-572, 571t-572t, 572f
phosphorylation of, 577-578, 577f-578f
reactivation of, 577-578, 577f
- Acetylcholinesterase inhibitors, 570-572, 571t-572t, 572f
irreversible, 572t, 577-581, 577f-578f, 580f
reversible, 572-576, 572t, 573f
- Acetyl-CoA, 563-564, 563f-564f
- Acetylmethadol (LAAM), 788f, 789
- Acetylsalicylic acid. *See* Aspirin
- ACh. *See* Acetylcholine
- AChE. *See* Acetylcholinesterase
- Acidosis, antiarrhythmic activity and, 632
- Acids, 12-17
conjugate, 12, 13t
definition of, 12
- percent ionization, 14-16, 15f-16f
reactions, 12, 13t
strength of, 12, 14, 14t
- AcipHex. *See* Rabeprazole sodium
- Acitretin, half-life of, 6
- Aclovate. *See* Alclometasone dipropionate
- Acquired immunity, 159t, 161-165
innate vs., 159, 159t
- Acrivastine, 741t, 756-757
- ACT-D. *See* Dactinomycin-D
- ACTH. *See* Adrenocorticotropic hormone; Corticotropin
- Acthar. *See* Corticotropin injection
- Acthar Gel. *See* Repository corticotropin injection
- Acthrel. *See* Corticorelin
- Actidil. *See* Triprolidine hydrochloride
- Actinomycin, 260t, 384, 384f, 388
- Actinomycin-D. *See* Dactinomycin-D
- Actinospectocin. *See* Spectinomycin hydrochloride
- Action potentials, neuronal membrane permeability during, 719-720
- Actiq. *See* Fentanyl
- Activase. *See* Alteplase; Alteplase, recombinant
- Activella, 846t
- Active-site-directed irreversible inhibition, 25
- Actonel. *See* Risedronate sodium
- Actoplus Met. *See* Metformin; Pioglitazone
- Actos. *See* Pioglitazone
- Actron. *See* Ketoprofen
- Acute gouty arthritis, 810-811, 810f
- Acute pain, 776-777
- Acute phase factors; 160, 160t
- Acyclovir, 341
metabolism of, 7-8
- Acyases, penicillin resistance and, 266
- AD 32. *See* Valrubicin
- Adalat. *See* Nifedipine
- Adamantanamines, 336
- Adapin. *See* Doxepin hydrochloride
- Adaptogen, 970
- Addison disease, 857, 859-860
- Adefovir dipivoxil, 340-341
- Adenine arabinoside, 40, 40f, 340, 378
- Adenosine monophosphate (AMP), 561-563
in platelet aggregation, 657, 657f
in smooth muscle relaxation, 618-619, 619f
- Adenosine monophosphate-activated protein kinase (AMPK), metformin activation by, 686
- Adenylate cyclase, 562-563, 562f
gastric acid secretion and, 760, 761f
- ADH. *See* Vasopressin
- Adjuvants, vaccines and, 176-177
- ADM. *See* Doxorubicin hydrochloride
- ADME models. *See* Absorption, distribution, metabolism, and elimination
- ADR. *See* Doxorubicin hydrochloride
- Adrenal cortex hormones, 853-864, 854f-857f, 858t, 860f, 864f
biological activities of, 855-856
biosynthesis of, 854-855, 854f
endogenous, 853-854
metabolism of, 855, 855f
mineralocorticoid receptor antagonists, 615, 864
structural classes of, 856-859, 856f-857f, 858t
therapeutic uses of, 859-860
- Adrenalin. *See* Epinephrine
- Adrenergic agents, 519-555, 520t
adrenergic receptor antagonists, 545-555
neurotransmitters, 519-524
drugs affecting, 528-531
receptors, 524-528
sympathomimetic agents, 531-545
- α -Adrenergic antagonists, 641
- Adrenergic-blocking agents, 519
- Adrenergic drugs, 558
centrally active, 641-642
- Adrenergic neurotransmitters, 519-524, 520t
biosynthesis of, 519, 521f, 522
drugs affecting, 528-531
metabolism of, 523-524, 523t, 524f
storage and release of, 522
structure and physicochemical properties of, 519, 520f
uptake of, 522-523
- Adrenergic receptors, 524-528
 α , 525-526, 525t-526t, 527f
antagonists, 545-555
 β , 525t, 526-527, 526t, 528f-529f
subtypes of, 524-525, 525t-526t
- Adrenergic stimulants, 519
- Adrenergic system inhibitors, 639
- Adrenocorticotropic hormone (ACTH), 810, 855, 891, 892t
- Adrenocorticotropic hormone injection, 891, 892t
- Adria. *See* Doxorubicin hydrochloride
- Adriamycin. *See* Doxorubicin hydrochloride
- Adrucil. *See* 5-Fluorouracil
- Adsorbed diphtheria and tetanus toxoid, 173
- Adsorbed tetanus and diphtheria toxoid for adults, 174
- Adsorbed tetanus toxoid, 173
- Adsorption, of virus, 333
- Advil. *See* Ibuprofen
- AeroBid. *See* Flunisolide
- Aerosporin. *See* Polymyxin B sulfate
- AF-DX 116, 567, 568f
- Aflatoxin B₁, metabolism of, 54, 56
- African sleeping sickness, 221
- Afrin. *See* Oxymetazoline
- Afrinol. *See* L-(+)-Pseudoephedrine
- Aftate. *See* Tolnaftate
- Age, drug metabolism and, 104
- Agenerase. *See* Amprenavir
- Agglutination, immunological, 164
- Aggregation, of recombinant proteins, 134
- Aggrenox. *See* Dipyridamole
- Aging, of cholinesterases, 578, 578f
- α -Agonists, 534-535, 540
 α_1 -Agonists, 525, 525t-526t
 α_2 -Agonists, 525, 525t-526t
 β -Agonists, 540-543
 β_2 -Agonists, 525, 525t-526t
 β_3 -Agonists, 543
- Akineton. *See* Biperiden
- Akineton hydrochloride. *See* Biperiden hydrochloride
- Alamast. *See* Pemirolast potassium ophthalmic solution
- Albamylin. *See* Novobiocin sodium
- Albendazole, 226
- Albiglutide, 690f, 691
- Albuminoids, 883t
- Albumins, 883t
- Albuterol. *See* Salbutamol
- Alclometasone, 861
- Alclometasone dipropionate, 857f
- Alcofenac, metabolism of, 53
- Alcohol(s)
as anti-infective agents, 181-182
metabolism of, 181-182
as sedative-hypnotics, 455-456
- Alcohol intolerance, cephalosporins and, 285
- Aldactone. *See* Spironolactone
- Aldehyde oxidase, 78

- Aldehydes
 as anti-infective agents, 182–183
 as sedative–hypnotics, 456–457
- Aldesleukin, 141, 909r, 911
- Aldomet. *See* Methyldopa
- Aldomet ester hydrochloride. *See* Methyldopate hydrochloride
- Aldosterone, 821f, 853–857, 854f, 856f, 858r
- Aldosterone antagonists, 615, 864
- Aleglitazar, 682, 683f
- Alemtuzumab, 148
- Alendronate sodium, 707r, 708
- Aleve. *See* Naproxen
- Alfenta. *See* Alfentanil
- Alfentanil, 787f, 788
- Alferon N. *See* Interferon alfa-n3
- Alfuzosin, 548
- Alidase. *See* Hyaluronidase for injection
- Alimta. *See* Pemetrexed
- Aliskiren, 614–615
- Alkalosis, antiarrhythmic activity and, 632
- Alkane anesthetics, structure–activity relationships of, 712–713, 712f
- Alkanol anesthetics, 713
- Alkeran. *See* Melphalan
- Alkylamine antihistamines. *See* Propylamine antihistamines
- Alkylating agents, 358–372
 busulfan, 362, 364f, 369–370
 dacarbazine, 366–367, 367f–368f, 371
 individual agents, 368–372
 mechanism of action of, 358–359, 358f–359f
 nitrogen mustards, 359–361
 nitrosoureas, 365, 366f–367f
 organoplatinum compounds, 362–365, 365f
 procarbazine, 366–367, 367f–368f, 371
 resistance to, 359
 temozolomide, 366–367, 367f–368f
 thiopeta, 361–362, 364f, 369
- Alkylation
 monoalkylation, 361–362
 process of, 358–359, 358f–359f
- Alkylbenzyltrimethylammonium chloride, 187–188
- Allegra. *See* Fexofenadine hydrochloride
- Allergic reactions
 to cephalosporins, 285
 glucocorticoids for, 859, 860f, 863
 histamine role in, 736, 739–740
 to local anesthetics, 724–726
 to penicillins, 268–269
- Alliin, 967f, 968
- Alliin, 967–968, 967f
- Allopurinol, 809f, 811
- All-*trans*-retinoic acid. *See* Tretinoin
- Allylamines antifungals, 199–200
- Allylic carbon atoms, oxidative reactions at, 55–58
- Allylisopropylacetamide, metabolism of, 55–56
- Almotriptan, 812–814, 812r, 813f
- Alogliptin, 692, 694f
- Alomide. *See* Lodoxamide tromethamine
- Alphagan. *See* Brimonidine
- Alpha-particle emission, 414
- Alprazolam, 449–450
- Alprostadil, 876–877
- Alex. *See* Loteprednol etabonate
- Altace. *See* Ramipril
- Alteplase, 889
 recombinant, 908r, 910
- Alternative complement pathway, 160–161, 160f
- Altretamine, 371–372
- Alupent. *See* Metaproterenol
- Amantadine, 336, 478
 metabolism of, 69–70
 methylation, 103–104
- Amaranth, metabolism of, 84–85
- Amaryl. *See* Glimepiride
- Amberonium, 572r
- Amberonium chloride, 575
- Ambien. *See* Zolpidem
- Ambodryl Hydrochloride. *See* Bromodiphenhydramine hydrochloride
- Ambrisentan, 638
- Amcill. *See* Ampicillin
- Amcinonide, 857f, 861
- AMD-3100, 351
- Amebiasis, 220
- Amenorrhea, progestins for, 839
- Amerge. *See* Naratriptan
- Amfenac, 799f, 800
- Amigesic. *See* Salsalate
- Amikacin, 294, 299–300
 inactivation of, 296
- Amikin. *See* Amikacin
- 7-Amino-5-nitroindazole, conjugation of, 90–91
- Amino acid solutions, 881
- Aminoalcohols, 592–594
- Aminoalcohol esters, 588–591
- Aminoalcohol ethers, 591–592
- Aminoalkyl ethers. *See* Ethanolamine antihistamines
- Amino amide local anesthetics, 726–729, 727f–728f
- Aminoamides, 594–595
- p*-Aminobenzoic acid (PABA), 217
 acetylation of, 97, 100
 in allergic reactions to local anesthetics, 724–726
- Aminoglutethimide, 835f, 836
- Aminoglycosides, 260r, 294–301
 chemistry of, 294–295
 discovery of, 294
 mechanism of action of, 295
 microbial resistance to, 295–296
 spectrum of activity of, 295
 structure–activity relationships of, 296–297
 types of, 297–301
- β -Aminoketones, 467–468
- 4-Aminoquinolines, 246r–247r, 248–250, 249f
- 8-Aminoquinolines, 246r–247r, 250–251, 250f
- Aminosalicylate sodium, 217
- 5-Aminosalicylic acid, 807f
- p*-Aminosalicylic acid (PAS), 215, 217
 acetylation of, 97, 100
- Amiodarone, 636
- Amitiza. *See* Lubiprostone
- Amitriptyline hydrochloride, 512
 metabolism of, 8, 55f
 metabolites of, 111
- Amlodipine, 623r, 626
- Amobarbital, 454, 454r
 metabolism of, 59–60
- Amodiaquine, 248, 249f, 250
- Amoxapine, 513
- Amoxicillin, 15, 268, 269r, 272–273
- Amoxicillin-clavulanate potassium, 275
- Amoxil. *See* Amoxicillin
- AMP. *See* Adenosine monophosphate
- Amphetamine sulfate, 506r, 507, 533
 metabolism of, 48, 68–69, 83, 104–105
- Amphicol. *See* Chloramphenicol
- Amphotericin B, 197–198, 260r
- Amphotericins, chemical classification of, 260
- Ampicillin, 268–269, 269r, 272
- Ampicillin-sulbactam, 276
- AMPK. *See* Adenosine monophosphate-activated protein kinase
- Amprenavir, 349–350
- Amrinone, 646–647
- Amylin analogs, 689–690, 689f
- Amyl nitrite, 617, 620–621, 620r
- Amytal. *See* Amobarbital
- Anabolic androgenic steroids. *See* Androgen(s)
- Anabolic steroids, 849–850
- Anadrol-50. *See* Oxymetholone
- Anafranil. *See* Clomipramine hydrochloride
- Analeptics, 504–505
- Analgesics, 776–815
 disease-modifying antirheumatic drugs, 806–809, 807f
 for gout and hyperuricemia, 809–811, 809f–810f
 NSAIDs, 792–806, 793f, 794r, 795f–797f, 799f, 801f–802f, 804f–806f
 opioids, 777–792, 779f–784f, 787f–789f, 791f
 triptans, 811–814, 812r, 813f
 urinary, 214
 World Health Organization ladder of, 777, 777f
- Analog inhibitors, 348
- Anamnestic response, 163, 164f
- Ananase. *See* Bromelains
- Anaprox. *See* Naproxen
- Anastrozole, 835f, 836
- Ancef. *See* Cefazolin sodium
- Ancobon. *See* Flucytosine
- Androgen(s), 847–853, 848f–849f, 848r, 851f–853f
 antiandrogens, 851–852, 851f
 biological activities of, 847, 848f
- danazol, 849f, 851
 endogenous, 847
 metabolism of, 847, 848f
 5 α -reductase inhibitors, 852, 852f–853f
 SARMs, 853, 853f
 in sports, 849–850
 structural classes of, 847–848, 848r, 849f
 therapeutic uses of, 848–849
- Androgen receptors (ARs), 825
- Androlone decanoate, 849f
- Androstenedione, 821f, 823f, 847, 848f
- Anectine. *See* Succinylcholine chloride
- Anesthesia, general, stages of, 711
- Anesthesiophoric agents, 588
- Anesthetics, 711–730
 inhaled general anesthetics, 711–716, 712r, 714f–716f
 injectable general anesthetics, 716–718, 717f–718f
 local, 718–730, 718f–719f, 721f–722f, 724f, 727f–728f
- Anger camera, 417–418, 417f
- Angina pectoris, 617
- Angiotensin, 607–609, 608f–609f
- Angiotensin amide, 905
- Angiotensin antagonists, 612–614
- Angiotensin-converting enzyme (ACE), 607–609, 609f
- Angiotensin-converting enzyme inhibitors, 609–610, 610f
 prodrugs, 610–612, 611f, 612r
- Angiotensin II, 607–609, 608f–609f, 614
- Angiotensin II blockers, 612–614
- Angiotensinogen, 607, 608f, 614
- Angiotensin receptor blockers (ARBs), 609
- Anhydroids, 583
- Anhydrosacetylcephalosporic acid, 279
- 4-Anilidopiperidines, 786–788, 787f
- Aniline
 acetylation of, 97, 100
 metabolism of, 70–71, 73–74
- Aniline-substituted sulfonamides, 230
- Anipamil, 623r
- Anisindione, 658
- Annihilation radiation, 414
- Anopheles* mosquito
 control of, 244–245
 malaria and, 242
- Ansaid. *See* Flurbiprofen
- Ansamycins, 218
- Anspor. *See* Cephradine
- Antabuse. *See* Disulfiram
- Antazolic phosphate, 746
- Antergan. *See* Phenbenzamine
- Anthelmintics, 224–227
- Anthracyclines, 385–389, 385f–387f
- Antiadrenergics, 519
- Antiandrogens, 851–852, 851f
- Antianginal agents, 617–629, 618f–619f, 620r, 622f–625f, 623r
 antithrombotic agents, 627–629
 calcium antagonists, 622–627, 622f–625f, 623r
 myocardial metabolism and, 618, 618f
 nitrovasodilators, 618–622, 619f, 620r
 sodium channel blockers, 627
- Antiarrhythmic agents, 629–637, 630f–631r, 634f
 arrhythmia mechanisms, 630–631, 630f
 cardiac electrophysiology and, 629–630, 630f
 class I (membrane-depressant), 631–635, 631r, 634f
 class II (β -blockers), 631, 631r, 636
 class III (repolarization prolongators), 631, 631r, 636–637
 class IV (calcium channel blockers), 631–632, 631r, 637
 pH and activity of, 632
- Antibacterial potencies of alcohols, 181
- Antibiotics, 258–326
 aminoglycosides, 260r, 294–301
 antifungal, 196–199
 as anti-infective agents, 180
 antineoplastic, 383–400
 actinomycins, 260r, 384, 384f, 388
 anthracyclines, 385–389, 385f–387f
 bleomycin, 394–396, 395f
 camptothecins, 391–394, 392f–393f
 epipodophyllotoxins, 389–391, 390f–391f
 mechanism of action of, 383–384
 taxanes, 398–400, 398f–399f, 400r
 vinca alkaloids, 396–398, 396f, 972

Antibiotics (continued)

- antitubercular agents, 218–220
 - β -lactam, 260–261
 - β -lactamase inhibitors, 274–278
 - cephalosporins, 278–293
 - chemical classification of, 260
 - commercial production of, 259
 - current status, 259
 - discovery of, 326
 - historical background on, 258–259
 - lincomycins, 313–315
 - macrolides, 308–313
 - mechanism of action of, 259–260, 260*t*
 - microbial resistance to, 260
 - monobactams, 293–294
 - newer, 324–326
 - penicillins, 261–274
 - polyene, 197–199
 - polypeptides, 315–320
 - spectrum of activity of, 259
 - sulfonamides, 228–239
 - synthetic, 206–220
 - tetracyclines, 259–260, 260*t*, 301–308, 302*t*, 305*t*
 - unclassified, 320–324
- Antibody**
- antigen reactions with, 163–164, 164*f*
 - formation, 157*f*, 163
 - molecular structure of, 163, 163*f*
 - production, 146–150, 147*f*, 157*f*, 163
 - hybridoma techniques, 146–147, 147*f*
 - types and reactions, 164–165
- Anticancer drugs, medicinal herbs, 972, 973*f***
- Anticholinergic agents, 478**
- Anticoagulants, 654–658, 654*t*, 655*f*–657*f***
- mechanisms of, 655–656, 656*f*
 - recombinant, 144
- Anti conformations, 28, 28*f***
- Anticonvulsants, 491–501**
- carbamazepine, 53, 86, 88, 497–498, 498*f*
 - disease states requiring, 491–492
 - felbamate, 498–499, 499*f*
 - flurofelbamate, 498–499, 499*f*
 - fosphenytoin, 495–497, 496*f*
 - future development of, 501
 - gabapentin, 493, 498, 498*f*
 - mechanism of action of, 492–494
 - excitatory glutamate-mediated receptors, 494
 - GABA receptors, 493–494
 - voltage-gated ion channels, 492–493
 - for neuropathic pain, 492
 - novel broad-spectrum, 499–500, 499*f*
 - oxcarbamazepine, 497–498, 498*f*
 - phenobarbital, 48, 454–455, 454*t*, 497, 497*f*
 - phenytoin, 16, 48–49, 51, 104–105, 109, 492, 492*f*, 495–497, 496*f*
 - pregabalin, 493, 498, 498*f*
 - primidone, 497, 497*f*
 - selective molecular target action, 500–501, 501*f*
 - valproic acid, 494–495, 495*f*
- Antidepressants, 509–515**
- α_2 antagonists, 515
 - 5-HT_{1A} antagonists, 515
 - miscellaneous, 515
 - monoamine oxidase inhibitors, 509–510, 510*t*
 - monoamine reuptake inhibitors, 510–511
 - nonselective serotonin-norepinephrine reuptake inhibitor, 514
 - selective norepinephrine reuptake inhibitors, 514
 - selective serotonin reuptake inhibitors, 513–514, 710
 - 5-HT_{2A} antagonists and, 514–515
- Antidiuretic hormone (ADH). See Vasopressin**
- Antiepileptics. See Anticonvulsants**
- Antiestrogens, 832–835, 833*f***
- Antifungal agents, 191–206**
- allylamines, 199–200
 - antibiotic, 196–199
 - azole, 200–206, 201*f*
 - nucleoside, 196, 196*f*
 - topical, 194–196
- Antigen**
- antibody reactions with, 163–164, 164*f*
 - for vaccines, 176–177
- Antihemophilic factor, 908*t*–909*t*, 912**
- recombinant, 656, 908*t*–909*t*, 912–913
- Antihistamines, 737–757**
- cardiotoxicity of, 741, 753
 - dual-acting, 759–760

- first-generation H₁ (classical) antagonists, 740*t*–741*t*, 741–753, 741*f*, 743*f*, 747*f*, 749*f*, 751*f*, 753*f*
 - general pharmacological and therapeutic considerations for, 739–741, 740*t*–741*t*
 - H₂-antagonists, 760–773, 761*f*, 762*t*, 766*f*, 766*t*–767*t*, 768*f*, 769*t*
 - H₃-receptor ligands, 773, 773*f*–774*f*
 - H₄-receptor ligands, 773, 773*f*–774*f*
 - mast cell stabilizers, 757–759
 - mechanism of action of, 737
 - second-generation H₁ (nonsedating) antagonists, 740*t*–741*t*, 753–757, 754*f*
 - structure–activity relationships of, 739, 739*f*, 740*t*
- Antihyperlipidemic agents, 647–654, 647*f*–648*f*, 649*t*, 652*f***
- HMG-CoA reductase inhibitors, 652–654, 652*f*
- Antihypersecretory agents**
- antihistamines, 760–765, 761*f*, 762*t*
 - proton pump inhibitors, 765–773, 766*f*, 766*t*–767*t*, 768*f*, 769*t*
- Antihypertensive agents, 637–647, 639*f*–640*f*, 643*f*, 645*f***
- ACE inhibitor prodrugs, 610–612, 611*f*, 612*t*
 - adrenergic system inhibitors, 639
 - agents depleting neurotransmitter stores, 639–641, 639*f*–640*f*
 - aldosterone antagonists, 615, 864
 - angiotensin antagonists, 612–614
 - centrally active adrenergic drugs, 641–642
 - endothelin receptor antagonists, 638–639
 - phosphodiesterase type 5 inhibitors, 644
 - positive inotropic agents, 645–647
 - potassium channel agonists, 644–645, 645*f*
 - renin–angiotensin system inhibitors, 609–610, 610*f*
 - renin inhibitors, 614–615
 - selective α -adrenergic antagonists, 641
 - vasodilators, 642–643, 643*f*
- Anti-infective agents, 179–240**
- alcohols and related compounds, 181–183
 - anthelmintics, 224–227
 - antibacterial sulfonamides, 228–239
 - antifungal agents, 191–206
 - antipedicular agents, 227–228
 - antiprotozoal agents, 220–224
 - antiscabious agents, 227–228
 - cationic surfactants, 186–188, 187*t*
 - chlorine-containing compounds, 186
 - classification of, 180, 181*t*
 - dihydrofolate reductase inhibitors, 239
 - dyes, 188–189
 - historical perspective on, 179–180
 - iodophors, 185–186
 - mercurials, 189–190
 - oxidizing agents, 185
 - phenols and derivatives, 183–185
 - preservatives, 190–191
 - sulfones, 239–240
 - synthetic antibiotics, 206–220
- Anti-inflammatory**
- chamomile, 968, 968*f*
 - glucocorticoids, 853–864, 854*f*–857*f*, 858*t*, 860*f*, 864*f*
 - NSAIDs, 792–806, 793*f*, 794*t*, 795*f*–797*f*, 799*f*, 801*f*–802*f*, 804*f*–806*f*
- Antileprotic agents, 239–240**
- Antimalarials, 242–256**
- 4-aminoquinolines, 248–250, 249*f*
 - 8-aminoquinolines, 250–251, 250*f*
 - cinchona alkaloids, 245–248, 248*f*
 - fixed combinations, 253–255
 - formulations of, 245–256
 - future trends in, 255–256
 - indications for, 246*t*–247*t*
 - mechanism of action of, 243*f*, 245
 - polycyclic, 251–253, 251*f*
 - for treatment, 246*t*–247*t*
- Antimanic agents, 468–469**
- Antimetabolites, 372–383**
- description of, 372
 - folates, 379, 380*f*–381*f*
 - products, 379–383
 - purines, 378–379, 378*f*–379*f*
 - pyrimidines, 372–378, 373*f*, 375*f*
- Antiminth. See Pyrantel pamoate**
- Antimony, for anti-infective agents, 179**

- Antimuscarinics, 583–584
 - Antineoplastic agents, 355–410
 - alkylating agents, 358–367
 - antibiotics, 383–400
 - actinomycins, 260*t*, 384, 384*f*, 388
 - anthracyclines, 385–389, 385*f*–387*f*
 - bleomycin, 394–396, 395*f*
 - camptothecins, 391–394, 392*f*–393*f*
 - epidophyllotoxins, 389–391, 390*f*–391*f*
 - mechanism of action of, 383–384
 - taxanes, 398–400, 398*f*–399*f*, 400*t*
 - vinca alkaloids, 396–398, 396*f*, 972
- antimetabolites, 372–383**
- arsenic trioxide, 410
 - asparaginase, 409–410
 - bezarotene, 407*f*, 409
 - bortezomib, 407–408, 407*f*–408*f*
 - estrastimustine, 407*f*, 410
 - mechanism of action of, 357–358, 357*f*
 - protein kinase inhibitors, 400–406
 - temsirolimus, 406–407, 407*f*
 - trastuzumab, 407*f*, 409
 - vitamin E, 931
 - vorinostat, 407*f*, 408–409, 409*f*
- Antiparkinsonian drugs, 584, 591–592**
- Antipedicular agents, 227–228**
- Antiplatelet agents, 627–629**
- aspirin, 797
- Antiprotozoal agents, 220–224**
- Antipseudomonal cephalosporins, 284**
- Antipsychotics, 443, 457–469, 478–488**
- β -aminoketones, 467–468
 - antimanic agents, 468–469
 - benzamide, 468
 - benzazepines, 463–465
 - butyrophenones, 481–483, 481*f*
 - classification of, 458, 459*t*
 - dibenzodiazepines, 463–465
 - dibenzoxazepines, 463–465
 - discovery and development of, 458
 - first-generation, 478–479
 - fluorobutyrophenones, 465–468, 465*f*
 - future directions for, 488
 - phenothiazines, 458–463, 462*f*, 479–481
 - second-generation, 483–488, 483*t*
 - thioxanthenes, 479–481
- Antipyretics**
- acetaminophen and related analogs, 803–806, 804*f*–806*f*
 - salicylates, 796–798, 797*f*
- Antirheumatic drugs, 806–809, 807*f***
- Antiscabious agents, 227–228**
- Antischizophrenic drugs. See Antipsychotics**
- Antisecretory agents, 583–584**
- Antisense technology, 152**
- Antiseptics, 180**
- classification of, 180, 181*t*
 - evaluation of effectiveness of, 180–181
 - improper use of, 181
 - phenol coefficient of, 183
 - wound healing and, 180–181
- Antisialagogues, 583**
- Antispasmodics, 583–584, 588**
- Antithrombin III, 655**
- Antithrombotic agents, 627–629**
- Antithyroid drugs, 663–664**
- Antitoxin, 165**
- Antitubercular agents, 214–218**
- antibiotics, 218–220
- Ant ulcer agents, 760–773, 761*f*, 762*t*, 766*f*, 766*t*–767*t*, 768*f*, 769*t***
- antihistamines, 760–765, 761*f*, 762*t*
 - proton pump inhibitors, 765–773, 766*f*, 766*t*–767*t*, 768*f*, 769*t*
- Antivert. See Meclizine hydrochloride**
- Antiviral agents, 330–352**
- biochemical targets for, 331, 333
 - chemokine receptor binders, 351
 - combination antiviral therapy, 352
 - DNA polymerase inhibitors, 339–343
 - gp41 fusion activity inhibitors, 352
 - HIV entry inhibitors, 351
 - HIV protease inhibitors, 348–351
 - integrase inhibitors, 352
 - interferons, 337–338, 338*f*–339*f*
 - metabolites of, 111–112
 - neuraminidase inhibitors, 336–337

- nonnucleoside reverse transcriptase inhibitors, 347–348
- nucleoside antimetabolites, 339–346
- reverse transcriptase inhibitors, 343–346
- short-interfering RNA, 352
- types of, 339–352
- Anturane. *See* Sulfinpyrazone
- Anxiolytics, sedatives and hypnotics, 443–457
- classification of, 443–444
- properties of, 444
- side effects of, 444
- Apidra. *See* Insulin glulisine
- Apidra Solostar. *See* Insulin glulisine
- Apigenin, 968, 968f
- Apokyn. *See* Apomorphine hydrochloride
- Apolipoproteins, 647, 647f
- Apomorphine hydrochloride, 476–477
- Apoptin, 45
- Apoptosis, 356–357, 357f
- Apoptosome, 357
- Apraclonidine, 538
- Aprisoline. *See* Hydralazine
- Aprisoline hydrochloride. *See* Hydralazine hydrochloride
- Ara-C. *See* Cytarabine
- Arachidonic acid, 657
- Arachidonic acid 2-glycerol ester, 517
- 2-Arachidonol glycerol ether, 517
- Aramine. *See* Metaraminol
- Arava. *See* Leflunomide
- ARBs. *See* Angiotensin receptor blockers
- Arcitumomab, 149
- Arduan. *See* Pilocarpine bromide
- Arecoline, 567
- Aredia. *See* Pamidronate disodium
- Arenes, oxidation of, 47–52, 48f, 50f
- Arenols, oxidation of, 47–52, 48f, 50f
- Arfonad. *See* Trimethaphan camsylate
- Aricept. *See* Donepezil
- Arimidex. *See* Anastrozole
- Aripiprazole, 467, 483t, 486–487, 487f
- Aromasin. *See* Exemestane
- Aromatase inhibitors, 835–837, 835f
- Aromatic hydroxylation, 47–52, 48f, 50f
- Arrhythmias, 629–631
- ARs. *See* Androgen receptors
- Arsenic, for anti-infective agents, 179
- Arsenic trioxide, 409
- Arsobal. *See* Melarsoprol
- Artane. *See* Trihexyphenidyl hydrochloride
- Artemether, 246t–247t, 252f, 255
- Artemisinin, 246t–247t, 252–253, 252f
- Artemotil, 252f
- Artesunate, 252f, 255
- Arthritic. *See* Piperazine
- Arthritis
- acute gouty, 810–811, 810f
- rheumatoid, 806–807
- Arthropan. *See* Choline salicylate
- Arthrosec. *See* Diclofenac; Misoprostol-diclofenac
- Articaine, 729
- Arylacetic acids, 799–800, 799f
- 1 β -Arylamino hallucinogens, 516–517
- N-Arylanthranilic acids, 801–803, 802f
- Aryloxypropanolamines, 549–550
- Arylpropanoic acids, 800–801, 801f
- Aryltrioxanes, 252f
- Arzoxifene, 833–834, 833f
- AS203. *See* Arsenic trioxide
- Ascorbic acid, 954–956, 954f–956f
- Ascorbyl palmitate, 956, 956f
- Asendin. *See* Amoxapine
- Asmanex. *See* Mometasone furoate
- L-ASNase. *See* Asparaginase
- Asparaginase, 409–410
- L-Asparaginase. *See* Asparaginase
- Aspirin, 627–628, 794t, 796–798, 797f
- as antiplatelet agent, 797
- as cardiovascular agent, 798
- COX-1 selectivity of, 796
- metabolism of, 86
- Aspro. *See* Aspirin
- Assembly, of virus, 333, 335–336
- Astemizole, 740t, 753, 754f
- Asthma, glucocorticoids for, 859, 860f, 863
- Atacand. *See* Candesartan
- Atazanavir, 350
- Atenolol, 552–553, 553f
- Atherosclerosis, 617, 647
- Athrombin-K. *See* Warfarin potassium
- Ativan. *See* Lorazepam
- Atorvastatin, 626, 653–654
- metabolism of, 48
- Atovaquone, 222–223, 246t–247t, 253f, 254–255
- ATRA. *See* Tretinoin
- Atracurium besylate, 596, 601–602, 602f
- Atromid-S. *See* Clofibrate
- Atrophic vaginitis, HRT for, 846
- Atropine, 568, 584–585, 597
- structure–activity relationships of, 581–582, 588
- therapeutic actions of, 583–584
- Atropine sulfate, 585–586
- Atropisol. *See* Atropine sulfate
- Atroscine, 586
- Atrovent. *See* Ipratropium bromide
- Augmentin. *See* Clavulanate-amoxicillin
- Auranofin, 807f
- Aureobasidins, 206–207
- Aureomycin hydrochloride. *See* Chlortetracycline hydrochloride
- Auroate. *See* Gold sodium thiomalate
- Aurothioglucose, 807f
- Autocrine signaling, 356
- Automaticity, 630
- Autonomic nervous system, 558, 596–597
- Avandamet. *See* Metformin; Rosiglitazone
- Avandaryl. *See* Glimepiride; Rosiglitazone
- Avandia. *See* Rosiglitazone
- Avapro. *See* Irbesartan
- Aventyl. *See* Nortriptyline hydrochloride
- Avlosulfon. *See* Dapsone
- Avodart. *See* Dutasteride
- Avonex. *See* Interferon beta-1a
- Axepin. *See* Cefepime
- Axert. *See* Almotriptan
- Axid. *See* Nizatidine
- Azactam. *See* Aztreonam disodium
- 5-Azacytidine, 375f, 378
- Azaepothilone B. *See* Ixabepilone
- Azalides, 312
- Azapyrimidine nucleosides, 378
- Azatadine, 740t
- Azatadine maleate, 752–753
- Azathioprine
- conjugation of, 96
- metabolism of, 7–8
- Azelastine, 740t
- Azelastine hydrochloride ophthalmic solution, 759
- Azotropic isopropyl alcohol, 182
- Azilect. *See* Rasagiline mesylate
- Azimilide, 637
- Aziridine, 361–362
- Azithromycin, 312
- Azlocillin, 268
- Azmacort. *See* Triamcinolone acetonide
- Azochloramid. *See* Chloroazodin
- Azole antifungals, 200–206, 201f
- Azolidic. *See* Phenylbutazone
- Azor. *See* Amlodipine
- Aztreonam disodium, 294, 324–325
- Azulfidine. *See* Sulfasalazine
- B**
- Bacampicillin hydrochloride, 272
- Bacitracins, 260r, 315, 317–318
- chemical classification of, 260
- Bacterial resistance, to penicillins, 265–267
- Bacterial vaccines, 172–173
- Bactericidal factor, 159–160, 159r
- Bacteriolysis, immunological, 164
- Bacteriophage, for vector cloning, 125, 125f
- Bactroban. *See* Mupirocin
- BAL. *See* Dimeracapol
- Baltimore Classification Scheme, for viruses, 330–331, 331t
- Banthine bromide. *See* Methantheline bromide
- Barbiturates, 452–454, 453f, 454t
- intermediate duration, 454, 454t
- long duration, 453–454, 454t
- mechanism of action of, 452
- preparation of, 452–453
- short duration, 454, 454t
- structure–activity relationships of, 453, 453f
- Barium sulfate, 432–433
- Bases, 12–17
- conjugate, 12, 13r
- definition of, 12
- percent ionization, 14–16, 15f–16f
- reactions, 12, 13r
- strength of, 12, 14, 14r
- Basic fuchsin, 189
- Basiliximab, 148
- Basophils, 157, 157f
- BAY 43-9006. *See* Sorafenib tosylate
- Baycol. *See* Cerivastatin
- Baypress. *See* Nitrendipine
- Bazedoxifene, 833–834, 833f
- B cells, 157f, 159
- BCNU. *See* Carmustine
- BC powder. *See* Salicylamide
- Becaplermin, 138
- Becum. *See* Carmustine
- Beclomethasone dipropionate, 860f, 861, 863
- Beclvent. *See* Beclomethasone dipropionate
- Beconase. *See* Beclomethasone dipropionate
- β -Elimination, of recombinant proteins, 132
- Belladonna, 584
- Benadryl. *See* Diphenhydramine; Diphenhydramine hydrochloride
- Benazepril hydrochloride, 611, 611f, 612r
- Benemid. *See* Probenecid
- Benicar. *See* Olmesartan
- Benign prostatic hyperplasia (BPH), 852
- Bentyl. *See* Dicyclomine hydrochloride
- Benzdadrine. *See* Amphetamine sulfate
- Benzalkonium chloride, 187–188
- Benzamides, 468
- Benzazepines, dibenzoxazepines, and dibenzodiazepines, 463–465
- Benzazocines. *See* Benzomorphans
- Benzedrex. *See* Propylhexedrine
- Benzethonium chloride, 188
- Benzilylcarbocholine, 581
- Benimidazole proton pump inhibitors, 765, 766f, 766t–767t, 767–768, 768f
- Benznidazole, 223
- Benzo[a]pyrene, metabolism of, 51–52, 52f
- Benzocaine, 726
- Benzodiazepines, 501
- agents, 447–451
- discovery and development of, 445–446
- GABA_A receptor binding of, 444–445
- general structure of, 445
- metabolism of, 446–447, 446f
- properties of, 446
- Benzoic acid, 191, 195
- conjugation of, 90–91, 94
- Benzomorphans, 786
- Benzphetamine hydrochloride, 506r, 508
- metabolism of, 63–64
- Benztropine, 478, 591
- Benztropine mesylate, 591–592
- Benzyl alcohol, 191
- Benzyl benzoate, 227–228
- Benzyl carbon atoms, oxidative reactions at, 55
- Benzylpenicillin, 260–261, 267–269, 269r
- 2-Benzylthio-5-trifluoromethylbenzoic acid, metabolism of, 75, 77
- Bepidil, 623r
- Bepidil hydrochloride, 627
- Berberi, 938
- Beta cells, in glucose metabolism disorders, 667–670, 670f
- Betadine. *See* Povidone-iodine
- Betagan. *See* Levobunolol
- Betamethasone, 822r, 857f, 858r, 859, 861
- Betamethasone acetate, 822r
- Betamethasone NaPO₄, 822r
- Betapace. *See* Sotalol
- Betaseron. *See* Interferon beta-1b, recombinant
- Betaxolol, 552–553, 553f
- Bethanechol chloride, 569
- Betoptic. *See* Betaxolol
- Bexarotene, 407f, 409
- Bexxar. *See* Iodine (¹³¹I) tositumomab
- BH⁺ acids, 15
- lipid barrier passage of, 16, 17f
- Biapenem, 278
- Biaxin. *See* Clarithromycin
- Bicalutamide, 851–852, 851f
- Bicillin. *See* Penicillin G benzathine

- BICNU. *See* Carmustine
 Bi-Est. *See* Estriol
 Bifunctional chelating agents, 419
 Biguanides, 685–687, 685f–686f
 Bilacril. *See* Metrifonate
 Biltricide. *See* Praziquantel
 Bimatoprost, 878
 Biological activity, optical isomerism and, 30–31, 31f–32f
 Biotechnology, 119–153
 antisense technology, 152
 for development of pharmaceutical proteins and peptides, 907–909, 908t–909t, 910f
 gene therapy, 153
 genomics, 150–152, 151f
 literature of, 119
 new drug development and, 119–121
 overview of, 119, 120f–121f
 pharmaceutical care and, 119
 products, 134–150
 antibody production, 146–147, 147f
 cytokines, 136–138, 136t, 137f
 enzymes, 142–145
 hormones, 134–136
 in-home test kits, 150
 interferons, 138–141, 138f, 139t–140t
 interleukins, 141–142
 monoclonal antibodies, 147–149
 monoclonal antibody radionuclide test kits, 149–150
 therapeutic radionuclide monoclonal antibody, 149–150
 tumor necrosis factor, 142
 vaccines, 145–146, 146t
 recombinant DNA, 121–126, 122f–125f, 123t–124t
 Biotechnology-derived pharmaceuticals, 908t–909t, 909–913
 Biotherapy, 907
 Biotin, 947–948, 947f–948f, 947t
 Biperiden, 591–593
 Biperiden hydrochloride, 593
 Biphasic combination contraceptive tablets, 842t–843t, 844
 Birth control. *See* Contraceptive agents
 Bisabolol, 968, 968f
 Bisguanidines, 662
 Bisoprolol, 552–553, 553f
 Bisphosphonates, 706–708, 706f, 707t
 Bithion. *See* Bithionol
 Bithionol, 226
 Bitolterol, 542–543
 Blenoxane. *See* Bleomycin sulfate
 Bleo. *See* Bleomycin sulfate
 Bleomycin, 394–396, 395f
 Bleomycin hydrolase, 395
 Bleomycin sulfate, 394–396, 395f
 BLM. *See* Bleomycin sulfate
 Blocadren. *See* Timolol
 α -Blockers, 540, 545–549
 irreversible, 546–547, 547f
 nonselective, 546
 α_1 -Blockers, 525, 525t–526t, 547–548
 α_2 -Blockers, 548–549
 β -Blockers, 540, 549–554
 with α_1 -blocker activity, 554
 nonselective, 550–551, 552f
 structure–activity relationship of, 549–550
 β_1 -Blockers, 525, 525t–526t, 551–554, 553f
 β -Blockers, as antiarrhythmic agents, 631, 631t, 636
 Blood-clotting factors, recombinant, 142–144, 143t
 Blood coagulation, 654–656, 654t, 655f
 platelets in, 656–657, 657f
 Blood degradation, 656
 Blood pressure, regulation of, 637–639, 641
 renin–angiotensin system in, 607–609, 608f–609f
 Blood proteins, 906–907
 BMS-354825. *See* Dasatinib
 Bone disease, agents treating, 705–710
 bisphosphonates, 706–708, 706f, 707t
 hormone therapy, 708–710, 709f
 monoclonal antibodies, 710
 Bone formation, serotonin regulation of, 710
 Bone remodeling, 705
 Bonine. *See* Meclizine hydrochloride
 Bortezomib, 407–408, 407f–408f
 Bosentan, 638
 Bovine insulin, 668, 668t
 BPH. *See* Benign prostatic hyperplasia
 Bradykinin, 607–608, 609f, 905–906
 Breast cancer
 aromatase inhibitors for, 835
 estrogen treatment of, 831
 progestins for, 839
 SERM treatment of, 832
 Brethine. *See* Terbutaline
 Brevityl. *See* Brevityl tosylate
 Brevibloc. *See* Esmolol
 Bricanyl. *See* Terbutaline
 Bromonidine, 538
 British anti-Lewisite. *See* Dimercaprol
 Broad-spectrum antibiotics, 259
 Bromelains, 890
 Bromfenac, 799f, 800
 Bromobenzene, metabolism of, 52
 Bromocriptine mesylate, 475–476
 Bromodiphenhydramine hydrochloride, 743
 Brompheniramine, 740t
 conjugation of, 94
 metabolism of, 63–64
 Brompheniramine maleate, 749–750
 Brompheniramine tannate, 749–750
 Brookhaven Protein Databank, 37
 BuChE. *See* Butyrylcholinesterase
 Bucladin-S. *See* Buclizine hydrochloride
 Buclizine hydrochloride, 748
 Budding, viruses, 336
 Budesonide, 860f, 861–863
 Bufadienolides, 645–646
 Bufferin. *See* Aspirin
 Bufornin, 685f
 Bunolol, metabolism of, 82
 Bupivacaine, 31f, 728–729
 Buprenorphine, 791
 Bupropion, 515
 Burimamide, 760, 762t
 Burn therapy, topical sulfonamides for, 238
 Burst size, in viral infections, 330
 Buserelin, 698, 698f
 BuSpar. *See* Buspirone
 Buspirone, 515
 Busulfan, 362, 364f, 369–370
 Busulfex. *See* Busulfan
 Butabarbital, 454, 454t
 Butane, potential energy for, 34, 34f
 Butazolidin. *See* Phenylbutazone
 Butaconazole nitrate, 202
 Butorphanol, 790
N-*t*-Butylchlorocyclizine, metabolism of, 63, 66
 Butylparaben, 190
 Butyrophenones, 481–483, 481f
 agents, 482–483
 discovery of, 481
 mechanism of action of, 481
 metabolic pathway of, 482, 482f
 pharmacokinetic properties of, 482, 482f
 Butyrylcholinesterase (BuChE), 570, 571t
 phosphorylation of, 577–578, 577f–578f
 reactivation of, 577–578, 577f
 Byetta. *See* Exenatide
 C
 Cabergoline, 475–476
 Caffeine, 505–506, 505t
 Calan. *See* Verapamil
 Calbindin, 926
 Calcifediol, 927t, 928f
 Calcimar. *See* Calcitonin, salmon
 Calcipotriene, 927t, 928f
 Calcitonin, 905
 in calcium regulation, 708
 salmon (sCT), 708–709
 Calcitriol, 708–709, 709f, 925–926, 927t, 928f
 Calcium
 in bone, 705–706
 regulation of, 708
 Calcium antagonists, 622–627, 622f–625f, 623t
 excitation–contraction coupling in muscle, 622, 622f
 ion channels and calcium, 623, 623f
 Calcium channel blockers
 as antianginals/vasodilators, 623–624, 623f–624f, 623t
 as antiarrhythmic agents, 631–632, 631t, 637
 cardiovascular effects of, 624
 Calcium ion
 in muscle contraction/relaxation, 618–619, 619f, 622, 622f
 as second messenger, 623
 Calcium ion channels, 623, 623f–624f
 Calculated conformations, 32–35, 34f–35f
 cAMP. *See* Cyclic AMP
 Campath. *See* Alemtuzumab
 Camptosar. *See* Irinotecan hydrochloride
 Camptothecins, 391–394, 392f–393f
 Cancer. *See also* Antineoplastic agents
 apoptosis and, 356–357, 357f
 breast
 aromatase inhibitors for, 835
 estrogen treatment of, 831
 progestins for, 839
 SERM treatment of, 832
 cell cycle and, 356–357, 356f
 definition of, 355
 drug activity against, 357–358
 endometrial, progestins and, 839
 estrogens and risk of, 831
 growth factors and receptors in, 401, 401t
 HRT and, 847
 medicinal herbs used for, 972, 973f
 oncogenes and, 356, 356t
 prostate
 antiandrogens for, 851
 estrogen treatment of, 831
 Ras pathways and, 401, 402f, 403
 viral infections and, 335
 Candesartan, 613
 Cantil. *See* Mepenzolate bromide
 Capastat sulfate, 219–220
 Capcitabine, 375, 375f, 377f, 380
 Capoten. *See* Captopril
 Capreomycin, 219–220
 antitubercular activity of, 215
 Capromab pendetide, 150
 Capsaicin, 729, 967, 967f
 Capsicum, 967, 967f
 Captopril, 609–610, 610f
 Carafate. *See* Sucralfate
 Carbachol, 569, 571, 572t
 Carbamazepine, 497–498, 498f
 metabolism of, 53, 86, 88
 Carbamide peroxide topical solution, 185
 Carbapenems, 276–278
 Carbarsone, 220
 Carbenicillin disodium, 267–268, 269t, 273
 metabolism of, 86–87
 Carbenicillin indanyl sodium, 273
 Carbidopa, 474, 478
 Carbinolamide, metabolism of, 70, 72
 Carbinoxamine, 740t
 Carbinoxamine maleate, 743–744
 Carbocholines, 581
 Carbolic acid, 179, 183
 β -Carboline, 444–445
 Carbomycin A, 308
 Carbon–nitrogen systems, oxidative reactions in, 62–73
 Carboplatin, 363–365, 365f, 370
 Carboprost tromethamine, 876
 Carboxide, 182
 Carbutamide, 672f
 Cardene. *See* Nicardipine hydrochloride
 Cardenolides, 645–646
 Cardiac arrhythmias, 629–631
 Cardiac electrophysiology, 629–630, 630f
 Cardiac glycosides, 645–649
 Cardiac muscarinic receptors, 561
 Cardilate. *See* Erythryl tetranitrate, diluted
 Cardiolute. *See* Technetium (^{99m}Tc) sestamibi
 Cardioquin. *See* Quinidine polygalacturonate
 Cardiotoxicity, of antihistamines, 741, 753
 Cardiovascular agents, 617–665
 antianginal agents, 617–629, 618f–619f, 620t, 622f–623f, 623t
 antiarrhythmic agents, 629–637, 630f, 631t, 634f
 anticoagulants, 654–658, 654t, 655f–657f
 antihyperlipidemic agents, 647–654, 647f–648f, 649t, 652f
 antihypertensive agents, 637–647, 639f–640f, 643f, 645f

- antithyroid drugs, 663–664
 aspirin, 798
 synthetic hypoglycemic agents, 658–669
 thyroid hormones, 663
 vasodilators, 617–629, 618f–619f, 620t, 622f–625f, 623t
- Cardiovascular disease, 617–618, 618f
 Cardizem. *See* Diltiazem hydrochloride
 Cardomec. *See* Ivermectin
 Cardura. *See* Doxazosin
 Carisoprodol, 456
 Carmubris. *See* Carmustine
 Carmustine, 365, 366f, 370–371
 α -Carotene, 919–921, 919f, 920t
 β -Carotene, 919–921, 919f, 920t
 sources of, 923
 toxicity of, 923
 γ -Carotene, 919–921, 919f
 Carotenoids
 chemistry of, 919–920
 sources of, 917, 919
 Carteolol, 551, 552f
 Cartrol. *See* Carteolol
 Carvedilol, 554–555
 Casodex. *See* Bicalutamide
 CAT. *See* Computed axial tomography
 Cataflam. *See* Diclofenac
 Catapres. *See* Clonidine; Clonidine hydrochloride
 Catecholamines
 biosynthesis, drugs affecting, 528, 529f–530f, 530
 endogenous, 534–535
 storage and release of, drugs affecting, 530–531
 Catechol-*O*-methyltransferase (COMT) inhibitors, 477–478
 Caverject. *See* Alprostadil
 CBDCA. *See* Carboplatin
 CCI-779. *See* Temsirolimus
 CCK-PZ. *See* Cholecystokinin-pancreozymin
 CCNU. *See* Lomustine
 2-CDA. *See* Cladribine
 cDNA, preparation of, 123, 123f
 CEA-Scan. *See* Arcitumomab
 Ceclor. *See* Cefaclor
 Cedax. *See* Cefibuten
 CEENU. *See* Lomustine
 Cefaclor, 280t, 286
 Cefadroxil, 280t, 286
 Cefadyl. *See* Cephapirin sodium
 Cefamandole, 281t, 283
 Cefamandole nafate, 287–288
 Cefazolin sodium, 281t, 287
 Cefepime, 292
 Cefixime, 280t, 290–291
 Cefizox. *See* Ceftizoxime sodium
 Cefmetazole sodium, 282t, 289
 Cefobid. *See* Cefoperazone sodium
 Cefonicid sodium, 281t, 283, 288
 Cefoperazone sodium, 281t, 284, 288–289
 Ceforanide, 281t, 283, 288
 Cefotan. *See* Cefotetan disodium
 Cefotaxime sodium, 281t, 283–284, 291
 Cefotetan disodium, 282t, 289
 Cefoxitin sodium, 282t, 289
 Cefpirome, 292
 Cefpodoxime proxetil, 280t, 290
 Cefprozil, 27, 280t, 286–287
 Cefrom. *See* Cefpirome
 Ceftazidime sodium, 281t, 291–292
 Cefibuten, 292
 Cefitin. *See* Cefuroxime axetil
 Cefprozil sodium, 281t, 283–284, 291
 Ceftriaxone disodium, 281t, 283–284, 291
 Cefuroxime axetil, 280t, 290
 Cefuroxime sodium, 281t, 283–284, 289–290
 Cefzil. *See* Cefprozil
 Celebrex. *See* Celecoxib
 Celecoxib, 792, 794t, 803, 804f
 COX-2 binding of, 795, 795f
 metabolism of, 55, 57
 Celexa. *See* Citalopram
 Cell cycle, 356–357, 356f
 Cell membrane
 drug receptors and, 10
 partition coefficient and, 18–20, 19f–20f
 penicillin and, 266–267
 Cellular antigen from pathogen, vaccine, 166
 Celontin. *See* Methsuximide
 Cenestin. *See* Synthetic conjugated estrogens
 Centrally active adrenergic drugs, 641–642
 Central nervous system, 558
 Central nervous system depressants, 443–469
 antipsychotics, 457–469
 anxiolytics, sedatives and hypnotics, 443–457
 Central nervous system stimulants, 504–517
 analeptics, 504–505
 antidepressants, 509–515
 methylxanthines, 505–506, 505t
 miscellaneous, 515–517
 psychomotor stimulants, 506–509, 506t
 Central sympathomimetic agents, 506–509, 506t
 medical indications for, 506–507
 products, 506t, 507–509
 structures of, 506, 506t
 Cephalixin, 280t, 286
 Cephalosporanic acid, 278–279
 Cephalosporin(s), 260t, 278–293
 adverse reactions of, 285
 antipseudomonal, 284
 β -lactamase resistance of, 282–284, 284f
 classification of, 260, 285, 285t
 degradation of, 279, 283f
 drug interactions with, 285
 future developments in, 292–293
 historical background on, 278
 nomenclature of, 278
 oral, 279, 282
 parenteral, 282
 semisynthetic derivatives of, 278–279
 spectrum of activity of, 282
 structures of, 280f–282f
 types of, 286–293
 Cephalosporin C, 278
 Cephalosporin P1, 278
 Cephalosporoic acid, 279
 Cephalothin sodium, 280t, 287
 Cepham, 278–279
 Cephamycin, 284
 parenteral, 282t
 Cephamycin C, 284
 Cephapirin sodium, 280t, 287
 Cephhradine, 280t, 286
 Cerebryx. *See* Fosphenytoin
 Ceretec. *See* Technetium (^{99m}Tc) exametazime
 Cerezyme. *See* Imiglucerase; Imiglucerase injection
 Cerivastatin, 654
 Cerubidine. *See* Daunorubicin hydrochloride
 Cestocide. *See* Niclosamide
 Cestode infections, 224–225
 Cetazone T. *See* Salicylamide
 Cetirizine, 740t–741t, 755–756
 Cetorelix, 699t, 700f, 701
 Cetrotide. *See* Cetorelix
 Cetylpyridinium chloride, 188
 Cevimeline hydrochloride, 570
 CG. *See* Chorionic gonadotropin
 cGMP. *See* Cyclic GMP
 Chagas disease, 221, 223
 Chamazulene, 968, 968f
 Chamomile, 968, 968f
 Charton's steric parameter, 20
 ChAT. *See* Choline acetyltransferase
 Chelating agents, 423
 Chemical bonds, type of, 25, 25t
 Chemoprophylaxis, for viral infections, 331, 333, 336
 Chemotherapy, 355
 CHF. *See* Congestive heart failure
 Chickenpox vaccine, 170
 Chili pepper, 967, 967f
 Chimeric protein, 128, 128f
 Chinosol. *See* Oxine
 Chloral hydrate, 456–457, 457f
 Chlorambucil, 360, 360f, 368
 Chloramphenicol, 260t, 320–321
 conjugation of, 90–91
 metabolism of, 78–79, 84
 spectrum of activity, 259
 Chloramphenicol palmitate, 321
 solubility of, 4
 Chloramphenicol sodium succinate, 321
 Chlorcyclizine hydrochloride, 747
 Chlordiazepoxide, 589
 Chlordiazepoxide hydrochloride, 447
 Chlorhexidine gluconate, 188
 Chlorine-containing compounds, 186
 Chloroacetaldehyde, 361, 363f
 Chloroazodin, 186
 Chlorobutanol, 190–191
 Chlorocresol, 184
 2-Chlorodeoxyadenosine. *See* Cladribine
 Chloroethyl-cyclohexyl-nitrosourea. *See* Lomustine
 bis-Chloroethyl-nitrosourea. *See* Carmustine
 Chloroform, metabolism of, 78–79
p-Chloro-*m*-xylenol, 184
 Chloromycetin. *See* Chloramphenicol
p-Chlorophenol, 183
 Chloroprocaine, 726
 Chloroquine, 246t–247t, 248–250, 249f, 807f, 808
 Chloroquine phosphate, 248–250
 Chlorphenesin carbamate, 456
 Chlorpheniramine, 740t–741t
 metabolism of, 80–81
 Chlorpheniramine maleate, 749
 Chlorphentermine, metabolism of, 69–70
 Chlorpromazine hydrochloride, 460–461, 461t, 479–481, 480t, 483t
 metabolism of, 49, 63–64
 Chlorpropamide, 659–660, 671f, 673t, 677f, 680–681
 metabolism of, 59–60, 71–72
 Chlorprothixene, 480t
 Chlortetracycline hydrochloride, 302t, 305t, 306
 Chlor-Trimeton. *See* Chlorpheniramine maleate
 Cholecalciferol, 923–924, 925f, 926, 927t, 928f
 bioactivation of, 924, 926f
 Cholecystokinin-pancreozymin (CCK-PZ), 904
 Cholera vaccine, 173
 Cholesterol, 647–648, 821f, 822t
 ketoconazole and, 203
 in lipid membrane, 193, 193f
 Cholestyramine resin, 650–651
 Choletec. *See* Technetium (^{99m}Tc) mebrofenin
 Choline, 563–564, 563f–564f
 Choline acetyltransferase (ChAT), 563–564, 563f–564f
 Cholinergic agonists, 564–567, 565f–567f, 565t–567t
 stereochemistry of, 564–565, 565f–566f, 565t–566t
 structure–activity relationships of, 566–567, 566f–567f, 567t
 Cholinergic blocking agents, 581–596
 aminoalcohol esters, 588–591
 aminoalcohol ethers, 591–592
 aminoalcohols, 592–594
 aminoamides, 594–595
 miscellaneous, 595–596
 solanaceous alkaloids and analogues, 584–588
 structure–activity relationships of, 581–583, 588
 cationic head, 581–582
 cyclic substitution, 582–583
 esteratic group, 582
 hydroxyl group, 582
 synthetic, 588–596
 therapeutic actions of, 583–584
 Cholinergic drugs, 558–605
 cholinergic agonists, 564–567, 565f–567f, 565t–567t
 cholinergic blocking agents, 558, 581–596
 cholinergic neurochemistry, 563–564, 563f–564f
 cholinergic receptor antagonists, 567–581, 568f
 cholinergic receptors, 559–563, 559f–562f, 559t
 ganglionic blocking agents, 596–599, 597f, 597t
 neuromuscular blocking agents, 599–605, 602f
 parasympathetic postganglionic blocking agents, 583–584
 stereochemistry of, 564–565, 565f–566f, 565t–566t
 Cholinergic neurochemistry, 563–564, 563f–564f
 Cholinergic receptor, 559–563
 activation of, 562–563, 562f
 muscarinic, 560–563, 561f–562f, 566–567, 566f
 nicotinic, 559–560, 559f–560f, 559t
 Cholinergic receptor antagonists, 567–581, 568f
 cholinesterase inhibitors, 570–572, 571t–572t, 572f
 irreversible, 572t, 577–581, 577f–578f, 580f
 reversible, 572–576, 572t, 573f
 Cholinergic stereochemistry, 564–565, 565f–566f, 565t–566t
 Choline salicylate, 798
 Cholinesterase, 570–572, 571t–572t, 572f
 phosphorylation of, 577–578, 577f–578f
 reactivation of, 577–578, 577f

- Cholinesterase inhibitors, 570–572, 571*t*–572*t*, 572*f*
 irreversible, 572*t*, 577–581, 577*f*–578*f*, 580*f*
 reversible, 572–576, 572*t*, 573*f*
- Choloxin. *See* Dextrothyroxine sodium
- Chorionic gonadotropin (CG), 696
- Chorionic growth-hormone prolactin. *See* Human placental lactogen
- Chromosome walking, 126
- Chronic pain, 776–777
- Chrysin, 835*f*, 836
- Chylomicrons, 647–648, 649*t*
- Chymar. *See* Chymotrypsin
- Chymotrypsin, 888*t*, 889
- Cialis. *See* Tadalafil
- Ciclesonide, 860*f*, 863
- Ciclopirox olamine, 196
- Cidex. *See* Glutaraldehyde disinfectant solution
- Cidofovir, 343
- Ciglitazone, 681, 682*f*
- Cilastatin-imipenem, 276–277
- Cimetidine, 760–761, 762*t*, 763, 767*t*
 metabolism of, 76, 78
- Cinacalcet, 709–710, 709*f*
- Cinchona, as anti-infective agent, 179
- Cinchona alkaloids, 245–248, 246*t*–247*t*, 248*f*
- Cinobac. *See* Cinoxacin
- Cinoxacin, 208, 210
- Cipro. *See* Ciprofloxacin
- Ciprofloxacin, 208, 208*t*, 210*f*, 211
- Cipro IV. *See* Ciprofloxacin
- Cisplatin, 362–365, 365*f*, 370
- Cispro. *See* Insulin injection
- Cistemography, 420–421
- Citalopram, 514
- Cladinose, 309
- Cladribine, 378, 382
- Clafen. *See* Cyclophosphamide
- Claforan. *See* Cefotaxime sodium
- Clarinox. *See* Desloratadine
- Clarithromycin, 311–312
- Classical complement pathway, 160–161, 162*f*
- Clavulanate-amoxicillin, 275
- Clavulanate potassium, 275
- Clavulanate-ticarcillin, 275
- Clemastine, 740*t*
- Clemastine fumarate, 744
- Cleocin. *See* Clindamycin hydrochloride
- Cleocin Pediatric. *See* Clindamycin palmitate hydrochloride
- Cleocin Phosphate. *See* Clindamycin phosphate
- Clidinium bromide, 588–589
- Clindamycin hydrochloride, 313–315
- Clindamycin palmitate hydrochloride, 315
- Clindamycin phosphate, 315
- Clinoril. *See* Sulindac
- Clioquinol, 195
- Clistin. *See* Carbinoxamine maleate
- Clobenprobil, 774*f*
- Clobetasol, 859
- Clobetasol propionate, 857*f*, 862
- Clocortolone pivalate, 857*f*, 862
- Cloderm. *See* Clocortolone pivalate
- Clodronate, 706
- Clofarabine, 378
- Clofazimine, 217–218
- Clofibrate, 649
 metabolism of, 86–87
 metabolites of, 111
- Clomid. *See* Clomiphene citrate
- Clomiphene, 27, 832, 833*f*, 834
- Clomiphene citrate, 835
- Clomipramine hydrochloride, 511–512
- Clonazepam, 501, 501*f*
 metabolism of, 84
- Clonidine, 537–538
 metabolism of, 49
- Clonidine hydrochloride, 642
- Cloning. *See* Recombinant DNA technology
- Clopidogrel, 628
- Cloprostenol sodium, 878
- Clorazepate dipotassium, 446*f*, 448
- Clorpactin. *See* Oxychlorosene sodium
- Clotrimazole, 202
- Clotting factors, 654–656, 654*t*, 655*f*
- Clotting factor IX, recombinant, 144
- Cloxacillin sodium, 269*t*, 271
- Clozapine, 463–464, 468, 483–484, 483*t*, 484*f*
- Clozaril. *See* Clozapine
- CNS toxicity, of triptans, 813
- Coagulation, 654–656, 654*t*, 655*f*
 platelets in, 656–657, 657*f*
- Cobalamin, 951–954, 952*f*–953*f*
- Cocaine, 517
 as local anesthetic, 725
- Codeine, 783*f*–784*f*, 784
 metabolism of, 75
- Coenzyme A, 942–944, 943*f*
- Cogentin. *See* Benztropine mesylate
- Cognex. *See* Tacrine hydrochloride
- Colchicine, 810–811, 810*f*
- Colesevelam, 651
- Colestid. *See* Colestipol hydrochloride
- Colestipol hydrochloride, 651
- Colimicin-A. *See* Polymyxin B sulfate
- Colimycin-E. *See* Polymyxin B sulfate
- Colistimethate sodium, 319
- Colistin sulfate, 318–319
- Colomycin. *See* Polymyxin B sulfate
- Colony-stimulating factors, 908*t*, 912
- Colterol, 532–533, 542–543
- Coly-Mycin. *See* Polymyxin B sulfate
- Coly-Mycin M. *See* Colistimethate sodium
- Combination contraceptive tablets, 842, 842*t*–844*t*, 844
- Combined estrogen/progestin hormone replacement therapy, 846–847, 846*t*
- CombiPatch, 846*t*
- Combunox. *See* Oxycodone
- CoMFA. *See* Comparative molecular field analysis
- Comparative molecular field analysis (CoMFA), 36–37, 36*f*
- Compazine. *See* Prochlorperazine maleate
- Complementarity-determining regions, 147
- Complement pathway, 160
 alternative, 160–161, 160*f*
 classical, 160–161, 162*f*
- Computed axial tomography (CAT), 418
 contrast agents for, 430–436
 description of, 431, 431*f*
- Computed tomography (CT)
 contrast agents for, 413, 430–436
 description of, 431, 431*f*
- Computer-aided drug design, 17–40
 calculated conformations, 32–35, 34*f*–35*f*
 classification methods, 23–24
 conformational flexibility and multiple modes of action, 29–30, 29*f*
 database searching and mining, 37–38, 37*f*–38*f*, 38*t*
 drug-receptor interactions, 25–29, 25*t*
 isosterism, 39–40, 39*f*–40*f*, 39*t*
 newer methods for, 25
 optical isomerism and biological activity, 30–31, 31*f*–32*f*
 overview of, 17
 partition coefficient, 18–20, 19*f*–20*f*
 physicochemical and descriptor parameters, 20–22, 20*t*–21*t*
 QSAR success, 24
 statistical prediction of pharmacological activity, 17–18
 success of, 40
 three-dimensional quantitative structure–activity relationships, 36–37, 36*f*
 topological descriptors, 21*t*, 22–23, 22*f*
- Comtan. *See* Entacapone
- COMT inhibitors. *See* Catechol-*O*-methyltransferase inhibitors
- Convax, 145
- Concentration, of recombinant protein, 131
- Conformational flexibility, multiple modes of action and, 29–30, 29*f*
- Conformational isomers, 27
- Conformations, calculated, 32–35, 34*f*–35*f*
- Congestive heart failure (CHF), 645–646
- Conjugated estrogens, 828–829, 829*f*, 832
- Conjugation reactions, 8, 88–104
 acetylation, 97–102
 in drug metabolism, 43–44, 44*t*
 glucuronic acid, 89–91, 89*f*–90*f*, 89*t*
 with glycine, glutamine, and other amino acids, 93–94
 GSH or mercapturic acid conjugates, 94–97, 95*f*
 methylation, 102–104, 102*f*
 sulfate, 91–93, 92*f*
- Connectivity indices, 20
- Connectivity table, 21*t*, 22
- Conray. *See* Iothalamate meglumine
- Contraceptive agents, 841–847, 842*t*–844*t*, 846*t*
 estrogens in, 831
 ovulation inhibitors, 841–846, 842*t*–844*t*
 progestins in, 839
 safety of, 844–845
- Contraceptive implants, 843*t*–844*t*, 846
- Contraction, of muscle, 618–619, 619*f*, 622, 622*f*
- Contrast agents, 430–440
 for computed tomography, 413, 430–436
 conventional, 432
 criteria for, 432
 description of, 431–432
 high-osmolar, 432
 ionic ratio 1.5, 432
 low osmolar, 432
 for magnetic resonance imaging, 413, 436–440
 for radiography, 430–436
 reactions to, 432–433
 triiodinated, 432
 for ultrasound, 413, 440
 water-soluble, 432
- Conventional contrast agents, 432
- Cordarone. *See* Amiodarone
- Coreceptors, in viral binding, 334
- Coreg. *See* Carvedilol
- Corgard. *See* Nadolol
- Coronary atherosclerosis, 617
- Corticorelin, 892
- Corticosteroids, 853–864, 854*f*–857*f*, 858*t*, 860*f*, 864*f*
 biological activities of, 855–856
 biosynthesis of, 854–855, 854*f*
 endogenous, 853–854
 metabolism of, 855, 855*f*
 mineralocorticoid receptor antagonists, 615, 864
 structural classes of, 856–859, 856*f*–857*f*, 858*t*
 therapeutic uses of, 859–860
- Corticotropin, 810, 855, 891, 892*t*
- Corticotropin injection, 891, 892*t*
- Cortisone, 820*f*, 858–859, 858*t*
- Cortisone acetate, 856*f*, 861
- Cortrophin Gel. *See* Repository corticotropin injection
- Cortrophin-Zinc, 892*t*
- Cosyntropin. *See* Cosyntropin
- Corvert. *See* Ibutilide
- Corynanthine, 548–549
- Cosmegen. *See* Dactinomycin-D
- Cosyntropin, 891–892, 892*t*
- Cotazym. *See* Pancrelipase
- Cotinine, metabolism of, 70–71, 73
- Coumadin. *See* Warfarin sodium
- Coumestrol, 830*f*
- COX. *See* Cyclooxygenase
- COX-1. *See* Cyclooxygenase
- COX-2. *See* Cyclooxygenase
- Cozaar. *See* Losartan
- CP-358. *See* Erlotinib hydrochloride
- CP-358,774. *See* Erlotinib hydrochloride
- CPA. *See* Cyclophosphamide
- CPM. *See* Cyclophosphamide
- CPT-11. *See* Irinotecan hydrochloride
- Cranberry, 969
- Cresol, 184
- Crestor. *See* Rosuvastatin
- Cristanaspase. *See* Asparaginase
- Crixivan. *See* Indinavir
- Cromolyn sodium, 757–758
- Crotamiton, 228
- Cruex. *See* Undecylenic acid
- Cryptoxanthin, 919–921, 919*f*, 920*t*
- Crysticillin. *See* Penicillin G procaine
- Crystodigin. *See* Digitalis
- CT. *See* Computed tomography
- CTX. *See* Cyclophosphamide
- Cuemid. *See* Cholestyramine resin
- Curare/curare alkaloids, 599–601
- Curariform activity, 599–605, 602*f*
 synthetic compounds with, 601–605, 602*f*
- Cushing syndrome, 859
- Cutaneous mycoses, 192–193, 192*t*–193*t*
 topical agents for, 194–196
- Cutivate. *See* Fluticasone propionate
- Cyanocobalamin, 951–954, 952*f*–953*f*
- Cyanokit. *See* Hydroxocobalamin

- Cyclacillin, 268
 Cyclic AMP (cAMP), 561–563
 in platelet aggregation, 657, 657f
 in smooth muscle relaxation, 618–619, 619f
 Cyclic GMP (cGMP), in smooth muscle relaxation, 618–619, 619f
 Cyclizine hydrochloride, 747
 Cyclizine lactate, 747
 Cyclizine lactate injection. *See* Cyclizine lactate
 Cyclizines. *See* Piperazine antihistamines
 Cycloalkane anesthetics, structure–activity relationships of, 712–713, 712f
 Cyclocort. *See* Amcinonide
 Cycloguanil, 254–255, 254f
 Cyclogyl. *See* Cyclopentolate hydrochloride
 Cycloheximide, 297, 335
 Cyclooxygenase (COX, COX-1, COX-2)
 acetaminophen interaction with, 804–805, 805f
 aspirin binding to, 796
 celecoxib binding to, 795, 795f
 enzymatic structure of, 794
 in inflammation, 792–793, 793f
 inhibition of, 627–628
 NSAID binding to, 794–795, 795f
 piroxicam and meloxicam binding to, 795–796, 796f
 potential COX-3 isoenzyme of, 804–805, 805f
 Cyclooxygenase inhibitors, 872
 conventional nonselective, 798–803, 799f, 801f–802f
 selective COX-2 inhibitors, 795, 795f, 803, 804f
 Cyclooxygenase pathway, 870–871, 870f
 Cyclopentolate hydrochloride, 588–589
 Cyclopentylpropionate, 829f
 Cyclophosphamide, 360, 361f–362f, 369
 metabolism of, 71–73
 Cycloplegic drugs, 583–584
 Cyclopropane, 712f, 713
 Cycloserine, 215, 219, 260t
 CYFOS. *See* Ifosfamide
 Cyclohexane oxide, metabolism of, 51
 Cylert. *See* Pemoline
 Cymbalta. *See* Duloxetine
 Cyproheptadine, 740t
 conjugation of, 90–91
 metabolism of, 53–54, 64, 66
 Cyproheptadine hydrochloride, 752
 Cyproterone acetate, 851f
 Cytadren. *See* Aminoglutethimide
 Cytarabine, 340, 375f, 380–381
 Cytochrome P450
 drug biotransformation role of, 45–47, 45t, 46f–47f
 drug–drug interactions, 106–108, 107t
 Cytokines
 rDNA-derived, 908t–909t, 910–911
 recombinant, 136–138, 136t, 137f
 Cytomel. *See* Liothyronine sodium
 Cytosar-U. *See* Cytarabine
 Cytosine arabinoside. *See* Cytarabine
 Cytotec. *See* Misoprostol
 Cytovene. *See* Ganciclovir
 Cytosan. *See* Cyclophosphamide
- D**
 D4T. *See* Stavudine
 DA. *See* Dopamine
 Dacarbazine, 366–367, 367f–368f, 371
 DACH-platinum. *See* Oxaliplatin
 Daclizumab, 148
 Dactinomycin-D, 384, 384f, 388
 Daidzein, 830f
 Dalfopristin/quinupristin, 322–323
 Dalmene. *See* Flurazepam hydrochloride
 4-DAMP. *See* 4-Diphenylacetoxy-N-methylpiperidine
 Danazol, 849f, 851
 Dantrium. *See* Dantrolene
 Dantrolene, metabolism of, 84
 Dapsone
 acetylation of, 97, 100
 antileptotic activity of, 239–240
 antitubercular activity of, 215
 metabolism of, 70–71
 Darbid. *See* Isopropamide iodide
 Darenthin. *See* Breythium tosylate
 Daricon. *See* Oxyphencyclimine hydrochloride
 Darifenacin hydrobromide, 594–595
 Darvocet. *See* Propoxyphene
 Darvocet-N. *See* Propoxyphene
- Darvon. *See* Propoxyphene
 Darvon-N. *See* Propoxyphene
 Dasatinib, 404f, 405
 Database searching and mining, 37–38, 37f–38f, 38t
 Daughter nucleide, 414
 Daunomycin. *See* Daunorubicin hydrochloride
 Daunorubicin hydrochloride, 385, 385f, 388
 metabolism of, 82
 Daxolin. *See* Loxapine
 Daypro. *See* Oxaprozin
 DCF. *See* Pentostatin
 DDAVP. *See* Desmopressin acetate
 ddCyd. *See* Zalcitabine
 ddl. *See* Didanosine
 DDP. *See* Cisplatin
 DDT. *See* Dichlorodiphenyltrichloroethane
 Deamidation, of recombinant proteins, 132
 Deazapyrimidine nucleosides, 378
 Debrisoquin, metabolism of, 55f
 Decamethonium, 559–560
 Decapryn Succinate. *See* Doxylamine succinate
 Decay, of radionuclides, 413
 Decitabine, 375f
 Declomycin. *See* Demeclocycline
 Definity. *See* Perflutren
 Degarelix acetate, 699t, 700f, 701
 Dehydrated ethanol, 182
 Dehydrocholic acid, 822t
 Dehydroemetine, 222
 Dehydroepiandrosterone (DHEA), 821f, 847
 Delavirdine, 348
 Demecarium, 572t
 Demecarium bromide, 575
 Demeclocycline, 302t, 305t, 306–307
 Demerol. *See* Meperidine
 4-Demethoxydaunomycin. *See* Idarubicin hydrochloride
 Demser. *See* Metyrosine
 Denaturation, 882–883
 Denatured alcohol, 181
 Denileukin difitox, 142
 Denosumab, 710
 Denvir. *See* Penciclovir
 2'-Deoxycoformycin. *See* Pentostatin
 Deoxycorticosterone, 858t
 11-Deoxycorticosterone, 855, 856f
 Deoxystreptomycin, 298
 6-Deoxytetracycline, 302, 304
 Depacon. *See* Valproic acid
 Depakene. *See* Valproic acid
 Depakote. *See* Valproic acid
 Depolarization, of neuronal membrane, 719–720, 719f
 Depolarizing ganglionic blocking agents, 597–598
 Depolarizing neuromuscular blocking agents, 600
 Depo-Provera, 843t, 845
 Depressant-intoxicant, 517
 Dermatophytoses, 192–193, 192t
 topical agents for, 194–196
 DES. *See* Diethylstilbestrol
 Desenex. *See* Undecylenic acid
 Desensitization, 600
 Desflurane, 712f, 712t, 713, 715
 Desipramine hydrochloride, 511
 conjugation of, 90–91
 metabolism of, 8
 Desloratadine, 740t–741t, 755
 Desloreline acetate, 698, 698f
 Desmopressin, 895
 Desmopressin acetate (DDAVP), 896, 896t
 Desogestrel, 839f, 840
 Desonide, 857f, 862
 DesOwen. *See* Desonide
 Desoximetasone, 857f, 862
 Desoxy. *See* Methamphetamine hydrochloride
 Desulfuration, 75
 Desyrel. *See* Trazodone
 Detoxication, 43
 Detoxification, 43
 Detrol. *See* Tolterodine
 Dexamethasone, 857f, 858t, 862
 Dexbrompheniramine maleate, 750
 Dexchlorpheniramine maleate, 740t, 745
 Dextansoprazole, 30
 Dexamethylphenidate, 30
 Dextroamphetamine phosphate, 30, 507
 Dextroamphetamine sulfate, 507
- Dextromethorphan, 30, 31f, 786
 metabolism of, 63, 65
 Dextropropoxyphene, 31f
 Dextrothyroxine sodium, 650
 DFDC. *See* Gemcitabine
 DGD. *See* Diacylglycine decarboxylase
 DHAD. *See* Mitoxantrone hydrochloride
 DHEA. *See* Dehydroepiandrosterone
 DHPG, 341–342
 DHS. *See* Dopamine hypothesis of schizophrenia
 DiaBeta. *See* Glyburide
 Diabetes, 900
 glucagon in, 902
 hypoglycemics for, 659–663
 nonsteroidal therapies for, 666–695
 amylin analogs, 689–690, 689f
 biguanides, 685–687, 685f–686f
 glinides, 668–681, 670f–672f, 673t, 674f–680f, 676t
 glucose elevating agents, 694–695, 696f
 α -glucosidase inhibitors, 662–663, 687–689, 687f–688f
 incretin system modulating agents, 690–694, 690f, 693f–695f
 insulins and modified insulins, 667–668, 667f, 668t–669t
 sulfonylureas, 659–661, 668–681, 670f–672f, 673t, 674f–680f, 676t
 thiazolidinediones, 662, 681–685, 682f–685f, 684t
 Diabinese. *See* Chlorpropamide
 Diacylglycine decarboxylase (DGD), 945, 946f
 Diafen. *See* Diphenylpyraline hydrochloride
 Diagnostic imaging agents. *See* Radiopharmaceuticals
 Diamicon. *See* Glucilazide
 cis-Diaminedichloroplatinum. *See* Cisplatin
 Diaminocyclohexane platinum. *See* Oxaliplatin
 Diapid. *See* Lyppressin
 Diastase, 890
 Diastat. *See* Diazepam
 Diastereomeric, 30
 Diatrizoate, 433
 Diazepam, 110, 446f, 447, 501, 501f
 metabolism of, 49, 58–59, 70, 72
 metabolites of, 111
 Diazohydroxide, 365
 Diazomethane, 365, 366f–367f
 Diazoxide, 645, 695, 696f
 Dibenzocycloheptane antihistamines, 752–753, 753f
 Dibenzocycloheptane antihistamines, 740t, 752–753, 753f
 Dibenzodiazepines. *See* Benzazepines, dibenzoxazepines, and dibenzodiazepines
 Dibenzoxazepines. *See* Benzazepines, dibenzoxazepines, and dibenzodiazepines
 Dibenzylamine. *See* Phenoxybenzamine
 Dibucaine, 729
 Dichlorodiphenyltrichloroethane (DDT), for mosquito control, 244–245
 Dichloroisoproterenol, 550
 2,4-Dichloronitrobenzene, conjugation of, 95–96
 Diclofenac, 794t, 795, 802–803, 802f
 Dicloxacillin sodium, 269t, 271
 Dicumarol, 657–658
 Dicyclomine hydrochloride, 589
 Didanosine, 344
 Didrex. *See* Benzphetamine hydrochloride
 Didrone1. *See* Etidronate disodium
 Diethazine, 460
 Diethylcarbamazepine citrate, 225
 Diethylenediamine, 225
 Diethyl ether, 713
 Diethylpropion hydrochloride, 506t, 508
 metabolism of, 82
 Diethylstilbestrol (DES), 27, 829–830, 830f–831f
 metabolism of, 54–55, 56
 Diethylthiocarbamic acid, conjugation of, 90–91
 Diflorasone diacetate, 857f, 862
 Diflucan. *See* Fluconazole
 Diflunisal, 797f, 798
 Difluprednate, 860f, 862
 Digitalis, 646
 Digitalis glycosides, 645–647
 Digital radiography, 430
 Digitoxigenin, conjugation of, 97–98
 Digoxin, 646
 Dihydroartemisinin, 252f

- Dihydrofolate reductase inhibitors, 239
Dihydropyrimidine dehydrogenase (DPD), 375, 377f
Dihydrotaurochsterol, 927t, 928f
5 α -Dihydrotestosterone, 821f, 847, 848f, 852, 853f
1,25-Dihydroxycholecalciferol, in calcium regulation, 708–709, 709f
Dihydroxyphenylacetic acid (DOPAC), 472, 473f
Diiodohydroxyquin, 222
Diketo, 352
Dilantin. *See* Phenytoin; Phenytoin sodium
Dilaudid. *See* Hydromorphone
Diloxanide, 220–221
Diltiazem hydrochloride, 625, 625f
 as antiarrhythmic, 637
 as vasodilator, 623–625, 623t, 625f
Dimenhydrinate, 742–743
Dimercaprol, 224
Dimetane. *See* Brompheniramine; Brompheniramine maleate
Dimethindene maleate, 751
Dimethisterone, 838t
2,5-Dimethoxy-4-methylamphetamine (DOM), 516
1-(2,5-Dimethoxy-4-methylphenyl)-2-aminopropane, metabolism of, 69
Dimethyl-4-phenylpiperazinium (DMPP), 559–560
7,12-Dimethylbenz[*a*]anthracene, metabolism of, 52–53
Dimethylbenzylammonium chloride, analogues of, 186, 187t
2,5-Dimethyl-dicyanoquinonediimine (DMDA), 516
Dimethyl sulfoxide (DMSO), metabolism of, 76, 78, 86
Dimethyltryptamine, 516
5,7-Dinitroindazole, 110–111
Dinoprost trimethamine, 878
Diodoquin. *See* Iodoquinol
Diovan. *See* Valsartan
Dipeptidyl peptidase type 4 (DPP-4) inhibitors, 690–694, 690f, 693f–695f
Diphenyl methylsulfate, 593, 595
Diphenhydramine, 590, 740t–741t
 conjugation of, 94, 96
 metabolism of, 63–64
Diphenhydramine citrate, 742
Diphenhydramine hydrochloride, 742
Diphenhydramine tannate, 742
Diphenidol, metabolism of, 64, 66
Diphenoxylate, 787, 787f
 metabolism of, 86–87
4-Diphenylacetoxy-*N*-methylpiperidine (4-DAMP), 567, 568f
Diphenylheptanes, 788–789, 788f–789f
Diphenylpyraline hydrochloride, 744
Dipivalyl epinephrine. *See* Dipivefrin
Dipivefrin, 535
Dipole–dipole interactions, 28, 28f
Dipyridamole, 628
Diquinol. *See* Iodoquinol
Direct effect of radiation damage, 417
Dirithromycin, 312–313
Disalcid. *See* Salsalate
Disease-modifying antirheumatic drugs (DMARDs), 806–809, 807f
Disinfectant, 180
 classification of, 180, 181t
 evaluation of effectiveness of, 180–181
 improper use of, 181
 phenol coefficient of, 183
Disopyramide phosphate, 633
 metabolism of, 63–64
Dispermin. *See* Piperazine
Dissociative agents, 517
Disulfiram, metabolism of, 84–85
DMARDs. *See* Disease-modifying antirheumatic drugs
DMDA. *See* 2,5-Dimethyl-dicyanoquinonediimine
DMDR. *See* Idarubicin hydrochloride
DMP-850, 350–351
DMP-851, 350
DMPP. *See* Dimethyl-4-phenylpiperazinium
DMSO. *See* Dimethyl sulfoxide
DNA
 cloning of, 123, 123f
 expression of, 127
 strategies for, 126, 126t
 manipulation of, 127–128, 128f
 protein production, 121–122, 122f
DNA ligases, 124, 909
DNA microarrays, 151–152
DNA polymerase inhibitors, 339–343
DNA viruses, 331, 331t–332t, 335
DNM. *See* Daunorubicin hydrochloride
DNR. *See* Daunorubicin hydrochloride
Dobutamine, 110–111, 540, 647
 methylation, 102–103
Dobutrex. *See* Dobutamine
Docetaxel, 398–399, 398f
Docking programs, 35
Dofetilide, 636
Dolobid. *See* Diflunisal
Dolophine. *See* Methadone
Dolorex. *See* Salicylamide
DOM. *See* 2,5-Dimethoxy-4-methylamphetamine
Domagk, Gerhard, 187, 228–229
Donepezil, 573, 575–576
Donitriptan, 813, 813f
DOPAC. *See* Dihydroxyphenylacetic acid
Dopamine (DA), 24, 471–472, 472f
 agonists, 475–477
 ergot derivatives, 475–476
 nonergot derivatives, 476–477
 as antihypertensive, 647
 ganglionic stimulation by, 597, 597f
 levodopa/carbidopa, 474
 MAO-B inhibitors, 474–475
 metabolism of, 472, 473f
 methylation, 102
 Parkinson disease and, 473–474
 pathways of, 472, 473f
 receptors, 471–472, 472f
 storage and release of, 471, 472f
 as sympathomimetic, 534–535
 synthesis of, 471, 472f
 transporter, 472
Dopamine hypothesis of schizophrenia (DHS), 478
Dopaminergic signaling agents, 471–488
 antipsychotic drugs, 478–488
 dopamine, 471–472, 471f–472f
 Parkinson disease, 473–478
Dopram. *See* Doxapram hydrochloride
Doral. *See* Quazepam
Doriden. *See* Glutethimide
Dornase alpha, 888t, 889, 909t, 910
Dorzolamide, computer-aided design for, 34–35, 34f–35f
Dostinex. *See* Cabergoline
Doxacurium chloride, 596, 602–603
Doxapram hydrochloride, 504–505
Doxazosin, 547–548, 641
Doxepin hydrochloride, 27, 512, 741t
Doxercalciferol, 709, 709f, 927t, 928f
Doxorubicin hydrochloride, 385, 385f, 388
Doxycycline, 246t–247t, 251–252, 302, 302t, 305t, 307
Doxylamine succinate, 743
DPD. *See* Dihydropyrimidine dehydrogenase
DPP-4 inhibitors. *See* Dipeptidyl peptidase type 4 inhibitors
Dramamine. *See* Dimenhydrinate
Drixoral. *See* L-(+)-Pseudoephedrine
Droperidol, 466, 483
Drospirenone, 839f, 840–841
Drotrecogin alfa, 144
Droxia. *See* Hydroxyurea
Drug biotransformation
 asymmetric center and, 109–110
 cytochrome P450 role in, 45–47, 45t, 46f–47f
 sites of, 45
Drug design
 acid–base properties, 12–17
 advances in, 1–2
 biotechnology and, 119–121
 new targets for, 128–129, 129t
 computer-aided, 17–24
 drug distribution in, 3–11, 4f
 eicosanoids, 872, 873f, 874t–875t
 Web pages, 40
Drug distribution, 3–11, 4f
 drug metabolism, 4f, 7–8
 excretion, 4f, 8
 oral administration, 3–5
 parenteral administration, 4f, 5–6
 pK_a values and, 16–17, 16f–17f
 protein binding, 4f, 6–7
 receptors, 8–11
 summary for, 11
 tissue depots, 4f, 7
Drug metabolism, 4f, 7–8, 43–112
 conjugation reactions, 88–104
 acetylation, 97–102
 glucuronic acid, 89–91, 89f–90f, 89t
 with glycine, glutamine, and other amino acids, 93–94
 GSH or mercapturic acid conjugates, 94–97, 95f
 methylation, 102–104, 102f
 sulfate, 91–93, 92f
 drug biotransformation
 cytochrome P450 role in, 45–47, 45t, 46f–47f
 sites of, 45
 factors affecting, 104–112
 age differences, 104
 enzyme induction, 106–108, 107t
 enzyme inhibition, 108, 108f
 hereditary or genetic differences, 105
 miscellaneous, 108
 sex differences, 106
 species and strain differences, 104–105, 106f
 general pathways of, 43–44, 44t
 hydrolytic reactions, 86–88
 bioactivation of prodrugs, 87–88
 esters and amides, 86
 miscellaneous, 86–87
 overview of, 43
 oxidative reactions, 47–78
 alcohols and aldehydes, 76, 78
 at aliphatic and alicyclic carbon atoms, 59–60
 at allylic carbon atoms, 55–58
 aromatic hydroxylation, 47–52, 48f, 50f
 at benzylic carbon atoms, 55
 at carbon atoms α to carbonyls and imines, 58–59
 carbon–heteroatom systems, 60–61
 carbon–nitrogen systems, 62–73
 carbon–oxygen systems, 73–75
 carbon–sulfur systems, 75–76
 of olefins, 52–55
 other pathways, 78
 stereoselectivity, 110
 pharmacologically active metabolites, 111–112, 111t
 reductive reactions, 78–86
 aldehyde and ketone carbonyls, 80–83
 nitro and azo compounds, 83–84
 stereochemical aspects of, 108–111
Drug–receptor interactions
 efficacy and, 581
 intrinsic activity and, 581
 Paton rate theory of, 581
Drug receptors
 adverse reactions with, 10–11
 body locations of, 10–11
 cell membrane and, 10
 computer-generated representation of, 35, 35f
 drug distribution and, 8–11
 forces involved with, 25–26, 25t
 isolation and characterization of, 9–10
 side effects and, 9
 structure and, 9–10
Drug resistance
 alkylating agents, 359
 aminoglycosides, 295–296
 antibiotics, 260
 camptothecin, 393
 glucocorticoids, 856
 macrolides, 309
 penicillins, 265–267
 porins, 266–267
 sulfonamides, 235
 tetracyclines, 303, 308
 vinca alkaloids, 397
Drug screening
 high-throughput, 38, 38f
 novel strategies for, 129–131, 129f–130f
 in silico, 24
 virtual high-throughput screening, 25
Dryvax. *See* Smallpox vaccine
DTIC. *See* Dacarbazine
DTIC-Dome. *See* Dacarbazine
Dual-acting antihistamines, 759–760
Duetact. *See* Glimepiride; Pioglitazone
Duloxetine, 515
Duracillin. *See* Penicillin G procaine
Duragesic. *See* Fentanyl
Duraquin. *See* Quinidine gluconate
Duricef. *See* Cefadroxil

- Dutasteride, 852, 852f
 Dyes, 179, 188–189
 Dymelor. *See* Acetohexamide
 Dynabac. *See* Dirithromycin
 DynaCirc. *See* Isradipine
 Dynapen. *See* Diclloxacinilium sodium
 Dysrhythmias, 629–631
- E**
 E2020. *See* Donepezil
 EA 713. *See* Rivastigmine
 East African sleeping sickness, 221, 223–224
 Echinacea, 962–964, 963f–964f
 Echinocanadins, 206
 Echothiophate iodide, 572t, 578
 Econazole nitrate, 202
 Ecstasy. *See* 2,5-Dimethyl-dicyanoquinonediimine
 Eculizumab, 658
 EDCF. *See* Endothelium-derived contracting factor
 Edecrin. *See* Ethacrynic acid
 Ed-Flex. *See* Salicylamide
 EDRF. *See* Endothelium-derived relaxing factor
 Edrophonium chloride, 572t, 575–576, 601
 EES. *See* Erythromycin ethylsuccinate
 Efavirenz, 348
 Effexor. *See* Venlafaxine
 Efficacy, of drugs, 581
 Eflornithine, 223
 Efudex. *See* 5-Fluorouracil
 Ehrlich, Paul, 179
 Eicosanoids
 approved for human use, 876–877
 biological activities observed with, 868, 869t
 biosynthesis of, 869–871, 870f–871f
 degradation of, 872, 873f
 drug action mediated by, 872
 drug design for, 872, 873f, 874t–875t
 history of, 868–869, 869t
 receptors of, 875, 876t
 Elavil. *See* Amitriptyline hydrochloride
 Eldepryl. *See* Selegiline
 Electromagnetic radiation, 413, 417
 Electron capture, 414
 Electron volt, 413
 Elcatriptan, 812t, 813–814, 813f
 Eligard. *See* Leuprolide acetate
 Ellece. *See* Epirubicin hydrochloride
 Elocon. *See* Mometasone furoate
 Elspar. *See* Asparaginase
 Em. *See* Estramustine phosphate sodium
 EMCYT. *See* Estramustine phosphate sodium
 Emetine, 222
 Empirin. *See* Aspirin
 Emtricitabine, 346
 E-Mycin. *See* Erythromycin
 Enablex. *See* Darifenacin hydrobromide
 Enalapril, as prodrug, 5
 Enalapril maleate, 610, 611f, 612t
 Enantiomers, drug metabolism of, 109
 Enclomiphene, 833f
 Endocannabinoids, 517
 Endocrine disorders, nonsteroidal therapies for. *See* Nonsteroidal therapies for hormone-related disorders
 Endocytosis, in viral infection, 334
 Endometrial cancer, progestins and, 839
 Endometriosis, 851
 Endomorphins, 779
 β -Endorphin, 778, 893
 Endothelin receptor antagonists, 638–639
 Endothelium-derived contracting factor (EDCF), 562
 Endothelium-derived relaxing factor (EDRF), 562
 Enflurane, 712f, 712t, 713, 715
 Engerix-B, 145
 Enjuvia. *See* Synthetic conjugated estrogens
 Enkephalins, 778, 779f, 893
 Enoxacin, 208, 208t, 211
 Entacapone, 477–478, 524
 Entamoeba histolytica, 220
 Entocort. *See* Budesonide
 Enzactin. *See* Triacetin
 Enzyme(s), 880, 885–890, 886f–887f, 888t
 biotin-dependent, 947, 947t
 classification of, 887–888
 folic acid-dependent, 949, 951t
 induction, 106–108, 107t
 inhibition, 108, 108f
 rDNA-derived, 908t–909t, 910
 recombinant, 142–145
 structure–function relationships of, 885–887, 886f–887f
 synthesis and secretion of, 887
 vitamin B₁₂ and, 953, 953f
 zymogens, 887
 Eosinophils, 157, 157f
 Ephedra, 962, 968–969, 969f
 Ephedrine, 30, 533, 544–545, 696f, 969
 metabolism of, 83
 Epi-ADR. *See* Epirubicin hydrochloride
 4'-Epiadriamycin. *See* Epirubicin hydrochloride
 Epilepsy
 description of, 491
 initial drug therapy for, 491–492
 prevalence of, 491
 seizure classification, 491–492
 Epinephrine, 30, 474, 523–524, 524f
 in local anesthetics, 724–725
 as sympathomimetic, 532–535
 Epipodophyllotoxins, 389–391, 390f–391f
 Epirubicin hydrochloride, 385, 385f, 388–389
 Epiritracyclines, 302, 304
 Epitope tagging, 128
 Eplerenone, 615, 864, 864f
 Epoetin alfa, 908t, 912
 Epogen. *See* Epoetin alfa
 Epoprostenol. *See* Prostacyclin
 Epothilones, 399–400, 399f, 400t
 Eptifibatid, 629
 Equanal. *See* Meprobamate
 Equilibrium potential, of neuronal membrane, 719
 Equine estrogens, 828–829, 829f
 Equalan. *See* Ivermectin
 Ergocalciferol, 709, 709f, 923–924, 925f, 927t, 928f
 bioactivation of, 924, 926f
 Ergosterol
 in lipid membrane, 193, 194f
 photoactivation of, 923, 925f
 Ergot derivatives, 475–476
 Erlotinib hydrochloride, 403, 404f, 405
 ERs. *See* Estrogen receptors
 Ertapenem, 325
 Erypar. *See* Erythromycin stearate
 EryPed. *See* Erythromycin ethylsuccinate
 Erythryl tetranitrate, diluted, 620t, 621
 Erythrocin. *See* Erythromycin
 Erythrohydrobupropion, 515
 Erythromycin, 260t, 308–310
 Erythromycin estolate, 311
 Erythromycin ethylsuccinate, 311
 Erythromycin gluceptate, 311
 Erythromycin lactobionate, 311
 Erythromycin stearate, 310
 Erythromycinyclamine, 312–313
 Erythropoietin, 908t, 911–912
 Erythropoietin alfa, 137
 Escitalopram, 31f
 Eskazole. *See* Albendazole
 Esmolol, 552–553, 553f–554f
 Esomeprazole, 765, 767t, 768, 769t
 Esomeprazole magnesium, 769–770
 Essential hypertension, 637–638
 Esterified estrogens, 828–829, 829f, 832
 Ester local anesthetics, 725–726
 Estrace. *See* Estradiol
 Estradiol, 820f–821f, 822t, 827, 829f, 831, 831f
 17 β -Estradiol, 820f
 Estradiol benzoate, 822t
 Estramustine phosphate sodium, 407f, 410
 Estril, 827, 829f, 832
 Estrogen(s)
 aromatase inhibitors, 835–837, 835f
 biological activities of, 828
 biosynthesis of, 827
 endogenous, 827
 in HRT, 846–847, 846t
 metabolism of, 827–828, 828f
 in osteoporosis, 705–706
 SERMs and antiestrogens, 705, 832–835, 833f
 as sex hormones, 827–837, 828f–831f, 833f, 835f
 structural classes of, 828–831, 829f–831f
 therapeutic uses of, 831
 Estrogen receptors (ERs), 825
 Estrone, 821f, 827, 829f, 831–832, 835, 835f
 Estrumate. *See* Cloprostenol sodium
 Eszopiclone, 451
 Ethacrynic acid, 25
 conjugation of, 97–98
 Ethambutol, 215–217
 Ethanol, 181–182
 as sedative–hypnotics, 455
 Ethanalamine antihistamines, 740t, 741–744, 741f
 Ethchlorvynol, 455–456
 Ether, metabolism of, 75
 Ethinyl estradiol, 829f, 832
 Ethiodized oil, 433
 Ethiodol. *See* Ethiodized oil
 Ethionamide, 215–216
 Ethisterone, 838f, 838t
 Ethmozine. *See* Moricizine
 Ethopropazine, 460
 Ethopropazine hydrochloride, 593, 595
 Ethosuximide, 500, 501f
 Ethril. *See* Erythromycin stearate
 Ethylenediamine antihistamines, 740t, 744–746, 745f
 Ethylene oxide, 182
 N-Ethylnormorphine, metabolism of, 63, 65
 Ethylparaben, 190
 Ethynodiol diacetate, 838f, 840
 Etidocaine, 728
 Etidronate disodium, 706, 707t, 708
 Etodolac, 799f, 800
 Etomidate, 717
 Etonogestrel, 839f, 840
 Etoposide, 390–391, 390f
 Etretnate, half-life of, 6
 Eucatropine hydrochloride, 588–589
 Eugenol, 184
 Euphoriant-stimulant, 517
 Eurax. *See* Crotamiton
 Eutamide, 221
 Evamist. *See* Estradiol
 Evista. *See* Raloxifene
 Evoxac. *See* Cevimeline hydrochloride
 Excedrin. *See* Acetaminophen
 Excegran. *See* Zonisamide
 Excitation, of muscle, 622, 622f
 Excitatory glutamate-mediated receptors, anticonvulsants and, 494
 Excretion, drug distribution and, 4f, 8
 Exelderm. *See* Sulconazole nitrate
 Exelon. *See* Rivastigmine
 Exemestane, 835f, 836
 Xenatide, 690f, 691
 Exenatide LAR, 692
 Exocytosis, viruses, 336
 Extended insulin zinc suspension, 901, 901t–902t
 Extended oral contraceptive therapy, 844
 Extended-spectrum penicillins, 267–268
 Exuber. *See* Human insulin, recombinant
 Ezetimibe, 652
- F**
 Factor IX, recombinant, 656
 Factors. *See* Clotting factors
 Factor VIIa, recombinant, 656
 Factor VIII, recombinant, 143–144, 656
 Famciclovir, 342–343
 Famotidine, 762t, 763–764, 767t
 2-F-ara-AMP. *See* Fludarabine
 Fareston. *See* Toremifene
 Farnesyl diphosphate synthase (FPPS), 708
 Faslodex. *See* Fulvestrant
 Fat-soluble vitamins, 917–935
 vitamin A, 917–923
 vitamin D, 917–923
 vitamin E, 927–931
 vitamin K, 932–935
 Fatty acids
 as antifungals, 194
 essential, 686, 689t
 supplements, 875–876
 Febuxostat, 809f, 811
 Felbamate, 498–499, 499f
 Felbatol. *See* Felbamate
 Feldene. *See* Piroxicam
 Felodipine, 623t, 626
 Felypressin, 896
 Femara. *See* Letrozole

- Femguard. *See* Triple sulfa
Femhrt, 846t
Femstat. *See* Butoconazole nitrate
Fenamates, 801–803, 802f
Fenazox. *See* Amfenac
Fenfluramine hydrochloride, 506t, 508
Fenofibrate, 650
Fenopropfen, 801, 801f
 conjugation of, 90–91
Fenoterol, 541
Fentanyl, 787f, 788
Feridex. *See* Ferumoxides
Ferrihemoglobin, 70
Ferumoxides, 437–438
Ferumoxsil, 438
Feverfew, 964–965, 965f
Fexofenadine hydrochloride, 740t–741t, 753–755
Fibrin, 654–655, 655f
Fibrinogen, 654–655, 654t, 655f
Fibrinogen receptor, 628–629
Filgrastim, 908t, 912
Finasteride, 852, 852f–853f
Firing threshold, of neurons, 720
First-dose phenomenon, 548
“Fish oil” capsules, 875–876
Five-atom rule, 567
Fixed combination contraceptive tablets, 842t, 844
Flagyl. *See* Metronidazole
Flarex. *See* Fluorometholone
Flaxedil. *See* Gallamine triethiodide
Flecainide acetate, 635
Fleming, Alexander, 258
Fligrastrim, 137–138
Flomax. *See* Tamsulosin
Flonase. *See* Fluticasone propionate
Florinef acetate. *See* Fludrocortisone acetate
Flovent. *See* Fluticasone propionate
Floxin. *See* Ofloxacin
Floxin IV. *See* Ofloxacin
Floxuridine, 375f, 381
Fluconazole, 204–205
Flucytosine, 196, 196f
Fludara. *See* Fludarabine
Fludarabine, 378, 382
Fludrocortisone acetate, 856f, 858t, 861
Fluke infections, 224–225
Flumadine. *See* Rimantadine
Flumazenil, 444–445
Flunisolide, 860f, 862–863
Fluocinolone acetonide, 857f, 858t, 862
Fluocinonide, 858t
Fluorine radiopharmaceuticals, 418–419
2-Fluoro-2-deoxy-D-glucose (¹⁸F), 418–419
Fluorobutyrophenones, 465–468, 465f
 structure and activity of, 465, 465f
5-Fluorocytosine, 196
Fluoroxyuridine. *See* Floxuridine
Fluorometholone, 860f, 862
Fluor-Op. *See* Fluorometholone
Fluoroplex. *See* 5-Fluorouracil
Fluoroscopy, 431, 431f
5-Fluorouracil, 40, 40f, 372–373, 375, 375f–377f, 379–380
Fluoxetine, 513
Fluoxymesterone, 849f, 850
Fluphenazine hydrochloride, 461t, 463, 480t, 483t
Flurandrenolide, 857f–858t, 862
Flurazepam hydrochloride, 446f, 448
 metabolism of, 58–59, 71–72
Flurbiprofen, 801, 801f
Flurofelbamate, 498–499, 499f
Fluoroxene, metabolism of, 55–56
Flutamide, 851–852, 851f
Fluticasone 17 α -furoate, 860f
Fluticasone propionate, 860f, 862–863
Fluvastatin, 653
Fluvoxamine, 514
FML. *See* Fluorometholone
Folate reductase inhibitors, sulfonamides and, 235
Folates, 379, 380f–381f
Folex. *See* Methotrexate
Folic acid, 40, 40f, 379, 380f–381f, 948–951, 949f–950f, 951t
Follicle-stimulating hormone (FSH), 696–697, 699, 826–827, 826f, 890, 894
 recombinant, 136
Foradil. *See* Formoterol
Forhstal Maleate. *See* Dimethindene maleate
Formaldehyde solution, 182–183
Formalin, 182–183
Formic acid, 182–183
Formoterol, 542
Formulation, of recombinant protein, 131
Fortamet. *See* Metformin
Fortaz. *See* Ceftazidime sodium
Forteo. *See* Teriparatide injection
Fosamax. *See* Alendronate sodium
Fosamprenavir, 350
Foscarnet sodium, 343
Foscavir. *See* Foscarnet sodium
Fosfomycin tromethamine, 323–324
Fosinopril sodium, 611f, 612, 612t
Fosphenytoin, 495–497, 496f
FPPS. *See* Farnesyl diphosphate synthase
Froben. *See* Flurbiprofen
Frova. *See* Frovatriptan
Frovatriptan, 812t, 813–814, 813f
FSH. *See* Follicle-stimulating hormone
5-FU. *See* 5-Fluorouracil
FUDR. *See* Floxuridine
Fulvestrant, 832, 833f, 834
Functional expression cloning, 126, 126t
Functional genomics, 151, 151f
Functionalization, in drug metabolism, 43–44, 44t
Fungacetin. *See* Tricactin
Fungal infections
 cutaneous, 192–193, 192t–193t
 historical perspective on, 191–192
 opportunistic, 192
 subcutaneous, 193, 193t
 superficial, 193t
 systemic, 192, 193t
 tissue reaction to, 193–194
Fungizone. *See* Amphotericin B
Furacin. *See* Nitrofurazone
Furadantin. *See* Nitrofurantoin
Furamide, 221
Furazolidone, 213
Furoxone. *See* Furazolidone
Fusion protein, 128, 128f
- ## G
- GABA
 degradation inhibition, 494
 enhancement of, 493–494, 493f
 reuptake inhibition, 494
GABA_A receptors, 444–451
 alcohols and carbamate derivatives, 455–456
 aldehydes and derivatives, 456–457
 amides and imides, 454–455
 anticonvulsants and, 493–494
 barbiturates, 452–454, 453f, 454t
 benzodiazepines, 447–451
 binding to, 444–445
 general anesthetic interaction with, 713, 717
 melatonin receptor agonist, 451–452
 modulation of, 494
 pentylene-tetrazole, 504
 picrotoxin, 504
 subunits of, 444
Gabapentin, 493, 498, 498f
GABA system, 444
Gabitril. *See* Tiagabine
Gadobenate dimeglumine, 438
Gadodiamide, 438
Gadolinium, for MRI, 437
Gadopentetate dimeglumine, 438–439
Gadoteridol, 438–439
Gadoversetamide, 439
Galantamine, 573, 576
Galegine, 658
Gallamine triethiodide, 598, 601–603
Gallium citrate (⁶⁷Ga), 419
Gallium radiopharmaceuticals, 419
Galvus. *See* Vildagliptin
Gamma camera, 417–418, 417f
Gamma (γ) rays, 413, 417
Ganciclovir, 341–342
Ganglionic blocking agents, 596–599, 597f, 597t
 depolarizing, 597–598
 nondepolarizing competitive, 598
 nondepolarizing noncompetitive, 598–599
 organ-specific effects of, 597, 597f
Ganglionic stimulation, 596–597, 597f
Ganirelix diacetate, 699t, 700–701, 700f
Gantanol. *See* Sulfamethoxazole
Gantrisin. *See* Sulfisoxazole
Garamyacin. *See* Gentamicin sulfate
Garlic, 967–968, 967f
Gastric acid hypersecretory disease, 760–773, 761f, 762t, 766f, 766t–767t, 768f, 769t
Gastric acid secretagogues, 903
Gastric acid secretion, histamine role in, 736, 760, 761f
Gastric inhibitory peptide (GIP), 904
Gastrin, 903
Gastrointestinal complications, of NSAIDs, 793, 794t, 795
Gastrointestinal hormones, 903–904
GastroMARK. *See* Ferumoxsil
Gauche conformations, 28, 28f
GDP-binding proteins. *See* Guanosine diphosphate-binding proteins
Gefitinib, 403, 404f, 405
Gelatin, 884, 884t
Gelatin film, 884, 884t
Gelatin sponge, absorbable, 884, 884t
Gelfilm. *See* Gelatin film
Gelfoam. *See* Gelatin sponge, absorbable
Gemcitabine, 375f, 378, 381–382
Gemfibrozil, 649–650
Gemtuzumab ozogamicin, 148
Gemzar. *See* Gemcitabine
GenBank, growth of, 119, 120f
Gene cloning. *See* Recombinant DNA technology
Gene expression, 151
General anesthesia, stages of, 711
General anesthetics
 inhaled, 711–716, 712t, 714f–716f
 injectable, 716–718, 717f–718f
Gene therapy, 153
Genetically engineered pathogens, vaccine, 166–167, 167f
Genetic engineering. *See* Recombinant DNA; Recombinant DNA technology
Genistein, 830f
Genomics, 150–152, 151f
 DNA microarrays, 151–152
 functional, 151, 151f
 informatics, 150–151
 pharmacogenomics, 152
 proteomics, 152
Gentamicin sulfate, 300
 inactivation of, 295–296
Gentian violet, 179, 189
Geocillin. *See* Carbenicillin indanyl sodium
Geodon. *See* Ziprasidone
Geometric isomers, 27
Geopen. *See* Carbenicillin disodium
Germicides, 180
 classification of, 180, 181t
 evaluation of effectiveness of, 180–181
 improper use of, 181
 phenol coefficient of, 183
 wound healing and, 180–181
Ginkgo biloba, 963, 969–970, 970f
Ginseng, 962, 970–971, 970f–971f
Ginsenosides, 970–971, 970f–971f
GIP. *See* Gastric inhibitory peptide; Glucose-dependent insulinotropic peptide
Girostan. *See* Thiotepta
Glandular muscarinic receptors, 562
Gla proteins, 933–934
Gleevec. *See* Imatinib mesylate
Gliadel. *See* Carmustine
Glibenclamide. *See* Glyburide
Gliclazide, 661, 671f, 677, 677f, 679
Glimepiride, 661, 670, 671f, 673t, 678f, 681
Glinides, 668–681, 670f–672f, 673t, 674f–680f, 676t
 acid–base and lipid partitioning character of, 672, 674, 676t
 biotransformation of, 676t, 679–680, 679f
 structure–activity relationships of, 674, 674f–676f
Glipizide, 660–661, 671f, 673t, 678f, 681
Gliquinone, 671f, 683f
Glisoxepide, 671f
Glitazones. *See* Thiazolidinediones
Global minimum, 32

- Globin zinc insulin injection, 901t
 Globulins, 883t, 906–907
 GLP-1, 690–692, 690f
 GlucaGen. *See* Glucagon, recombinant
 GlucaGen Diagnostic Kit. *See* Glucagon
 GlucaGen HypoKit. *See* Glucagon
 Glucagon, 901–903
 recombinant, 135, 694–695
 Glucocorticoid receptors (GRs), 825
 Glucocorticoids, 853–864, 854f–857f, 858t, 860f, 864f
 biological activities of, 855–856
 resistance to, 856
 structural classes of, 856–859, 856f–857f, 858t
 Glucophage. *See* Metformin
 Glucose-6-phosphate dehydrogenase deficiency,
 malaria and, 244
 Glucose-dependent insulinotropic peptide (GIP),
 690–691, 690f
 Glucose elevating agents, 694–695, 696f
 Glucose metabolism
 nonsteroidal therapies for disorders of, 666–695
 amylin analogs, 689–690, 689f
 biguanides, 685–687, 685f–686f
 glinides, 668–681, 670f–672f, 673t, 674f–680f,
 676t
 glucose elevating agents, 694–695, 696f
 α -glucosidase inhibitors, 662–663, 687–689,
 687f–688f
 incretin system modulating agents, 690–694,
 690f, 693f–695f
 insulins and modified insulins, 667–668, 667f,
 668t–669t
 sulfonylureas, 659–661, 668–681, 670f–672f,
 673t, 674f–680f, 676t
 thiazolidinediones, 662, 681–685, 682f–685f,
 684t
 by normal vs. ischemic myocardium, 618, 618f
 α -Glucosidase inhibitors, 662–663, 687–689, 687f–688f
 Glucotrol. *See* Glipizide
 Glucotrol XL. *See* Glipizide
 Glucovance. *See* Glyburide; Metformin
 Glucuronic acid conjugation, 89–91, 89f, 89t, 90f
 Glumetza. *See* Metformin
 Glustin. *See* Pioglitazone
 Glutamate, vitamin K and, 933, 934f
 Glutaraldehyde disinfectant solution, 183
 Glutathione, conjugation of, 94–95
 Glutathione reductase, inhibition of, 256, 256f
 Glutelins, 883t
 Glutethimide, 455
 enantiomers of, 109
 Glyburide, 660, 671f, 673t, 674, 674f, 676, 676f,
 678f, 681
 Glycopyrrolate, 589–590
 Glycylcyclines, 308
 Glycyrrhetic acid, 973–974, 973f
 Glycyrrhizin, 973–974, 973f
 Glynase. *See* Glyburide
 Gly-Oxide. *See* Carbamide peroxide topical solution
 Glyset. *See* Miglitol
 GMP. *See* Guanosine monophosphate
 GnRH. *See* Gonadotropin-releasing hormone
 Gold compounds, 807f, 808–809
 Gold sodium thiomalate, 807f, 808–809
 Gonadoliberin. *See* Gonadotropin-releasing hormone
 Gonadotropin-releasing hormone (GnRH), 695–701,
 696f, 697t, 698f, 699t, 700f, 826–827, 826f,
 890, 894
 Gonadotropin-releasing hormone agonists, 697t,
 698–699, 698f
 Gonadotropin-releasing hormone antagonists,
 699–701, 699t, 700f
 Gonadotropins, 695–701, 696f, 697t, 698f, 699t, 700f,
 726–827, 826f, 890, 894
 Gonal-F. *See* Follicle-stimulating hormone
 Goserelin, 698, 698f
 Gout, 809–811, 809f–810f
 GPIIb/IIIa receptors, 628–629
 G proteins, 560–563, 562f
 GR-69153, 293
 Gramlicidin, 319–320
 Grand mal seizure, 492
 Granulocytes, 156, 157f
 Grapefruit, drug metabolism and, 108, 108f
 GRF. *See* Growth-releasing factor
 Grifulvin. *See* Griseofulvin
 Grisactin. *See* Griseofulvin
 Griseofulvin, 199, 260t
 Gris-PEG. *See* Griseofulvin
 Ground state, 414
 Growth factors and receptors, in cancer, 401, 401t
 Growth hormone, 893–894
 Growth-releasing factor (GRF), 890
 GRs. *See* Glucocorticoid receptors
 GSK572016. *See* Lapatinib ditosylate
 GTP-binding proteins. *See* Guanosine triphosphate-
 binding proteins
 Guanabenz, 538–539
 Guanabenz acetate, 642
 Guanadrel, 531
 Guanadrel sulfate, 640–641
 Guanethidine, 531, 640
 Guanethidine monosulfate, 640, 640f
 Guanfacine, 538–539
 Guanfacine hydrochloride, 642
 Guanidine, 686f
 Guanosine, 342–343
 Guanosine diphosphate (GDP)-binding proteins, 562
 Guanosine monophosphate (GMP), in smooth muscle
 relaxation, 618–619, 619f
 Guanosine triphosphate (GTP)-binding proteins,
 560–562, 562f
 G-Well. *See* Lindane
 Gyne-Lotrimin. *See* Clotrimazole
- ## H
- H₁-antagonists. *See* Antihistamines
 H₁ receptors, 735–736, 736t
 structure–activity relationships at, 739, 739f, 740t
 H₂-antagonists. *See* Antihistamines
 H₂ receptors, 736, 736t
 H₃-receptor ligands. *See* Antihistamines
 H₃ receptors, 736, 736t
 H₄-receptor ligands. *See* Antihistamines
 H₄ receptors, 736, 736t
 HA acids, 15
 lipid barrier passage of, 16, 16f
 Haemophilus influenzae type B conjugate vaccine, 172
 Halazepam, 446f, 447
 Halazone, 186
 Halcinonide, 857f, 862
 Halcion. *See* Triazolam
 Haldol. *See* Haloperidol
 Haldol decanoate. *See* Haloperidol deconate
 Halfantrine, 246t–247t, 251f, 252
 Halobetasol propionate, 857f, 862
 Halogenation, of inhalational general anesthetics, 713
 Haloperidol, 465, 465f, 482, 482f, 483t
 conjugation of, 94, 96
 Haloperidol deconate, 482–483
 Haloproglin, 195
 Halotestin. *See* Fluoxymesterone
 Halotex. *See* Haloproglin
 Halothane, 712f, 712t, 714, 714f
 metabolism of, 78–79
 Hammett's constant, 20
 HAV. *See* Hepatitis A vaccines
 HBV. *See* Hepatitis B vaccines
 HC-3. *See* Hemicholinium
 hCG. *See* Human chorionic gonadotropin
 HCV. *See* Hepatitis C vaccines
 Heart disease
 HRT and, 847
 ischemic, 617–618, 618f
Helicobacter pylori, 760, 764
 Helixate. *See* Antihemophilic factor, recombinant
 Helminthic infections, 224–225
 Hemabate. *See* Carboxiprost tromethamine
 Hemagglutinin, 336
 Hematopoietic factors, rDNA-derived, 908t, 911
 Hematopoietic growth factors, 136–137, 136t, 137f
 Hemicholinium (HC-3), 563
 Hemoglobin, 906–907
 Hemoglobin C, malaria and, 244
 Hemophilia A, 656
 Hemophilia B, 656
 Hemophil M. *See* Antihemophilic factor
 Henderson-Hasselbalch equation, 12
 Heparin, 655, 657–658
 Hepatitis A vaccines (HAV), 170
 Hepatitis B vaccines (HBV), 171
 Hepatitis C vaccines (HCV), 171
 Hepatitis E vaccines (HEV), 171
 Hepatitis vaccines, 170–171
 Hepatobiliary aminodiacetic acids, 424
 Hepatobiliary iminodiacetic acids (HIDA), 425
 Hepatolite. *See* Technetium (^{99m}Tc) disofenin
 Hepatotoxicity, of acetaminophen and phenacetin,
 805–806, 806f
 Heptane antihistamines, 740t
 Herbal medicines, as anti-infective agent, 179
 Herbs. *See* Medicinal herbs
 Herceptin. *See* Trastuzumab
 Heroin, 783f, 784
 Herplex. *See* Idoxuridine
 Heteroarylacetic acids, 799–800, 799f
 Heteroarylpropanoic acids, 800–801, 801f
 Heterotopic ossification, 705
 HETP. *See* Hexaethyltetraphosphate
 Hetrazan. *See* Diethylcarbamazepine citrate
 HEV. *See* Hepatitis E vaccines
 Hexabrix. *See* Ioxaglate
 Hexachlorophene, 184
 Hexaethyltetraphosphate (HETP), 578
 Hexahydropyrazine, 225
 Hexahydrosiladifenidol (HHSiD), 567, 568f
 Hexalen. *See* Altretamine
 Hexamethonium, 559–560, 581, 596, 598
 Hexamethonium bromide, 598
 Hexamethonium chloride, 598
 Hexamethylenetetramine mandelate, 214
 Hexamethylmelamine. *See* Altretamine
 Hexamethylpropyleneamine oxime, 424
 Hexobarbital, metabolism of, 55, 58, 71–72, 86, 88
 Hexylresorcinol, 185
 HHSiD. *See* Hexahydrosiladifenidol
 Hibiclen. *See* Chlorhexidine gluconate
 High-density lipoprotein, 647–648
 High-osmolar contrast medium (HOCM), 432
 High-throughput screening, 38, 38f
 Himbacine, 567, 568f
 Hiprex. *See* Methenamine hippurate
 Hirudin, 144
 Hispril. *See* Diphenylpyraline hydrochloride
 Histadyl. *See* Methapyrilene hydrochloride
 Histamine, 733–737
 acetylation of, 100–101
 biosynthesis and distribution of, 733–734, 735f
 as chemical messenger, 733–737, 735f, 736t
 in gastric acid secretion, 760, 761f
 ionization of, 733, 734f
 metabolism of, 737, 738f
 methylation, 102
 pharmacological intervention and, 737
 physiologic functions mediated by, 735–737, 736t
 stereochemistry of, 733, 735f
 storage and release of, 734–735
 tautomerization of, 733, 734f
 termination of action of, 737, 738f
 Histamine H₁-antagonists. *See* Antihistamines
 Histamine H₂-antagonists. *See* Antihistamines
 Histamine H₃-antagonists. *See* Antihistamines
 Histamine H₄-antagonists. *See* Antihistamines
 Histamine receptors, 735–737, 736t
 structure–activity relationships at, 739, 739f, 740t
 Histone deacetylase inhibitors, 408–409, 409f
 Histones, 883t, 885
 Histrelin acetate, 697t, 698–699, 698f
 HMG-CoA reductase inhibitors, 652–654, 652f
 HMM. *See* Altretamine
 HOCM. *See* High-osmolar contrast medium
 Homatrocel. *See* Homatropine hydrobromide
 Homatropine hydrobromide, 587
 Homatropine methylbromide, 587
 Homology-based cloning, 126, 126t
 Homovanillic acid (HVA), 472, 473f
 Hormonal contraceptives. *See* Contraceptive agents
 Hormone(s), 890–906, 892t, 896t, 897f, 898t,
 901t–902t. *See also* Steroid hormone(s)
 angiotensins, 905
 gastrointestinal, 903–904
 gonadotropins, 695–701, 696f, 697t, 698f, 699t,
 700f, 726–827, 826f, 890, 894
 hypothalamic, 890–891
 neurohypophyseal, 895–896, 896t
 pancreatic, 897–903, 897f, 898t, 901t–902t
 parathyroid, 904–905
 in calcium regulation, 708–709

- Hormone(s) (*continued*)
 pituitary, 891–894, 892*t*
 placental, 895
 plasmakinins, 905–906
 rDNA-derived, 908*t*, 910
 recombinant, 134–136
 somatostatin, 890, 894–895
 thyroglobulin, 906
 thyroid, 663
 thyrotropin, 894
 Hormone-related disorders, nonsteroidal therapies for.
 See Nonsteroidal therapies for hormone-related disorders
 Hormone replacement therapy (HRT)
 with androgens, 848–849
 combined estrogen/progestin, 846–847, 846*t*
 estrogens in, 831
 Hormone therapy, for bone disease, 708–710, 709*f*
 hPL. *See* Human placental lactogen
 HPMPC. *See* Cidofovir
 hPTH. *See* Teriparatid injection
 HPV. *See* Human papillomavirus vaccine
 HRT. *See* Hormone replacement therapy
 5-HT_{1A} antagonists, 515
 5-HT_{1B/1D} receptors, triptan binding to, 811–814
 5-HT_{2A} antagonists, SSRIs and, 514–515
 Humalog. *See* Insulin lispro
 Humalog Kwipen. *See* Insulin lispro
 Humalog Mix. *See* Insulin lispro
 Humalog Mix Kwipen. *See* Insulin lispro
 Humalog pen. *See* Insulin lispro
 Human chorionamniotropin. *See* Human placental lactogen
 Human chorionic gonadotropin (hCG), 895
 Human deoxyribonuclease I, recombinant, 144–145
 Human growth hormone, recombinant, 135–136
 Human immunodeficiency virus entry inhibitors, 351
 Human immunodeficiency virus infection
 chemokine receptor binders for, 351
 combination antiviral therapy, 352
 entry inhibitors, 351
 gp41 fusion activity inhibitors for, 352
 integrase inhibitors, 352
 newer agents for, 346–352
 nonnucleoside reverse transcriptase inhibitors, 347–348
 protease inhibitors, 348–351
 reverse transcriptase inhibitors for, 343–346
 short-interfering RNA, 352
 vaccine for, 347
 Human immunodeficiency virus protease inhibitors, 348–351
 Human insulin, recombinant, 667–668, 667*f*, 668*t*–669*t*, 898, 900, 901*t*–902*t*
 Human papillomavirus vaccine (HPV), 171–172
 Human placental lactogen (hPL), 895
 Humate-P. *See* Antihemophilic factor
 Humatin. *See* Paramomycin sulfate
 Humatrope. *See* Somatropin, rDNA origin
 Humorsol. *See* Demecarium bromide
 Humulin. *See* Human insulin, recombinant
 Humulin 70/30. *See* Neutral protamine Hagedorn insulin
 Humulin 70/30 Pen. *See* Neutral protamine Hagedorn insulin
 Humulin N. *See* Neutral protamine Hagedorn insulin
 Humulin R. *See* Human insulin, recombinant
 Humulin R Pen. *See* Human insulin, recombinant
 HVA. *See* Homovanillic acid
 Hyaluronidase for injection, 888*t*, 889
 Hybridoma techniques, 146–147, 147*f*
 Hycamtamine. *See* Topotecan hydrochloride
 Hycamtin. *See* Topotecan hydrochloride
 Hydralazine, acetylation of, 100–101
 Hydralazine hydrochloride, 643, 643*f*
 Hydrax. *See* Hydroxyurea
 Hydrocodone, 783*f*, 785
 Hydrocortisone, 821*f*, 822*t*, 853–855, 854*f*–856*f*, 857–859, 858*t*, 861
 metabolism of, 855, 855*f*
 Hydrocortisone acetate, 822*t*
 Hydrocortisone NaPO₄, 822*t*
 Hydrocortisone valerate, 856*f*
 Hydrogen bond, 26, 28–29, 28*f*
 Hydrolytic reactions, 86–88
 bioactivation of prodrugs, 87–88
 esters and amides, 86
 miscellaneous, 86–87
 of penicillin, 265
 of recombinant proteins, 132
 Hydromorphone, 783*f*, 785
 Hydrophilic, 43
 Hydrophilic bond, 26
 Hydrophobic bonds, 26, 881
 Hydroous benzoyl peroxide, 185
 Hydroxocobalamin, 954
N-Hydroxy-2-acetylaminofluorene, conjugation of, 90–91
 2-Hydroxy-17 β -estradiol, conjugation of, 97, 99
 Hydroxyamphetamine, 544
 Hydroxyapatite, 705
 Hydroxypropylbenzoic acid derivatives, 190
 Hydroxybupropion, 515
 Hydroxychloroquine, 246*t*–247*t*, 249*f*, 250, 807*f*, 808
 4-Hydroxycoumarin, conjugation of, 90–91
N-Hydroxydapson, conjugation of, 90–91
 2-Hydroxyethyltriethylammonium, 563–564
 Hydroxyflutamide, 851*f*
 Hydroxylamine, metabolism of, 69–70
 Hydroxymethyl OMPA, 579–580
m-Hydroxyphenol, 195
p-Hydroxyphenytoin, conjugation of, 89–90
 17 α -Hydroxypregnenolone, 821*f*
 Hydroxyprogesterone caproate, 838*f*, 838*t*, 839–840
 8-Hydroxyquinoline, 221–222
 Hydroxystreptomycin, 297
 4-Hydroxytamoxifen, 833*f*
 Hydroxyurea, 383
 Hydroxyzine, 740*t*–741*t*
 Hylarel. *See* Guanadrel; Guanadrel sulfate
 Hyoscine. *See* Scopolamine
 Hyoscine hydrobromide. *See* Scopolamine hydrobromide
 Hyoscyamine, 30, 582, 584–586
 Hyoscyamine sulfate, 586
 Hypercalcemia, malignancy related, 705
 Hypercins, 965–966, 966*f*
 Hyperlipidemia, 647
 Hyperlipoproteinemia, 648–649, 649*t*
 Hyperparathyroidism, 709–710, 709*f*
 Hyperpolarization, of neuronal membrane, 719–720, 719*f*
 Hypersensitivity
 to cephalosporins, 285
 histamine role in, 736, 739–740
 to local anesthetics, 724–726
 Hyperstat IV. *See* Diazoxide
 Hypertensin. *See* Angiotensin amide
 Hypertension, 637–639, 641
 renin–angiotensin system in, 607–609, 608*f*–609*f*
 Hyperthyroidism, 663–664
 Hyperuricemia, 809–811, 809*f*–810*f*
 Hypervariable regions, 147
 Hypervitaminosis
 vitamin A, 922–923
 vitamin B₁, 938
 vitamin B₂, 939
 vitamin B₃, 942
 vitamin B₅, 944
 vitamin B₆, 947
 vitamin B₇, 948
 vitamin B₉, 951
 vitamin B₁₂, 954
 vitamin C, 955
 vitamin D, 927
 vitamin E, 931
 vitamin K, 935
 Hypnotics. *See* Anxiolytics, sedatives and hypnotics
 Hypochlorous acid, 186
 Hypoglycemic agents, 658–669
 biguanides, 685–687, 685*f*–686*f*
 bisguanidines, 662
 glimides, 668–681, 670*f*–672*f*, 673*t*, 674*f*–680*f*, 676*t*
 α -glucosidase inhibitors, 662–663, 687–689, 687*f*–688*f*
 metaglimides, 661
 sulfonylureas, 659–661, 668–681, 670*f*–672*f*, 673*t*, 674*f*–680*f*, 676*t*
 thiazolidinediones, 662, 681–685, 682*f*–685*f*, 684*t*
 Hypothalamus, hormones of, 890–891
 Hypothyroidism, 663
 Hypoxanthine, 40, 40*f*
 Hytrin. *See* Terazosin; Terazosin hydrochloride
- I**
 Ibandronate, 706, 708
 Ibritumomab tiuxetan, 150
 Ibuprofen, 31, 32*f*, 794*t*, 795, 800, 801*f*
 metabolism of, 59, 61
 Ibutilide, 636–637
 Idarubicin. *See* Idarubicin hydrochloride
 Idarubicin hydrochloride, 385, 385*f*, 389
 IDDM. *See* Insulin-dependent diabetes mellitus
 Idoxuridine, 339–340
 IFEX. *See* Ifosfamide
 IFO. *See* Ifosfamide
 Ifosfamide, 360–361, 361*f*, 363*f*, 369
 Ifosfamidum. *See* Ifosfamide
 IG. *See* Immune globulin
 IgA, 165, 165*f*
 IgD, 165
 IgE, 165
 IgG, 162*f*, 164
 IGIV. *See* Intravenous immune globulin
 IgM, 163*f*, 164
 Iletin, 667
 Iloprost, 877
 Ilosone. *See* Erythromycin estolate
 Ilotycin. *See* Erythromycin
 Ilotycin Gluceptate. *See* Erythromycin gluceptate
 Imaging studies. *See* Radiopharmaceuticals
 Imatinib mesylate, 403, 404*f*, 405
 Imciromab pentetate, 150
 Imetit, 773, 773*f*
 Imidazolines, 534
 Imiglucerase, 145, 908*t*, 910
 Imiglucerase injection, 888*t*, 889
 Imigrain. *See* Sumatriptan
 Impipenem–cilastatin, 276–277
 Imipramine hydrochloride, 511
 metabolism of, 8, 55*f*, 62–63
 Imitrex. *See* Sumatriptan
 Immepip, 773, 773*f*
 Immune function, histamine role in, 736–737
 Immune globulin (IG), 165
 Immune system
 acute phase factors, 160, 160*t*
 cells of, 156–159, 157*f*–158*f*, 158*t*
 complement pathway
 alternative, 160–161, 160*f*
 classical, 160–161, 162*f*
 immunity, 159–165
 interferons, 161, 161*f*, 161*t*, 337–338
 Immunity, 159–165
 acquired, 159*t*, 161–165
 acquisition of, 165–174
 innate, 159–161, 159*t*, 160*t*
 Immunization. *See also* Vaccines
 bacterial vaccines, 172–173
 childhood schedule for, 174, 174*f*–175*f*
 toxoids, 166–168, 173–174
 viral vaccines, 168–172
 Immunobiologicals, 156–178
 bacterial vaccines, 172–173
 definitions of, 165–166
 immune system cells, 156–159, 157*f*–158*f*, 158*t*
 immunity, 159–165
 storage and handling of, 167–168
 toxoids, 166–168, 173–174
 vaccines, 166–168
 adjuvant technologies, 174–177
 bacterial, 172–173
 nucleic acid, 177–178
 viral, 168–172
 viral vaccines, 168–172
 Immunoglobulin, structure and function of, 162–163, 162*f*
 Immunosuppressants, glucocorticoids, 853–864, 854*f*–857*f*, 858*t*, 860*f*, 864*f*
 Imodium. *See* Loperamide
 Implanon, 846
 Imuran. *See* Azathioprine
 Inactivated polio vaccine (IPV), 168–169
 Inapsine. *See* Droperidol
 Increlex. *See* Mecasermin
 Incretin mimetics, 690–694, 690*f*, 693*f*–695*f*
 Incretin system modulating agents, 690–694, 690*f*, 693*f*–695*f*
 Inderal. *See* Propranolol
 Indinavir, 349
 Indirect effect of radiation damage, 417

- Indium (¹¹¹In) capromab pendetide, 419–420
 Indium chloride (¹¹¹In), 420
 Indium (¹¹¹In) oxyquinoline, 420
 Indium (¹¹¹In) pentetate, 420–421
 Indium (¹¹¹In) pentetate, 421
 Indium radiopharmaceuticals, 419–421
 Indocin. *See* Indomethacin
 Indolethylamines, 516
 Indomethacin, 15, 794–795, 794*t*, 795*f*, 799, 799*f*
 metabolism of, 75–76, 86, 88
 Infarct, myocardial, 613
 Inflammation
 COX-1, COX-2, and prostaglandin role in, 792–793, 793*f*
 histamine role in, 736
 neurogenic, 812
 Influximab, 149
 Influenza type A, 336–337
 Influenza type B, 336–337
 Influenza vaccine, 168
 Informatics, 150–151
 Inhaled general anesthetics, 711–716, 712*t*, 714*f*–716*f*
 ideal, 711–712, 712*t*
 mechanism of action of, 713–714
 structure–activity relationships of, 712–713, 712*f*
 Inhibitors, 885
 Inhiston. *See* Pheniramine maleate
 Injectable general anesthetics, 716–718, 717*f*–718*f*
 Injection, for drug distribution, 5
 Innate immunity, 159–161, 159*t*–160*t*, 165
 acquired vs., 159, 159*t*
 pattern recognition receptors and, 176
 Inocor. *See* Amrinone
 Inotropic agents. *See* Positive inotropic agents
 Insecticides
 drug metabolism and, 108
 for mosquito control, 244–245
 In silico screening, 24
 Inspra. *See* Eplerenone
 Insulin
 bovine, 668, 668*t*
 in glucose metabolism disorders, 667
 metabolic effects of, 899–900
 as pancreatic hormone, 897–901, 897*f*, 898*t*, 901*t*–902*t*
 porcine, 668, 668*t*
 recombinant, human, 134–135
 recombinant human, 667–668, 667*f*, 668*t*–669*t*, 898, 900, 901*t*–902*t*
 secretion of, 669–670, 670*f*, 676, 898
 structure of, 667, 668*f*
 Insulin aspart, 668*t*–669*t*
 Insulin-dependent diabetes mellitus (IDDM), 667
 Insulin detemir, 668*t*–669*t*
 Insulin glargine, 668*t*–669*t*
 Insulin glulisine, 668*t*–669*t*
 Insulin injection, 900, 901*t*–902*t*
 Insulin lispro, 668*t*–669*t*
 Insulin secretagogues. *See* Sulfonylureas
 Insulin sensitivity, 667
 Insulin zinc suspension, 901, 901*t*–902*t*
 Intal. *See* Cromolyn sodium
 Integrase inhibitors, 352
 Integrilin. *See* Eptifibatid
 Interferon alpha-2a, 139, 139*t*
 recombinant, 909*t*, 911
 Interferon alpha-2b, 139–140, 139*t*
 recombinant, 908*t*, 911
 Interferon alfacon-1, 139*t*, 140
 Interferon alpha-n1, 139*t*, 140
 Interferon alpha-n3, 139*t*, 140, 908*t*, 911
 Interferon beta-1a, 140–141, 140*t*, 909*t*, 911
 Interferon beta-1b, 140*t*, 141
 recombinant, 908*t*, 911
 Interferon gamma-1b, 141
 Interferons, 161, 161*f*, 161*t*, 337–338, 908*t*–909*t*, 910–911
 alfa, 337–338, 338*f*–339*f*
 beta, 337–338, 338*f*–339*f*
 classification of, 337–338, 338*f*
 function of, 337–338, 339*f*
 gamma, 337–338, 338*f*
 mechanism of, 337–338, 338*f*–339*f*
 recombinant, 138–141, 138*f*, 139*t*–140*t*
 α-Interferons, recombinant, 139–140, 139*t*
 β-Interferons, recombinant, 140–141, 140*t*
 γ-Interferons, recombinant, 141
 Interleukins, recombinant, 141–142
 Intermediate-density lipoprotein, 647–648
 Interpolar microtubules, 397
 Interstitial cell–stimulation hormone. *See* Luteinizing hormone
 Intestinal disorders, sulfonamides for, 238–239
 Intocostin, 600
 Intrauterine ring, 844*t*, 845–846
 Intravenous immune globulin (IGIV), 165
 Intrinsic activity, of drugs, 581
 Intron A. *See* Interferon alfa-2b, recombinant
 Intrans, 122, 122*f*
 Intropin. *See* Dopamine
 Invars. *See* Ertapenem
 Inversine. *See* Mecamylamine hydrochloride
 Invirase. *See* Saquinavir
 Iodine radiopharmaceuticals, 421–422
 Iodine (¹³¹I) tositumomab, 422
 Iodipamide meglumine, 433
 Iodixanol, 434
 Iodophors, 185–186
 Iodoquinol, 220, 222
 Iohexol, 434
 Ionamin. *See* Phentermine ion-exchange resin
 Ion channels. *See also* Voltage-gated ion channels
 acetylcholine and, 559–560, 559*f*–560*f*, 562–563
 calcium, 623, 623*f*–624*f*
 inhalation general anesthetic interaction with, 713–714
 local anesthetic binding to, 720, 721*f*–722*f*, 722–723, 724*f*
 in nerve conduction, 719–720, 721*f*–722*f*
 sodium, 720, 721*f*–722*f*, 722–723, 724*f*
 Ionic ratio 1.5 contrast agents, 432
 Ionizing radiation, 413, 416
 Iopamidol, 434
 Iopidine. *See* Apraclonidine
 Iopromide, 435
 Iothalamate meglumine, 435
 Ioversol, 435
 Ioxaglate, 436
 Ioxilan, 436
 Iphosphamide. *See* Ifosfamide
 Ipratropium bromide, 587–588
 IPV. *See* Inactivated polio vaccine
 Irbesartan, 613
 Iressa. *See* Gefitinib
 Irinotecan hydrochloride, 392*f*, 393, 394*f*
 Iron oxide, for MRI, 437
 Isaglitazone, 682
 Ischemic heart disease, 617–618, 618*f*
 Ismelin. *See* Guanethidine
 Isobars, 413
 Isocarboxazid, 523
 Isodine. *See* Povidone-iodine
 Isoetharine, 542
 Isoflurane, 712*f*, 712*t*, 713, 715, 715*f*
 Isoflurophate, 572*t*, 577*f*, 578
 Isomeric transition, 414
 Isomers, 413
 conformational, 27
 geometric, 27
 Isoniazid, 215–216
 acetylation of, 100–101
 conjugation of, 94, 96
 Isopentaquine, 250, 250*f*
 Isophane insulin. *See* Neutral protamine Hagedorn insulin
 Isopropamide iodide, 592, 594
 Isopropyl alcohol, 182
 Isoproterenol, 45, 532–533, 540–541
 methylation, 102–103
 Isoptin. *See* Verapamil
 Isordil. *See* Isosorbide dinitrate; Isosorbide dinitrate, diluted
 Isosorbide dinitrate
 conjugation of, 97–98
 diluted, 620*t*, 622
 Isosterism, 39–40, 39*f*–40*f*, 39*t*
 Isotones, 413
 Isotopes, 413
 Isovuc. *See* Iopamidol
 Isradipine, 623*t*, 626
 Isuprel. *See* Isoproterenol
 Itraconazole, 204
 Ivermectin, 227
 Ivomec. *See* Ivermectin
 Ixabepilone, 399–400, 399*f*, 400*t*
 Ixempra. *See* Ixabepilone
 J
 Jacksonian motor epilepsy, 492
 Jadelle, 846
 Janumet. *See* Metformin; Sitagliptin phosphate
 Januvia. *See* Sitagliptin phosphate
 JE-2147, 351
 K
 Kabikinase. *See* Streptokinase
 Kallidin, 905–906
 Kanamycin sulfate, 294, 299
 antitubercular activity of, 215
 inactivation of, 295–296
 Kantrex. *See* Kanamycin sulfate
 Kapseals. *See* Phenytoin
 Keflex. *See* Cephalexin
 Keflin. *See* Cephalothin sodium
 Keforal. *See* Cephalexin
 Kefzol. *See* Cefazolin sodium
 Kemadrol. *See* Procyclidine hydrochloride
 Kepra. *See* Levettiracetam
 Kerlone. *See* Betaxolol
 Ketamine, 717–718, 718*f*
 metabolism of, 65, 67
 Ketek. *See* Telithromycin
 Ketoconazole, 203–204
 Ketoprofen, 794*t*, 795, 801, 801*f*
 Ketorolac, 799*f*, 800
 Ketotifen fumarate ophthalmic solution, 759–760
 Khellin, 757
 Kidney. *See* Renal system drugs
 Killed pathogen, vaccine, 166
 Kinins, 607–608
 Klonopin. *See* Clonazepam
 Koate HP. *See* Antihemophilic factor
 Koch, Robert, 179
 KoGENate. *See* Antihemophilic factor, recombinant
 Kogenate. *See* Antihemophilic factor, recombinant
 Kwell. *See* Lindane
 Kwildane. *See* Lindane
 L
 LAAM. *See* Acetylmethadol
 Labetalol, 554–555
 β-Lactam antibiotics, 260–261. *See also*
 Cephalosporin(s); Monobactams; Penicillin(s)
 mechanism of action of, 261
 β-Lactamase(s)
 cephalosporin resistance to, 282–284, 284*f*
 inactivation of, 274, 275*f*
 penicillin resistance and, 265–266
 β-Lactamase inhibitors, 274–278
 classification of, 274
 discovery of, 274
 types of, 275–278
 Lamictal. *See* Lamotrigine
 Lamisil. *See* Terbinafine hydrochloride
 Lamivudine, 345–346
 Lamotrigine, 492, 499*f*, 500
 Lampit. *See* Nifurtimox
 Lamprene. *See* Clofazimine
 Lanosterol 14α-demethylase, 201, 201*f*, 203
 Lanoxin. *See* Digoxin
 Lanreotide acetate, 895
 Lansoprazole, 765, 766*t*–767*t*, 767–768, 770
 Lantus. *See* Insulin glargine
 Lapatinib ditosylate, 404*f*, 406
 Larotid. *See* Amoxicillin
 Lasofoxicene, 833–834, 833*f*
 Latanoprost, 878
 LCR. *See* Vincristine sulfate
 Lee and Richards surface, 35
 Leflunomide, 807*f*, 808
 Leishmaniasis, 221, 224
 Lente insulin, 901, 901*t*–902*t*
 Lepirudin, recombinant, 144
 Leprosy, 215, 239–240
 Lescol. *See* Fluvastatin
 Letairis. *See* Ambrisentan
 Letrozole, 835*f*, 836
 Letter. *See* Levthyroxine sodium
 L-Leucine, 498, 498*f*
 Leucine-enkephalin, 778, 893
 Leucovorin, 379, 381*f*, 951

- Leukine. *See* Sargramostin
 Leukotrienes. *See* Eicosanoids
 Leuprolide acetate, 697f, 698–699, 698f
 Leurocristine. *See* Vincristine sulfate
 Leustatin. *See* Cladribine
 Levalbuterol, 542
 Levamisole, 30
 Levatol. *See* Penbutolol
 Levemir. *See* Insulin detemir
 Levetiracetam, 499f, 500
 Levitra. *See* Vardenafil hydrochloride
 Levobunolol, 551, 552f
 Levobupivacaine, 30
 Levobuvacaine, 728–729
 Levocetirizine, 740t–741t
 Levocetirizine dihydrochloride, 756
 Levodopa, 30, 471, 472f, 474, 478, 523
 methylation, 102–103
 Levo-Dromoran, 786
 Levofloxacin, 213
 Levoid. *See* Levothyroxine sodium
 Levomethorphan, 31f
 Levonorgestrel, 840
 Levonorgestrel-releasing intrauterine system (LRIS), 843t, 845
 Levophed. *See* Norepinephrine
 Levopropoxyphene, 31f
 Levorphanol, 785–786
 Levothyroxine, 30
 Levothyroxine sodium, 663
 Levoxine. *See* Levothyroxine sodium
 Levsin sulfate. *See* Hyoscyamine sulfate
 LH. *See* Luteinizing hormone
 Librax. *See* Clidinium bromide
 Librium. *See* Chlordiazepoxide; Chlordiazepoxide hydrochloride
 Licorice, 973–974, 973f
 Lidocaine, 45, 726–727, 727f
 metabolism of, 7, 63, 86, 88
 Lidocaine hydrochloride, 633–634, 634f
 Ligand-gated sodium channels, 720, 721f–722f
 local anesthetic binding to, 720, 721f–722f, 722–723, 724f
 Ligation, 124
 Linagliptin, 693, 694f
 Lincocin. *See* Lincomycin hydrochloride
 Lincomycin hydrochloride, 313–314
 Lincomycins, 260t, 313–315
 Lindane, 228
 Linezolid, 323
 Liothyronine sodium, 663
 Lipid(s)
 classes of, 647–648, 647f
 metabolism of, 648, 648f
 structure of, 647, 647f
 Lipid-lowering agents, 647–654, 647f–648f, 649t, 652f
 HMG-CoA reductase inhibitors, 652–654, 652f
 hyperlipoproteinemias, 648–649, 649t
 lipoprotein classes, 647–648, 647f
 lipoprotein metabolism, 648, 648f
 Lipid membrane
 cholesterol in, 193, 193f
 ergosterol in, 193, 194f
 Lipid microspheres. *See* Perflutren
 Lipinski Rule of Five, 37–38, 38t
 Lipitor. *See* Atorvastatin
 Lipophilic, 43
 Lipoprotein(s)
 classes of, 647–648, 647f
 metabolism of, 648, 648f
 structure of, 647, 647f
 Lipotropins, 778, 779f, 893
 Lipoxigenase pathway, 870–871, 871f
 Liquified phenol, 183
 Liraglutide, 690f, 691
 Lisinopril, 610
 Lister, Joseph, 179, 183
 Lithium carbonate, 468–469
 Lithium citrate, 468–469
 Lithium salts, 468–469
 Live/attenuated pathogen, vaccine, 166
 Live/attenuated related pathogen, vaccine, 166
 Lobac. *See* Salicylamide
 Local anesthetic effect, 550–551
 Local anesthetics, 718–730, 718f–719f, 721f–722f, 724f, 727f–728f
 allergic reactions to, 724–726
 amino amide, 726–729, 727f–728f
 esters, 725–726
 future directions of, 729–730
 mechanism of action of, 722–723, 722f
 methemoglobinemia associated with, 725
 structure–activity relationships of, 723–724, 724f
 vasoconstrictors used with, 724–725
 LOCM. *See* Low osmolar contrast medium
 Lodine. *See* Etodolac
 Lodoxamide tromethamine, 758
 Log D values, 976t–983t
 Log P values, 976t–983t
 Lomefloxacin, 208, 208t, 212
 Lomotil, 787
 Lomustine, 365, 366f, 371
 Loniten. *See* Minoxidil
 Loperamide, 787–788, 787f
 Lipid. *See* Gemfibrozil
 Lopinavir, 349
 Lopressor. *See* Metoprolol
 Loprox. *See* Ciclopirox olamine
 Lorabid. *See* Loracarbef
 Loracarbef, 280t, 287
 Loratadine, 740t–741t, 755
 Lorazepam, 449
 Lorelco. *See* Probucool
 Loroithidol. *See* Bithionol
 Lortab. *See* Hydrocodone
 Lortab ASA. *See* Hydrocodone
 Losartan, 612–613
 Losec. *See* Omeprazole
 Lotemax. *See* Loteprednol etabonate
 Lotensin. *See* Benazepril hydrochloride
 Loteprednol etabonate, 860f, 862
 Lotrimin. *See* Clotrimazole
 Lovastatin, 653
 Lovaza, 875
 Low-density lipoprotein, 647–649, 649t
 Low osmolar contrast medium (LOCM), 432
 Loxapine, 463–464
 LRIS. *See* Levonorgestrel-releasing intrauterine system
 LSD. *See* (+)-Lysergic acid diethylamide
 Lubiprostone, 877
 Ludiomil. *See* Maprotiline hydrochloride
 Lumefantrine, 246t–247t, 251f, 252, 255
 Lumiracoxib, 802–803, 802f
 Lunesta. *See* Eszopiclone
 Lupron. *See* Leuprolide acetate
 Lupron Depot. *See* Leuprolide acetate
 Lutalyse. *See* Dinoprost trimethamine
 Luteinizing hormone (LH), 696–697, 699, 826–827, 826f, 890, 894
 Luteinizing hormone-releasing hormone. *See* Gonadotropin-releasing hormone
 Luteolin, 968, 968f
 Luvox. *See* Fluvoxamine
 LY 303366, 206
 Lybrel, 844
 LYMERIX, 145
 Lymphoid cell line, 157f, 159
 Lyovac Cosmegen. *See* Dactinomycin-D
 Lypressin, 896
 Lyrica. *See* Pregabalin
 (+)-Lysergic acid diethylamide (LSD), 516–517
M
 M₁ receptors, 561, 567–568
 M₂ receptors, 561, 567–568
 M₃ receptors, 562, 567
 M₄ receptors, 562, 567–568
 M₅ receptors, 562, 567
 Macrodantin. *See* Nitrofurantoin
 Macrolides, 308–313
 chemistry of, 309
 mechanism of action of, 309
 microbial resistance to, 309
 spectrum of activity of, 309
 types of, 309–313
 Macrophages, 157–159, 157f–158f
 Mafenide acetate, 238
 Magan. *See* Magnesium salicylate
 Magnesium salicylate, 798
 Magnetic resonance imaging (MRI)
 contrast agents for, 413, 436–440
 description of, 436, 437f
 Magnevist. *See* Gadopentetate dimeglumine
 Ma huang, 962, 968–969, 969f
 Major histocompatibility antigens, 156
 Major histocompatibility complex (MHC), 20, 156
 Malaria, 242
 control of, 242
 drug-resistant, 249–250
 drug therapy for, 245–256
 history of, 242
 mosquito control for, 244–245
 pathophysiology of, 243–244, 243f
Plasmodium spp. and, 242–243, 243f
 poverty and, 245
 protective mutations against, 244
 vaccinations and, 245, 255
 Malathion, 578–579, 580f
 Malignancy, hypercalcemia of, 705
 Malignant hyperthermia (MH), 714
 Mandelamine. *See* Methenamine mandelate
 Mandol. *See* Cefamandole nafate
 Mangafodipir trisodium, 439
 Manganese, for MRI, 437
 Mannisidostreptomycin, 297
 Mansoni. *See* Niclosamide
 MAO. *See* Monoamine oxidase
 MAO-B inhibitors, 474–475
 MAOs. *See* Monoamine oxidase inhibitors
 Maolate. *See* Chlorphenesin carbamate
 Maprotiline hydrochloride, 513
 Marezin. *See* Cyclyzine hydrochloride
 Marplan. *See* Isocarboxazid
 Mast cells, 157, 157f
 Mast cell stabilizers, 757–759
 Matulane. *See* Procarbazine
 Mavik. *See* Trandolapril
 Maxair. *See* Pirbuterol
 Maxalt. *See* Rizatriptan
 Maxalt-MLT. *See* Rizatriptan
 Maxaquin. *See* Lomefloxacin
 Maxipime. *See* Cefepime
 McN-A-343, 561
 MDA. *See* 3,4-Methylenedioxymphetamine
 MDR. *See* Multidrug resistance
 Measles vaccine, 169
 Mebendazole, 225–226
 Mecamylamine, 598
 Mecamylamine hydrochloride, 595, 599
 Mecasermin, 895
 Mechanism of action of, discovery and development of, 457–458
 Mechlorethamine hydrochloride, 359–360, 359f–360f, 368
 Meclan. *See* Meclocycline sulfosalicylate
 Meclizine hydrochloride, 747–748
 Meclocycline sulfosalicylate, 307
 Meclofenamate, 802
 Meclofenamic acid, 802f
 Meclomen. *See* Meclofenamate
 Medazepam, metabolism of, 76, 78
 Medical imaging. *See* Radiopharmaceuticals
 Medicinal herbs, 961–974
 in cancer treatment, 972, 973f
 capsicum, 967, 967f
 chamomile, 968, 968f
 cranberry, 969
 definition of, 962
 as drugs, 962–963
 echinacea, 962–964, 963f–964f
 ephedra, 962, 968–969, 969f
 feverfew, 964–965, 965f
 garlic, 967–968, 967f
Ginkgo biloba, 963, 969–970, 970f
 ginseng, 962, 970–971, 970f–971f
 historic aspects of, 961–962
 licorice, 973–974, 973f
 milk thistle, 971–972, 971f
 pennyroyal, 972, 972f
 purity and standardization of, 962
 St. John's wort, 963, 965–967, 966f
 valerian, 972, 972f
 Medroxyprogesterone acetate, 838f, 838t, 840
 Mefenamic acid, 801–802, 802f
 Mefloquine hydrochloride, 246t–247t, 249f, 250

- Mefoxin. *See* Cefoxitin sodium
Megace. *See* Megestrol acetate
Megestrol acetate, 838f, 840
Meglitinide, 674, 675f–676f. *See also* Glinides
Melanocyte-stimulation hormone (MSH), 892–893
Melanotropins, 892–893
Melarsoprol, 223–224
Melatonin, 451–452
Melatonin receptor agonists, 451–452
Mel B. *See* Melarsoprol
Mellaril. *See* Thionidazine hydrochloride
Meloxicam, 794t, 795–796, 796f, 803
Melphalan, 360, 360f, 369
Membrane-depressant antiarrhythmic agents, 631–635, 631t, 634f
Membrane responsiveness, 630
Menadione, 4
Menaquinone, 932, 932f
Menest. *See* Esterified estrogens
Meningococcal polysaccharide vaccine, 173
Menopause, HRT for, 846
Menotropins, 894
Menstruation, steroid hormone regulation of, 826–827, 826f
Mepenzolate bromide, 589–590
Meperidine, 45, 475, 786–787, 787f
metabolism of, 63, 65
Mephobarbital, 453, 454t
metabolism of, 71–72
Mepivacaine, 727
Meprobamate, 455–456
conjugation of, 90–91
Mepron. *See* Atovaquone
6-Mercaptopurine, 40, 40f, 372, 378–379, 378f–379f, 382
metabolism of, 7–8
Mercaptopurinum. *See* Mercaptopurine
Mercapturic acid conjugates, 94–98, 95f
Mercuric oxide, 189
Mercury compounds, for anti-infective agents, 179, 189–190
Meridia. *See* Sibutramine
Meropenem, 277–278
Merozoites, 243–244, 243f
Merrem. *See* Meropenem
Mescaline, 516
acetylation of, 100–101
conjugation of, 94, 96
metabolism of, 69
Mesna, 360, 362f
Mesocortical pathway, 472, 473f
Mesolimbic pathway, 472, 473f
Mesopin. *See* Homatropine methylbromide
Mesoridazine besylate, 461t, 462–463
Mestison. *See* Pyridostigmine bromide
Mestranol, 829f, 832
Metabolic syndrome, 666–667. *See also* Diabetes
Metaglinides, 661
Metaglip. *See* Glipizide; Metformin
Metaphen. *See* Nitromersol
Metaproterenol, 533, 541
Metaraminol, 545
Metasep. *See* p-Chloro-m-xyleneol
Metastable state, 414
Metastasis, 355
Metformin, 662, 685–687, 685f
Methacholine, 567
conformation of, 565, 565f
Methacholine chloride, 568–569
Methacycline hydrochloride, 302, 306
Methadol, acetylation of, 100–101
Methadone, 28, 788–789, 788f–789f
metabolism of, 63–64
S(+)-Methadone, metabolism of, 82
Methamphetamine hydrochloride, 506t, 507, 533
metabolism of, 65, 67
Methantheline bromide, 590
Methapyrilene hydrochloride, 746
Methdilazine, 740r, 752
Methdilazine hydrochloride, 752
Methemoglobin, 70
Methemoglobinemia, after local anesthetic administration, 725
Methemoglobinemia toxicity, 70
Methenamine, 214
Methenamine hippurate, 214
Methenamine mandelate, 214
Methicillin sodium, 269t, 270–271
Methimazole, 664
conjugation of, 90–91
Methionine-enkephalin, 778, 893
Methural, metabolism of, 75, 77
Methocarbamol, 456
Methoctramine, 561, 567, 568f
Methotrexate, 40, 40f, 372, 379, 380f, 383
as DMARD, 807f, 808
Methoxamine, 536
Methoxyflurane, 712f, 712r, 715
Methsuximide, 500, 501f
trans-N-Methyl-4-(1-naphthylvinyl)pyridinium iodide, 564, 564f
N-Methyl-4-aminoazobenzene, metabolism of, 70, 72
cis-2-Methyl-4-trimethylammonium-1,3-dioxolane, 565–566
Methylation, 102–104, 102f
Methylbenzethonium chloride, 188
3-Methylcholanthrene, metabolism of, 55f
Methyldopa, 539–540, 540f
metabolism of, 69
methylation, 102–103
 α -Methyldopa, conjugation of, 91–92
L- α -Methyldopa. *See* Methyldopa
Methyldopate hydrochloride, 641–642
Methylene blue, 179, 189
3,4-Methylenedioxyamphetamine (MDA), 516
Methyl ethyl ethers, 713
 α -Methylhistamine, 773, 773f
Methylhydrazine, 366
 α -Methyl-L-tyrosine. *See* Metyrosine
Methylnaltrexone, 791f, 792
Methylparaben, 190
Methylparathion, 578
Methyl parathion, conjugation of, 95
Methylphenidate hydrochloride, 508–509
metabolism of, 65–67, 86–87
Methylprednisolone, 823f, 857f, 858t, 862
solubility of, 5
Methylprednisolone sodium succinate, 823f
17 α -Methyltestosterone, 823f, 848, 849f, 850
6-(Methylthio)-purine, metabolism of, 75–76
Methylxanthines, 505–506, 505t
Metamide, 761, 762t
metabolism of, 76, 78
Metipranolol, 551, 552f
Metoclopramide, 468
Metocurine iodide, 601
Metoprolol, 552–553, 553f
metabolism of, 55, 57, 75–76
Metrazol. *See* Pentylene tetrazole
Metrifonate, 573, 575
Metro IV. *See* Metronidazole
Metronidazole, 221
metabolism of, 70–71, 84
Metubine iodide. *See* Metocurine iodide
Metyrapone, metabolism of, 82
Metyrosine, 528, 529f–530f, 530
Mevacor. *See* Lovastatin
Mexate. *See* Methotrexate
Mexiletine hydrochloride, 634–635
Mexilitil. *See* Mexiletine hydrochloride
Meyer-Overton theory, 713
Mezlin. *See* Mezlocillin sodium
Mezlocillin sodium, 268, 269t, 273–274
MH. *See* Malignant hyperthermia
MHC. *See* Major histocompatibility complex
Miacalcin. *See* Calcitonin, salmon
Micardis. *See* Telmisartan
Micitin. *See* Miconazole nitrate
Michael addition, 97
Miconazole nitrate, 203
Microbial resistance
to aminoglycosides, 295–296
to antibiotics, 260
to macrolides, 309
to penicillins, 265–267
to sulfonamides, 235
to tetracyclines, 303, 308
Micronase. *See* Glyburide
Microsatellites, 363
instability, 363
Microsomes, 46
Microtubules, interpolyar, 397
Midazolam, 449, 451
Midodrine, 536
Mifeprax. *See* Mifepristone
Mifepristone, 841, 841f
Miglitol, 663, 687–689, 687f–688f
Migraine, 811–812
Milk thistle, 971–972, 971f
Milrinone, 647
Miltown. *See* Meprobamate
Mineralocorticoid receptor antagonists, 615, 864
Mineralocorticoid receptors (MRs), 825
Mineralocorticoids, 853–864, 854f–857f, 858r, 860f, 864f
biological activities of, 855–856
structural classes of, 856–859, 856f–857f, 858t
Minipill, 843t, 845
Minipress. *See* Prazosin; Prazosin hydrochloride
Minocin. *See* Minocycline hydrochloride
Minocycline hydrochloride, 302, 302t, 305, 305t, 307–308
Minoxidil, 645, 645f
metabolism of, 60, 62
Mintezol. *See* Thiabendazole
Miradon. *See* Anisindione
Miraluma. *See* Technetium (^{99m}Tc) sestamibi
Mirapex. *See* Pramipexole dihydrochloride
Mirena, 843r, 845
Mirtazapine, 515, 549
Mismatch repair (MMR), 363–365
Misoprostol, 772–773, 793, 877
Misoprostol-diclofenac, 877
MitC. *See* Mitomycin C
Mitiglinide, 675f
Mitochondria, cytochrome P450, 46
Mitomycin C, 260r, 400, 400f
Mitoxantrone hydrochloride, 387–389, 388f
Mivacron. *See* Mivacurium chloride
Mivacurium chloride, 599, 603
Mixed-function oxidases, 45, 45t
Mixed opioid agonist/antagonists, 790–791
MMR. *See* Mismatch repair
Moban. *See* Molindone hydrochloride
Mobic. *See* Meloxicam
Mobidin. *See* Magnesium salicylate
Mobile probes, 151
Moclobemide, 510
Modafinil, 504
Modified insulins, 667–668, 667f, 668t–669t
Molar refractivity, 20
Molecular connectivity, 22
Molecular mechanics, 32–33
Molindone hydrochloride, 468
Molybdenum-99/technetium-99m system, 415–416, 416f
Molybdenum radiopharmaceuticals, 415–416, 416f
Monmetasone furoate, 860f, 862–863
Monistat. *See* Miconazole nitrate
Monoalkylation, 361–362
Monoamine oxidase (MAO), 472, 523, 524f
Monoamine oxidase inhibitors (MAOIs), 509–510, 510t
Monoamine reuptake inhibitors, 509–511
Monoaminopropyl antihistamines. *See* Propylamine antihistamines
Monobactams, 293–294
Monocid. *See* Cefonicid sodium
Monoclate-P. *See* Antihemophilic factor
Monoclonal antibodies
for bone disease treatment, 710
production of, 146–147, 147f
products, 147–149
radionuclide test kits, 149–150
therapeutic radionuclide, 149–150
Monocytes, 157–159, 157f–158f
Mononine. *See* Factor IX, recombinant
Monooxygenases, 45, 45t
Monophasic combination contraceptive tablets, 842r, 844
Monopril. *See* Fosinopril sodium
Monurol. *See* Fosfomycin tromethamine
Moricizine, 635
Morphinan, 783f, 785–786
Morphine, 45, 782f–784f, 783–784
conjugation of, 89–90
metabolism of, 63, 65
methylation, 103–104
Mosquito control, for malaria, 244–245
Motilin, 904
Motor nerves, 558

- Motrin. *See* Ibuprofen
 6-MP. *See* Mercaptopurine; 6-Mercaptopurine
 MRI. *See* Magnetic resonance imaging
 mRNA, in biotechnology, 123, 123f
 MRP1. *See* Multidrug resistance protein
 MRs. *See* Mineralocorticoid receptors
 MSH. *See* Melanocyte-stimulation hormone
 MTA. *See* Pemetrexed
 MTC. *See* Mitomycin C
 MTX. *See* Methotrexate
 Multidrug resistance (MDR), vinca alkaloids, 397
 Multidrug resistance protein (MRP1), 397
 MultiHance. *See* Gadobenate dimeglumine
 Multiple modes of action, conformational flexibility and, 29–30, 29f
 Multivariate, 23
 Mumps vaccine, 170
 Mupirocin, 322
 Muromonab-CD3, 148–149
 Muscarine
 activity of, 565–566
 isomers of, 565, 566f
 structure of, 567f
 Muscarinic antagonists, 567–581, 568f
 Muscarinic receptors, 560–563, 561f–562f
 antagonists of, 567–568, 568f
 biochemical effects of stimulation of, 562–563, 562f
 structure of, 566–567, 566f, 567t
 subtypes of, 560–562
 Muscle
 contraction of, 618–619, 619f, 622, 622f
 excitation–contraction coupling of, 622, 622f
 relaxation of, 618–619, 619f
 Musculotropic drugs, 583–584
 Mustargen. *See* Mechlorethamine hydrochloride
 Mutamycin. *See* Mitomycin C
 Myambutol. *See* Ethambutol
 Mycelex. *See* Clotrimazole
Mycobacterium avium, 215
Mycobacterium intracellulare, 215
Mycobacterium kansasii, 215
Mycobacterium leprae, 215
Mycobacterium tuberculosis, 215, 218
 Mycoses. *See* Fungal infections
 Mycostatin. *See* Nystatin
 Mydracyl. *See* Tropicamide
 Mydratics, 583–584
 Myelosuppression, with alkylating agents, 359
 Myleran. *See* Busulfan
 Mylotarg. *See* Gemtuzumab ozogamicin
 Myocardial infarct, 613
 Myocardial ischemia, 617–618, 618f
 Myocardial metabolism, 618, 618f
 Myoscint Kit. *See* Imciromab pentetate
 Myosin, 318, 319f, 622, 622f
 Myoview. *See* Technetium (^{99m}Tc) tetrofosmin
 Mysoline. *See* Primidone
 Mytelase chloride. *See* Ambenonium chloride
 N
 Nabilone, metabolism of, 82
 Nabumetone, 799f, 800
 Nadolol, 551, 552f
 Nafarelin acetate, 697t, 698–699, 698f
 Nafcillin sodium, 269t, 271–272
 Naftifine hydrochloride, 200
 Naftin. *See* Naftifine hydrochloride
 Naked nucleic acids, for vaccines, 177–178
 Nalbuphine, 790
 Nalfon. *See* Fenpropfen
 Nalidixic acid, 206, 208–210, 208t
 Naliglutide. *See* Albiglutide
 Nalmefene, 791f, 792
 Naloxone, 791–792, 791f
 metabolism of, 82
 Naltrexone, 791, 791f
 metabolism of, 80, 82–83
 Naltrindole, 780, 781f
 Nandrolone decanoate, 851
 Naphazoline, 537
 Naprosyn. *See* Naproxen
 Naproxen, 794t, 795, 800–801, 801f
 conjugation of, 90–91
 Naramig. *See* Naratriptan
 Naratriptan, 812t, 813–814, 813f
 Narcan. *See* Naloxone
 Nardil. *See* Phelzeline sulfate
 Nasacort. *See* Triamcinolone acetonide
 Nasarel. *See* Flunisolide
 Nasonex. *See* Mometasone furoate
 Natacyn. *See* Natamycin
 Natamycin, 198–199
 Nateglinide, 661, 672, 674f–675f, 676t, 679–681, 680f
 Navane. *See* Thiothixene
 Navelbine. *See* Vinorelbine ditartrate
 Neamine, 298
 Nebcin. *See* Tobramycin sulfate
 Nebido. *See* Testosterone undecanoate
 Nebramycins, 300
 Nedocromil sodium, 758
 Nefazodone, 514–515
 Negatron emission, 414
 NegGram. *See* Nalidixic acid
 Nelfinavir, 349–350
 Neomycin sulfate, 297–298
 Neoplasia, 355
 Neosamine, 298
 Neosar. *See* Cyclophosphamide
 Neostigmine, 572t, 573f, 574, 601–602
 Neostigmine bromide, 574
 Neostigmine methylsulfate, 574
 Neo-Synephrine. *See* Phenylephrine
 Nepafenac, 799f, 800
 Nerves
 action potentials in, 719–720
 local anesthetic mechanism of action on, 722–723, 722f
 motor, 558
 physiology of, 718–719, 718f–719f
 somatic, 558
 Nervous system, divisions of, 558
 Netilmicin sulfate, 300–301
 Netoglitazone, 682, 682f
 Netromycin. *See* Netilmicin sulfate
 Neumega. *See* Oprelvekin
 Neupogen. *See* Filgrastim; Fligrastim
 Neupro. *See* Rotigotine
 Neural muscarinic receptors, 561
 Neuraminidase inhibitors, 336–337
 Neurogenic inflammation theory, of migraines, 812
 Neurohypophyseal hormones, 895–896, 896t
 Neuroleptic drugs. *See* Antipsychotics
 Neurolyte. *See* Technetium (^{99m}Tc) bicisate
 Neuromuscular blocking agents, 599–605, 602f
 curare/curare alkaloids, 599–601
 depolarizing, 600
 nondepolarizing, 600
 synthetic compounds with curariform activity, 601–605, 602f
 Neuromuscular junction, 599–600
 Neurontin. *See* Gabapentin
 Neuropathic pain, anticonvulsants for, 492
 Neurosteroids, 864, 864f
 Neurotensin, 904
 Neurotransmission, physiology of, 718–719, 718f–719f
 Neurotransmitters
 acetylcholine as, 558–559, 563–564, 563f–564f, 596–597, 597f
 adrenergic, 519–524
 antihypertensive agents depleting stores of, 639–641, 639f–640f
 ganglionic stimulation by, 596–597, 597f
 Neurotropic drugs, 583–584
 Neutralization, immunological, 163–164
 Neutral protamine Hagedorn (NPH) insulin, 668, 669t, 901, 901t–902t
 Neutrexin. *See* Trimetrexate
 Neutrophils, 156, 157f
 Nevanac. *See* Nepafenac
 Nevirapine, 348
 Nexavar. *See* Sorafenib tosylate
 Nexium. *See* Esomeprazole magnesium
 NH₂. *See* Mechlorethamine hydrochloride
 Niacin, 940–942, 940f–941f. *See also* Nicotinic acid
 Nicalex. *See* Nicotinic acid
 Nicardipine, 623t
 Nicardipine hydrochloride, 626
 Niclosamide, 226
 Nicotine, 24, 594
 ganglionic stimulation by, 596–598
 metabolism of, 64, 66
 Nicotinic acid, for hyperlipoproteinemia, 651
 Nicotinic hydroxamic acid, 578
 Nicotinic receptors, 559–560, 559f–560f, 559t
 NIDDM. *See* Non–insulin-dependent diabetes mellitus
 Nifedipine, as vasodilator, 623–625, 623t, 626f
 Nifurtimox, 223
 Nigrostriatal pathway, 472, 473f
 Nilandron. *See* Nilutamide
 Nilutamide, 851–852, 851f
 Nimetazepam, metabolism of, 58–59
 Nimodipine, 623t, 626
 Nimotop. *See* Nimodipine
 Nipent. *See* Pentostatin
 Nipride. *See* Sodium nitroprusside
 Nisoldipine, 627
 Nisoxetine, 514
 Nitrates, 620, 620t
 Nitrazepam, metabolism of, 84
 Nitrendipine, 627
 Nitric acid esters, 620, 620t
 Nitric oxide (NO), 620t
 formation of, 619
 malaria and, 244
 in smooth muscle relaxation, 618–619, 619f
 Nitrites, 617, 620, 620t
 Nitrofurans, 213–214
 Nitrofurantoin, 213–214
 Nitrofurazone, 213
 Nitrogen mustards, 359–361
 Nitroglycerin, 45, 619–621, 620t
 conjugation of, 97–98
 Nitromersol, 189–190
 Nitropress. *See* Sodium nitroprusside
 Nitroprusside, 620t
 Nitrosothiol, 620t
 Nitrosoureas, 365, 366f–367f
 Nitrostat. *See* Nitroglycerin
 Nitrous acid esters, 620, 620t
 Nitrous oxide, 712f, 712t, 714
 Nitrovasodilators, 618–622, 619f, 620t
 antianginal action of, 620
 esters of nitrous and nitric acids, 620, 620t
 metabolism of, 619–620, 620t
 oxidation states of, 620t
 smooth muscle relaxation and, 618–619, 619f
 speed and duration of action of, 620t
 NIV. *See* Nutrient intake value
 Nivalin. *See* Galantamine
 Nizatidine, 762t, 764–765, 767t
 Nizoral. *See* Ketoconazole
 NO. *See* Nitric oxide
 Nociception, 781
 Noctec. *See* Chloral hydrate
 Nofetumomab merpantan, 149
 Nolvadex. *See* Tamoxifen; Tamoxifen citrate
 Nomegestrol acetate, 838f, 840
 Nonaniline sulfonamides, 230
 Nondepolarizing competitive ganglionic blocking agents, 598
 Nondepolarizing neuromuscular blocking agents, 600
 Nondepolarizing noncompetitive ganglionic blocking agents, 598–599
 Non–insulin-dependent diabetes mellitus (NIDDM), 667
 Nonmevalonate pathway, inhibition of, 255f, 256
 Nonselective serotonin-norepinephrine reuptake inhibitor, 514
 Nonsteroidal anti-inflammatory drugs (NSAIDs), 792–806, 793f, 794t, 795f–797f, 799f, 801f–802f, 804f–806f
 acetaminophen and related analogs, 803–806, 804f–806f
 aspirin and salicylic acid derivatives, 796–798, 797f
 conventional nonselective cyclooxygenase inhibitors, 798–803, 799f, 801f–802f
 mechanism of action of, 792–793, 793f
 prostaglandins and, 869
 selective COX-2 inhibitors, 795, 795f, 803, 804f
 side effects of, 792–793, 793f, 794t
 structure–activity relationships of, 793–796, 794t, 795f–796f
 Nonsteroidal therapies for hormone-related disorders, 666–703
 aminyl analogs, 689–690, 689f
 biguanides, 685–687, 685f–686f
 glinides, 668–681, 670f–672f, 673t, 674f–680f, 676t
 glucose elevating agents, 694–695, 696f
 α -glucosidase inhibitors, 662–663, 687–689, 687f–688f
 gonadotropin-releasing hormone agonists, 697t, 698–699, 698f

- gonadotropin-releasing hormone antagonists, 699–701, 699*t*, 700*f*
- incretin system modulating agents, 690–694, 690*f*, 693*f*–695*f*
- insulins and modified insulins, 667–668, 667*f*, 668*t*–669*t*
- sulfonylureas, 659–661, 668–681, 670*f*–672*f*, 673*t*, 674*f*–680*f*, 676*t*
- thiazolidinediones, 662, 681–685, 682*f*–685*f*, 684*t*
- Norbinaltorphimine, 781, 782*f*
- Norcuron. *See* Vecuronium bromide
- Norelgestromin, 839*f*, 840
- Norepinephrine, 474, 523–524, 524*f*
methylation, 102–104
as sympathomimetic, 532–535
- Norethindrone, 838*f*, 838*t*, 840
metabolism of, 83
- Norethynodrel, 838*f*, 838*t*, 840
- Norflex. *See* Orphenadrine citrate
- Norfloxacin, 208, 208*t*, 209*f*, 210–211
- Norgestimate, 839*f*, 840
- Norgestrel, 838*f*, 838*t*, 840
metabolism of, 78–79
- Normodyne. *See* Labetalol
- Noroxin. *See* Norfloxacin
- Norpace. *See* Disopyramide; Disopyramide phosphate
- Norplant, 846
- Norpramin. *See* Desipramine hydrochloride
- 19-Norprogesterone, 838*t*
- Nortriptyline hydrochloride, 512
metabolism of, 8
- Norvasc. *See* Amlodipine
- Norvir. *See* Ritonavir
- Novantrone. *See* Mitoxantrone hydrochloride
- Novatropine. *See* Homatropine methylbromide
- Noviose, 231
- Novobiocin acid, 231
- Novobiocin sodium, 321–322
- Novocaine. *See* Procaine
- Novolin 70/30. *See* Neutral protamine Hagedorn insulin
- Novolin N. *See* Neutral protamine Hagedorn insulin
- Novolin R. *See* Human insulin, recombinant
- NovoLog. *See* Insulin aspart
- NovoLog Mix 70/30. *See* Insulin aspart
- Novo Seven. *See* Factor VIIa, recombinant
- NP-27. *See* Tolnafate
- NPH insulin. *See* Neutral protamine Hagedorn insulin
- NSAIDs. *See* Nonsteroidal anti-inflammatory drugs
- Nubain. *See* Nalbuphine
- Nuclear medicine, 413–415
- Nucleic acid vaccines, 177–178
- Nucleons, 413
- Nucleophiles, alkylation of, 358–359, 359*f*
- Nucleoproteins, 885
- Nucleoside antifungal agents, 196, 196*f*
- Nucleoside antimetabolites, 339–346
DNA polymerase inhibitors, 339–343
miscellaneous, 346
reverse transcriptase inhibitors, 343–346
- Nucleosomes, 885
- Nuclide, 413
- Nuprin. *See* Ibuprofen
- Nuromax. *See* Doxacurium chloride
- Nutrient intake value (NIV), 917
- NuvaRing, 844*t*, 845–846
- Nydrazid. *See* Isoniazid
- Nystatin, 198, 260*t*
- O**
- OCT1. *See* Organic cation transporter 1
- Octamethyl pyrophosphoramide (OMPA), 579–580
- Octanol/water system, for computer-aided drug design, 18–20, 19*f*–20*f*
- OctreoScan. *See* Indium (¹¹¹In) pentetate
- Ocufen. *See* Flurbiprofen
- Ocupress. *See* Carteolol
- Ofloxacin, 208, 208*t*, 211–212
- Olanzapine, 464–465, 483*t*, 484, 485*f*
- Oleandolide, 313
- Oleandomycin, 313
- Olefins, oxidative reactions of, 52–55
- Oleoyl-estrone. *See* Estrone
- 2',5'-Oligoadenylate, 338, 339*f*
- Olmesartan, 613–614, 626
- Olmotec. *See* Olmesartan
- Olsalazine
degradation of, 3–4
solubility of, 4
- Omacar. *See* Lovaza
- Omeprazole, 765, 766*t*–767*t*, 767–769, 768*f*, 769*t*
- Omnaris. *See* Ciclesonide
- Omnipaque. *See* Iohexol
- Omnipen. *See* Ampicillin
- Omniscan. *See* Gadodiamide
- OMPA. *See* Octamethyl pyrophosphoramide
- OMPA-*N*-methoxide, 579–580
- Oncogenes, 356, 356*t*
- OncoScint. *See* Satumomab pendetide
- Oncovin. *See* Vincristine sulfate
- Onglyza. *See* Saxagliptin
- Ontak. *See* Denileukin difitox
- Opana. *See* Oxymorphone
- Ophthalmic glucocorticoids, 860*f*
- Opioid agonists, 790–791
- Opioid antagonists, 790–792, 791*f*
- Opioid receptors, 778–782, 780*f*–782*f*
discovery of, 777–778
endogenous ligands for, 777–778
ligand binding site of, 779
structure–activity relationships at, 778, 779*f*, 782
- Opioids, 777–792, 779*f*–784*f*, 787*f*–789*f*, 791*f*
benzomorphans, 786
diphenylheptanes, 788–789, 788*f*–789*f*
4,5-epoxymorphinans, 782–785, 782*f*–784*f*
mixed agonist/antagonists, 790–791
morphinans, 783*f*, 785–786
opioid antagonists, 791–792, 791*f*
- Opium, 783
- Oprelvekin, 142
- Optical isomerism, biological activity and, 30–31, 31*f*–32*f*
- OptiMARK. *See* Gadoversetamide
- Optimine. *See* Azatidine maleate
- OptiPranolol. *See* Metipranolol
- Optiray. *See* Ioversol
- Optison. *See* Perflutren
- Optivar. *See* Azelastine hydrochloride ophthalmic solution
- Oral administration, drug distribution in, 3–5
- Oral cephalosporins, 279, 280*t*–282*t*, 282
- Oral contraceptives. *See* Contraceptive agents
- Orap. *See* Pimozide
- Organic cation transporter 1 (OCT1), 686
- Organoplatinum compounds, 362–365, 365*f*
- Orhoclone-OKT3. *See* Muromonab-CD3
- Orinase. *See* Tolbutamide
- Orinase Diagnostic. *See* Tolbutamide sodium
- Orlaam. *See* Acetylmethadol
- Orphanin receptors, 781–782
- Orphenadrine citrate, 591–592
- Ortho-Evra, 843*t*, 845
- Ortho-Prefest, 846*t*
- Orudis. *See* Ketoprofen
- Oseltamivir phosphate, 336–337
metabolites of, 112
- Ospemifene, 833–834, 833*f*
- Osteo deformans. *See* Paget disease of bone
- Osteomalacia, 706
- Osteoporosis, 705–706
HRT for, 846
- Osteoprotegerin, 710
- Otrivin. *See* Xylometazoline
- Ovarian failure, estrogen treatment of, 831
- Ovulation, steroid hormone regulation of, 826–827, 826*f*
- Ovulation inhibitors, 841–846, 842*t*–844*t*
- Oxacillin sodium, 269*t*, 271
- Oxaliplatin, 363–365, 365*f*, 370
- Oxamniquine, 226
- Oxandrin. *See* Oxandrolone
- Oxandrolone, 849*f*, 851
- Oxaprozin, 801, 801*f*
- Oxazepam, 448–450
- Oxcarbamazepine, 497–498, 498*f*
- Oxcarbazepine, 492
- Oxicans, 803
- Oxiconazole nitrate, 203
- Oxidative deamination, 65
- Oxidative *N*-dealkylation, 62–65
- Oxidative reactions, 47–78
alcohols and aldehydes, 76, 78
at aliphatic and alicyclic carbon atoms, 59–60
at allylic carbon atoms, 55–58
aromatic hydroxylation, 47–52, 48*f*, 50*f*
at benzylic carbon atoms, 55
at carbon atoms α to carbonyls and imines, 58–59
carbon–heteroatom systems, 60–61
carbon–nitrogen systems, 62–73
amides, 70–73
aromatic amines and heterocyclic nitrogen compounds, 70
secondary and primary amines, 65–69
tertiary aliphatic and alicyclic amines, 62–65
carbon–oxygen systems, 73–75
carbon–sulfur systems, 75–76
of olefins, 52–55
other pathways, 78
of recombinant proteins, 132
stereoselectivity, 110
- Oxidizing agents, 185
penicillin and, 265
- Oxilan. *See* Ioxilan
- Oxine, 221–222
- Oxistat. *See* Oxiconazole nitrate
- Oxisuran, metabolism of, 76, 78, 83
- Oxolinic acid, 208
- Oxotremorine, 567, 567*f*
- Oxprenolol, metabolism of, 65, 67
- Oxy-5. *See* Hydrous benzoyl peroxide
- Oxy-10. *See* Hydrous benzoyl peroxide
- Oxybutynin, 591
- Oxychlorosene sodium, 186
- Oxycodone, 783*f*, 785
- OxyContin. *See* Oxycodone
- Oxymetazoline, 537
- Oxymetholone, 849*f*, 851
- Oxymorphone, 783*f*, 785
- Oxyphenyclimine hydrochloride, 590–591
- Oxyprim. *See* Oxypurinol
- Oxypurinol, 809*f*, 811
- Oxyquinophenol, 221–222
- Oxytracycline hydrochloride, 302*t*, 305*t*, 306
- Oxytocin, 895–896, 896*f*
- Oxytocin injection, 896, 896*t*
- Oxytocin nasal solution, 896, 896*t*
- Oxytrol. *See* Oxybutynin
- P**
- PABA. *See* *p*-Aminobenzoic acid
- Pacemaker cells, 630
- Paclitaxel, 398–399, 398*f*, 400*t*, 972, 973*f*
- Paget disease of bone, 705
- PAH. *See* Pulmonary arterial hypertension
- Pain, 776–777, 777*f*
- Pain management, 776–777, 777*f*. *See also* Analgesics
- Paliperidone, 486
- 2-PAM. *See* Pyridine-2-aldoxime methiodide
- L-PAM. *See* Melphalan
- Pamaquine, 250, 250*f*
- Pamelor. *See* Nortriptyline hydrochloride
- Pamidronate disodium, 707*t*, 708
- PAMPs. *See* Pathogen-associated molecular patterns
- Panado. *See* Acetaminophen
- Panaxosides, 970–971, 970*f*–971*f*
- Pancreatic hormone(s), 897–903, 897*f*, 898*t*, 901*t*–902*t*
- Pancreatin, 888, 888*t*
- Pancrelipase, 888*t*, 889
- Pancuronium bromide, 599, 603–604
- Panmycin. *See* Tetracyclines
- Pantheric. *See* Pancreatin
- Pantoprazole, 765, 766*t*–767*t*, 767–768
- Pantoprazole sodium, 770–771
- Pantothenic acid, 942–944, 942*f*
- Panwarfin. *See* Warfarin sodium
- Papain, 887*f*, 890
- Papase. *See* Papain
- Papaverine, 110, 583–584
as smooth muscle relaxant, 619
- Papaverine hydrochloride, 594–596
- Paracetamol. *See* Acetaminophen
- Paraformaldehyde, 182–183
- Paraldehyde, 457
- Paramomycin sulfate, 298–299
- Paraoxon, 572*t*, 579–580
- Paraplat. *See* Carboplatin
- Paraplatin. *See* Carboplatin
- Parasympathetic ganglia, 596–597
- Parasympathetic nervous system, 558
- Parasympathetic postganglionic blocking agents, 583–584. *See also* Cholinergic blocking agents

- Parasympatholytics, 558
 Parasympathomimetics, 558
 Parathion, 578–580
 metabolism of, 75, 77
 Parathyroid hormone (PTH), 904–905
 in calcium regulation, 708–709
 Parathyroid injection, 904
 Paredrine. *See* Hydroxyamphetamine
 Parenteral administration, drug distribution, 4f, 5–6
 Parenteral cephalosporins, 280t–282t, 282
 Parenteral cephamycins, 282t
 Parent nuclide, 414
 Paricalcitol, 709, 709f, 927t, 928f
 Parkinson disease (PD), 473–478
 anticholinergic agents, 478
 anticholinergic drugs for, 584, 591–592
 COMT inhibitors, 477–478
 dopamine agonists, 475–477
 levodopa/carbidopa, 474
 MAO-B inhibitors, 474–475
 mechanism of, 473–474
 Parlodel. *See* Bromocriptine mesylate
 Parnate. *See* Tranylcypromine sulfate
 Paromomycin, 220
 Paroxetine, 513
 Paroxysmal nocturnal hemoglobinuria (PNH), 656
 Parsidol. *See* Ethopropazine hydrochloride
 Parthenolide, 965, 965f
 Partial least squares (PLS), 36
 Partial seizures, 492
 Particulate radiation, 413, 417
 Particulate removal, for recombinant protein, 131
 Partition coefficient, 18–20, 19f–20f
 PAS. *See* *p*-Aminosalicylic acid
 Patholon. *See* Tridihexethyl chloride
 Pathocil. *See* Dicloxacillin sodium
 Pathogen-associated molecular patterns (PAMPs), 176–177
 Pathogens, vaccines, 166–167, 167f
 Paton rate theory, 581
 Pattern recognition receptors, 176
 Pavulon. *See* Pancuronium bromide
 Paxil. *See* Paroxetine
 PBPs. *See* Penicillin-binding proteins
 PCB. *See* Procarbazine
 PCP. *See* *Pneumocystis carinii* pneumonia
 PCZ. *See* Procarbazine
 PD. *See* Parkinson disease
 PD-178390, 350–351
 Peditamycin. *See* Erythromycin ethylsuccinate
 Pediculicides, 227
 Peginterferon alfa-2a, recombinant, 911
 Pegylated interferon alfa-2a, 139, 139f
 Pemtrexed, 379, 380f, 383
 Pemirolast potassium ophthalmic solution, 759
 Pemoline, 509
 Penbritin. *See* Ampicillin
 Penbutolol, 551, 552f
 Penciclovir, 342–343
 Penetrex. *See* Enoxacin
 Penicillanic acid, 263
 Penicillin(s), 260t, 261–274
 allergies to, 268–269
 chemical classification of, 260
 classification of, 269, 269t
 commercial production and unitage, 261
 definition of, 258
 degradation of, 263–265, 266f
 discovery of, 258
 extended-spectrum, 267–268
 historical background on, 258–259
 β -lactamase inhibitors with, 274
 mechanism of action of, 259–260, 260t
 microbial resistance to, 265–267
 nomenclature of, 261–262
 penicillinase-resistant, 267
 protein binding in, 268
 stereochemistry of, 262–263
 structures of, 262t
 synthesis of, 263, 264f
 Penicillinase-resistant penicillins, 267
 Penicillinases, 265–266
 Penicillin-binding proteins (PBPs), 261
 Penicillin G, 260–261, 267–269, 269t
 Penicillin G benzathine, 270
 Penicillin G procaine, 269–270
 Penicillin N, 278
 Penicillin V, 260, 267–268, 269t, 270
 Penicillic acid, 265
 Pennyroyal, 972, 972f
 Pentaerythritol tetranitrate, diluted, 620t, 621–622
 Pentagastrin, 903
 Pentamidine, 658
 Pentamidine isethionate, 222
 Pentaquine, 250, 250f
 Pentazocine, 45, 110, 786
 metabolism of, 55, 58
 Pentobarbital, 454–455, 454t
 metabolism of, 59–60
 Pentostam. *See* Sodium stibogluconate
 Pentostatin, 378, 382–383
 Pentritol. *See* Pentaerythritol tetranitrate, diluted
 Pentylene tetrazole, 504
 Pen Vec. *See* Penicillin V
 Pepcid. *See* Famotidine
 Peptavlon. *See* Pentagastrin
 Peptic ulcer disease (PUD), 760
 Peptide hormones. *See* Hormone(s)
 Percent ionization, 14–16, 15f–16f
 Percocet. *See* Acetaminophen; Oxycodone
 Percodan. *See* Oxycodone
 Perflutren, 440
 Pergolide, 24, 475–476
 Pergonal. *See* Menotropins
 Periactin. *See* Cyproheptadine; Cyproheptadine hydrochloride
 Peripheral nervous system, 558
 Peritrate. *See* Pentaerythritol tetranitrate, diluted
 Permapen. *See* Penicillin G benzathine
 Permethrin, 228
 Permitil. *See* Fluphenazine hydrochloride
 Perniciosa anemia, 951
 Perphenazine, 461t, 462–463, 480t, 481
 Persantine. *See* Dipyridamole
 Pertofrane. *See* Desipramine hydrochloride
 Pertussis vaccine, 172
 Pesticides, drug metabolism and, 108
 Pestox III. *See* Schradan
 PET. *See* Positron emission tomography
 Petit mal seizure, 492
 PGH synthase. *See* Cyclooxygenase
 pH, penicillin and, 265
 Phagocytes, 156–157, 157f
 Pharmacogenomics, 152
 Pharmacognosy, 962
 Pharmacological activity, statistical prediction of, 17–18
 Phenacemide, conjugation of, 94, 96
 Phenacetin, 803–804
 conjugation of, 93
 metabolism of, 8, 75
 toxicity in, 805–806, 806f
 Phenazopyridine hydrochloride, 214
 metabolism of, 104–106
 Phenbenzamine, 744, 746
 Phencyclidine, 517
 metabolism of, 60, 62
 Phendimetrazine tartrate, 508
 Phenelzine sulfate, 510, 510t, 523
 acetylation of, 100–101
 Phenergan. *See* Promethazine hydrochloride
 β -Phenethylamines, 966f, 968–969
 Phenformin, 659, 685f
 Phenindamine, 740t
 Phenindamine tartrate, 750–751
 Pheniramine, 748
 Pheniramine maleate, 749
 Phenmetrazine, metabolism of, 65–68
 Phenobarbital, 454–455, 454t, 497, 497f
 metabolism of, 48
 Phenol coefficient, 183
 Phenols, 179
 as anti-infective agents, 183–185
 topical, 195–196
 Phenothiazine antihistamines, 740t, 751–752, 751f
 Phenothiazines, 458–465, 459f, 459t, 479–481
 mechanism of action of, 459–460
 metabolism of, 460–461
 pharmacokinetic properties of, 479, 480f
 products, 461–463, 461t, 479–481, 480t
 ring analogs of, 463–465
 structure–activity relationships of, 458–460, 459f, 479, 480f
 Phenoxybenzamine, 546–547, 547f
 Phenoxyethylpenicillin, synthesis of, 263, 264f
 Phenoximide, metabolism of, 86, 88
 Phentermine hydrochloride, 506t, 507–508
 metabolism of, 68–70
 Phentermine ion-exchange resin, 506t, 507–508
 Phentolamine, 546
 Phenurone. *See* Phenacemide
 Phenylacetic acid, conjugation of, 93–94
 Phenylacetone, metabolism of, 69
 L-Phenylalanine mustard. *See* Melphalan
 Phenylbutazone
 conjugation of, 90–91
 drug metabolism and, 108
 metabolism of, 48
 metabolites of, 111
 Phenylephrine, 533, 536
 Phenylethyl alcohol, 191
 2-Phenylethylamines, 516
 5-Phenylhydantoin, metabolism of, 86, 88
 Phenylmercuric acetate, 191
 Phenylmercuric nitrate, 191
 4-Phenylpiperidine, 786–788, 787f
 Phenylpropanolamine, 545
 Phenyltrimethylammonium, 559–560
 Phenytoin. *See* Phenytoin
 Phenytoin, 16, 492, 492f, 495–497, 496f
 enantiomers of, 109
 hypersensitivity reaction of, 497
 metabolism of, 48–49, 51, 104–105, 496–497, 496f
 Phenytoin sodium, 634
 Pheochromocytoma, 637
 Phosphodiesterases, 11, 11f
 Phosphodiesterase type 5 inhibitors, 644
 Phosphoinositol system, 562, 562f
 Phospholine iodide. *See* Echothiophate iodide
 Phospholipase C, 562, 562f
 Phosphoramidate mustard, metabolism of, 72–73
 Phosphorothionates, 577
 Photons, 413
 Phthalazinone, 740t
 Phylloquinone, 932, 932f
 Physostigmine, 572–574, 572t, 573f
 Physostigmine salicylate, 573–574
 Physostigmine sulfate, 574
 Phytoestrogens, 830–831, 830f
 Phytonadione, 935
 Picromycin, 308
 Picrotoxin, 504
 Picrotoxinin, 504
 Pill, the. *See* Contraceptive agents
 Pilocarpine hydrochloride, 569–570
 Pilocarpine nitrate, 570
 Pimozide, 483
 Pindolol, 551, 552f
 Pinocytosis, 5
 Pinworm infections, 224–225
 Pioglitazone, 662, 681–682, 682f–683f, 684–685, 684t, 685f
 Papanol. *See* Trihexyphenidyl hydrochloride
 Pipecuronium bromide, 601, 604
 Piperacillin sodium, 268, 269t, 274
 Piperacillin-tazobactam, 276
 Piperazine, 225
 Piperazine antihistamines, 740t, 746–748, 747f
 Piperazine estrone sulfate, 829f, 832
 Piperidine antihistamines, 740t
 Pipracil. *See* Piperacillin sodium
 Pirbuterol, 541–542
 Pirenzepine, 561, 567, 568f
 Piroxicam, 794t, 795–796, 796f, 803
 Pitocin. *See* Oxytocin injection
 Pitressin. *See* Vasopressin injection
 Pitressin tannate. *See* Vasopressin tannate
 Pituitary gonadotropins, 695–701, 696f, 697t, 698f, 699t, 700f, 726–827, 826f, 890, 894
 Pituitary hormones, 891–894, 892t
 pK_a
 calculating, 12, 14t
 for computer-aided drug design, 20
 drug distribution and, 16–17, 16f–17f
 examples of, 12t, 14t
 percent ionization, 14–16, 15f–16f
 for sulfonamides, 230, 232
 values for, 976t–983t
 PKC ζ . *See* Protein kinase C type zeta

- Placental hormones, 895
 Placidyl. *See* Ethchlorvornol
 Plan B, 844*t*, 846
 Plaquenil. *See* Hydroxychloroquine
 Plaques, atherosclerotic, 647
 Plasmakinins, 905–906
 Plasmid, for vector cloning, 125, 125*f*
Plasmodium falciparum, 242, 244
Plasmodium malariae, 243
Plasmodium ovale, 243
Plasmodium spp., 242
 genome of, 244
 infection by, 243–244
 life cycle of, 243*f*
 types of, 242–243
Plasmodium vivax, 242, 244
 Platelet(s)
 activation and aggregation of, 627–628, 656–657, 657*f*
 inhibitors of, 656–657, 657*f*
 GPIIb/IIIa receptors of, 628–629
 Platensimycin, 326
 Platinol. *See* Cisplatin
 Platinol-AQ. *See* Cisplatin
 Platinum compounds, alkylating, 362–365, 365*f*
 Plavix. *See* Clopidogrel
 Plegine. *See* Phendimetrazine tartrate
 Plenaxis. *See* Abarelix acetate
 Plendil. *See* Felodipine
 PLS. *See* Partial least squares
 Pneumocanadins, 206
 Pneumococcal vaccine, 173
Pneumocystis carinii pneumonia (PCP), 220
 PNH. *See* Paroxysmal nocturnal hemoglobinuria
 Podophyllotoxin, 389, 390*f*
 Polaramine. *See* Dexchlorpheniramine maleate
 Polar surface area, 20
 Polio vaccines, 168–169
 Polychlorinated biphenyl mixtures, metabolism of, 49
 Polycillin. *See* Ampicillin
 Polyclonal antibodies, 146
 Polycyclic antimalarials, 246*t*–247*t*, 251–253, 251*f*
 Polyene antibiotics, 197–199
 Polymox. *See* Amoxicillin
 Polymyxin B sulfate, 318
 Polymyxins, 260*t*, 318–320
 Polypeptide antibiotics, 315–320
 Polypeptide chains, 881, 881*f*
 Polyvalent viral vaccines, 170
 Pondimin. *See* Fenfluramine hydrochloride
 Ponstan. *See* Mefenamic acid
 Ponstel. *See* Mefenamic acid
 Porcine insulin, 668, 668*t*
 Porins, penicillin resistance and, 266–267
 Posaconazole, 205
 Positional cloning, 126, 126*t*
 Positive inotropic agents, 645–647
 Positron emission, 414
 Positron emission tomography (PET), 414, 418, 418*f*
 Postcoital contraceptives, 844*t*, 846
 Potassium channel agonists, 644–645, 645*f*
 Potassium ion, in nerve conduction, 719–720
 Potassium leak channels, 719
 Potassium sorbate, 191
 Potential energy, for butane, 34, 34*f*
 Povidone-iodine, 185–186
 PPAR γ , thiazolidinedione binding to, 681–682, 683*f*
 Practolol, 550
 Pradimycins, 206–207
 Pralidoxime chloride, 577*f*, 580–581
 Pramipexole dihydrochloride, 476–477
 Pramlintide, 689–690, 689*f*
 PrandiMet. *See* Metformin; Repaglinide
 Prandin. *See* Repaglinide
 Prantal. *See* Diphenanil methylsulfate
 Pravachol. *See* Pravastatin
 Pravastatin, 653
 Prazepam, 446*f*, 447
 Praziquantel, 226–227
 Prazosin, 547–548
 metabolism of, 75–76, 86, 88
 Prazosin hydrochloride, 641
 Precef. *See* Ceforanide
 Precipitation
 immunological, 164
 of recombinant proteins, 134
 Precose. *See* Acarbose
 Prednicarbate, 857*f*, 862
 Prednisolone, 822*t*, 856*f*, 858–859, 858*t*, 861
 metabolism of, 86–87
 Prednisolone acetate, 822*t*
 Prednisolone NaPO $_4$, 822*t*
 Prednisone, 856*f*, 858–859, 858*t*, 861
 conjugation of, 97–98
 Pregabalin, 493, 498, 498*f*
 Pregnancy, folic acid and, 949, 951
 Pregnenolone, 821*f*
 Preludin. *See* Phenmetrazine
 Premarin. *See* Conjugated estrogens
 Premphase, 846*t*
 Prempro, 846*t*
 Preservatives, 190–191
 Prevacid. *See* Lansoprazole
 Preven, 844*t*, 846
 Prexige. *See* Lumiracoxib
 Prilocaine, 727–728, 728*f*
 Primacor. *See* Milrinone
 Primaquine, 246*t*–247*t*, 250–251, 250*f*
 Primary generalized seizures, 492
 Primary hypertension, 637–638
 Primaxin. *See* Imipenem-cilastatin
 Primidone, 497, 497*f*
 Principen. *See* Ampicillin
 Prinivil. *See* Lisinopril
 Priscoline. *See* Tolazoline
 Pristinamycin 1A, 322–323
 Pristinamycin 2A, 322–323
 Privine. *See* Naphazoline
 ProAmatine. *See* Midodrine
 Proarrhythmia, 631
 Pro-Banthine. *See* Propantheline bromide
 Probenecid, 810*f*, 811
 metabolism of, 49
 Probutol, 652
 Procainamide
 acetylation of, 97, 100
 metabolism of, 86–87
 Procainamide hydrochloride, 633
 Procaine, 724–726, 724*f*
 metabolism of, 86–87
 Procan SR. *See* Procainamide hydrochloride
 Procarbazine, 366–367, 367*f*–368*f*, 371
 Procardia. *See* Nifedipine
 Prochlorperazine maleate, 461*t*, 462, 480*t*
 Procrit. *See* Epoetin alfa
 Procyclidine hydrochloride, 591, 593
 Prodrugs, 43, 823
 oral administration of, 4–5
 parenteral administration of, 5–6
 solubility of, 4
 Productive infection, 330
 Product stereoselectivity, 110
 Proenzymes. *See* Zymogens
 Profenal. *See* Suprofen
 Progestasert IUD, 843*t*, 845
 Progesterone, 821*f*, 837, 837*f*–838*f*, 838*t*, 839
 Progesterone IUDs, 843*t*, 845
 Progesterone receptor antagonists, 841, 841*f*
 Progesterone receptors (PRs), 825
 Progestin only pill, 843*t*, 845
 Progestins, 827, 837–841, 837*f*–839*f*, 838*t*
 endogenous, 837
 in HRT, 846–847, 846*t*
 Progucagon, 690
 Proglycem. *See* Diazoxide
 Progot. *See* Allopurinol
 Proguanil hydrochloride, 246*t*–247*t*, 253*f*, 254–255, 254*f*
 ProHance. *See* Gadoteridol
 Prolactin, 894
 Prolamines, 883*t*
 Proloukin. *See* Aldesleukin
 Prolixin. *See* Fluphenazine hydrochloride
 Prolopr. *See* Trimethoprim
 Promazine, 461*t*, 462, 480*t*
 Promethazine, 460, 740*t*, 751
 Promethazine hydrochloride, 751–752
 Prometrium. *See* Progesterone
 Prompt insulin zinc suspension, 901, 901*t*–902*t*
 Pronestyl. *See* Procainamide; Procainamide hydrochloride
 Pronethalol, 550
 Protosil. *See* Sulfamidochrysidine
 Propacil. *See* Propylthiouracil
 Propadrine. *See* Phenylpropanolamine
 Propafenone, 635
 Propantheline bromide, 590–591
 Propecia. *See* Finasteride
 Propine. *See* Dipivefrin
 Propionic acid, 194
 Propofol, 716–717, 717*f*
 Propoxyphene, 45, 788*f*, 789
 metabolism of, 63–64
 Propranolol, 45, 550–551
 conjugation of, 90–91
 metabolism of, 48, 65, 67, 80–81
 Propylamine antihistamines, 740*t*, 748–751, 749*f*
 Propylhexedrine, 544
 Propylparaben, 190
 Propylthiouracil, 664
 conjugation of, 90–91
 Proscar. *See* Finasteride
 Prostacyclin, 877
 Prostaglandin(s). *See also* Eicosanoids
 acetaminophen interaction with synthesis of, 804–805, 805*f*
 analogs of, 874*t*–875*t*
 as antihypersecretory agents, 772–773
 in coagulation, 657
 in inflammation, 792–793, 793*f*
 for ophthalmic use, 878
 veterinary uses for, 878
 Prostaglandin E $_1$, 876–877
 Prostaglandin E $_2$, cyclodextrin, 877
 Prostaglandin endoperoxide synthase. *See* Cyclooxygenase
 Prostaphlin. *See* Oxacillin sodium
 ProstaScint Kit. *See* Capromab pendetide
 Prostate cancer
 antiandrogens for, 851
 estrogen treatment of, 831
 Prostigmin bromide. *See* Neostigmine bromide
 Prostigmin methylsulfate. *See* Neostigmine methylsulfate
 Prostin VR Pediatric. *See* Prostaglandin E $_1$
 ProstScint. *See* Indium (^{111}In) capromab pendetide
 Protamines, 883*t*
 Protamine sulfate, 657
 Protamine zinc insulin suspension (PZI), 668, 900–901, 901*t*–902*t*
 Protease inhibitors, anti-HIV, 348–351
 Proteases, 887, 887*f*
 Proteins, 880–885, 881*f*–882*f*, 883*t*–884*t*. *See also* Enzymes; Hormone(s)
 amino acid solutions, 881
 biotechnology-derived pharmaceuticals, 908*t*–909*t*, 909–913
 blood, 906–907
 chemical instability of, 132, 133*f*
 color tests, separation methods, and identification methods for, 883–884
 conformational features of, 881–882, 882*f*
 factors affecting structure of, 882–883
 impact of biotechnology on development of pharmaceutical products of, 907–909, 908*t*–909*t*, 910*f*
 physical instability of, 132, 134
 production of, 121–122, 122*f*
 properties of, 883
 protein hydrolysates, 880
 purification and classification of, 883, 883*t*
 recombinant
 delivery of, 134
 immunogenicity of, 134
 pharmacokinetics of, 134
 processing of, 131
 products, 134–150
 Protein binding
 for drug distribution, 4*f*, 6–7
 in penicillins, 268
 Protein C, 655
 Protein hydrolysates, 880
 Protein kinase C type zeta (PKC ζ), 686
 Protein kinase inhibitors, 400–406
 agents for, 405–406
 development of, 403–404
 growth factors and receptors, 401, 401*t*
 mechanism of action of, 403
 Ras pathways, 401, 402*f*, 403
 Protein-type A microspheres. *See* Perflutren

- Proteomics, 152
 Proteosomes, 407–408, 408f
 Prothrombin, 654–655, 654t, 655f
 Proton pump inhibitors, 765–773, 766f, 766t–767t, 768f, 769t
 drug interactions of, 769t
 Proto-oncogenes, 356, 356f
 Protopam chloride. *See* Pralidoxime chloride
 Protoporphyrin IX, 45
 Protostat. *See* Metronidazole
 Proprietyline hydrochloride, 512
 metabolism of, 53–54
 Protropin. *See* Somatrem
 Proventil. *See* Salbutamol
 Provera. *See* Medroxyprogesterone acetate
 Provigil. *See* Modafinil
 Provitamin A, 917, 919, 923
 Provitamin D, 923–925, 925f–926f
 Prozac. *See* Fluoxetine
 PRs. *See* Progesterone receptors
 Pseudochoolinesterase, 570, 571t
 Pseudoephedrine, 30, 696f, 969
 L-(+)-Pseudoephedrine, 544
 Pseudomonic acid A. *See* Mupirocin
 Pseudotropine, 584
 structure of, 582
 Psilocin, 516
 Psilocybin, 516
 Psychomotor stimulants, 506–509, 506t
 medical indications for, 506–507
 structures of, 506, 506t
 Psychoses, 457–458, 478
 PTH. *See* Parathyroid hormone
 PUD. *See* Peptic ulcer disease
 Pulegone, 972, 972f
 Pulmicort. *See* Budesonide
 Pulmonary arterial hypertension (PAH), 638, 644
 Pulmozyme. *See* Dornase alpha
 Purification, of recombinant protein, 131
 Purines, 372, 374f, 378–379, 378f–379f
 Purinethol. *See* Mercaptopurine
 Purkinje fibers, 630, 630f
 Puromycin, 335
 PVP-iodine. *See* Povidone-iodine
 Pyopen. *See* Carbenicillin disodium
 Pyrantel pamoate, 225
 Pyrazinamide, 215–216
 Pyrazinecarboxamide (PZA), 216
 Pyribenzamine Citrate. *See* Tripeleminamine
 Pyridine-2-aldoxime methiodide (2-PAM), 577f, 578
 Pyridium. *See* Phenazopyridine hydrochloride
 Pyridostigmine bromide, 572t, 574–575
 Pyridoxal, 944, 945f
 Pyridoxamine, 944, 945f
 Pyridoxine, 944, 945f
 Pyrilamine maleate, 740t, 745–746
 Pyrimethamine, 220, 246t–247t, 253–254, 253f
 sulfadoxine and, 238
 Pyrimidines, 372–378, 373f, 375f
 Pyrodox acid, 944–947, 945f–946f
 Pyronaridine, 251f, 255
 Pyronil. *See* Pyrrobutamine phosphate
 Pyrrobutamine phosphate, 750
 Pyruvate kinase deficiency, malaria and, 244
 PZA. *See* Pyrazinecarboxamide
 PZI. *See* Protamine zinc insulin suspension
- Q**
 QSAR. *See* Quantitative structure–activity relationships
 Quantitative structure–activity relationships (QSAR), 17–18, 18f–19f, 18t
 classification methods, 23–24
 high-throughput screening and, 38, 38f
 physicochemical parameters and, 21–22, 21t
 success of, 24
 three-dimensional quantitative structure–activity relationships and, 36–37, 36f
- Quantum mechanics, 32–33
 Quarzan. *See* Clidinium bromide
 Quasense, 844
 Quazepam, 446f, 448
 Questran. *See* Cholestyramine resin
 Quetiapine, 464–465, 483t, 484–486, 485f
 Quinacrine hydrochloride, 251f, 252
 Quinaglut. *See* Quinidine gluconate
 Quinapril hydrochloride, 611, 611f, 612t
- Quineprox. *See* Hydroxychloroquine
 Quinidine, 246t–247t, 247–248, 248f
 metabolism of, 55, 58
 Quinidine gluconate, 632–633
 Quinidine polygalacturonate, 633
 Quinidine sulfate, 632
 Quinine, 242, 246t–247t, 247–248, 248f
 Quinolones, 206–213
 properties of, 206–209, 208t, 209f
 types of, 209–213
 Quinophenol, 221–222
 Quinolol. *See* Oxine
 Quinupristin/dalfopristin, 322–323
 QVAR. *See* Beclomethasone dipropionate
 QX-314, 722, 729
- R**
 Rabepazole, 765, 766t–767t, 767–768
 Rabepazole sodium, 771
 Racemization, of recombinant proteins, 132
 Radanil. *See* Benznidazole
 Radiation
 biological effects of, 416–417
 description of, 414–415
 electromagnetic, 413
 ionizing, 413
 particulate, 413
 Radiation absorbed dose, 416
 Radiation dosimetry, 417
 Radioactive decay law, 414
 Radioactive tracers, 413, 417
 Radioactivity, 413–415
 decay calculations for, 414–415
 Radiographic contrast, 430
 Radiography
 contrast agents for, 430–436
 description of, 430–431, 431f
 digital, 430
 Radioimmunoassay, 417
 Radionuclide
 daughter, 414
 decay calculations for, 414–415
 parent, 414
 production of, 415–416, 416f
 Radiopharmaceuticals, 413–440
 fluorine, 418–419
 gallium, 419
 indium, 419–421
 iodine, 421–422
 technetium, 422–429
 thallium, 429–430
 xenon, 430
 Radiotracers. *See* Radioactive tracers
 Radio waves, 413
 Raloxifene, 10, 10f, 832–834, 833f
 Ramelteon, 452
 Ramipril, 611–612, 611f, 612t
 Ranexa. *See* Ranolazine
 Ranitidine, 762t, 764, 767t
 RANKL. *See* Receptor activator of nuclear factor- κ B ligand
 Ranolazine, 627
 Rasagiline mesylate, 475
 Rasilez. *See* Aliskiren
 Ras pathways, 401, 402f, 403
 Raudixin. *See* Rauwolfia serpentina, powdered
 Rau-Sed. *See* Reserpine
 Rauserpal. *See* Rauwolfia serpentina, powdered
 Rauval. *See* Rauwolfia serpentina, powdered
 Rauwolfia serpentina, powdered, 639
 rDNA technology. *See* Recombinant DNA technology
 Reactive oxygen species (ROS), 386
 Rebif. *See* Interferon beta-1a
 Reboxetine, 514
 Receptor activator of nuclear factor- κ B ligand (RANKL), 706, 710
 Receptors. *See* Drug receptors
 δ -Receptors, 780–781, 781f
 κ -Receptors, 781, 782f
 μ -Receptors, 779–780, 779f, 783
 Recombinant DNA, 121–126, 123f–125f, 123t–124t
 antisense technology, 152
 cloning strategies, 126, 126t
 DNA ligases, 124
 DNA manipulation, 127–128, 128f
 DNA overview, 121–123, 122f
- expression of cloned DNA, 127
 gene therapy, 153
 genomics, 150–152, 151f
 new biological targets, 128–129, 129t
 novel drug-screening strategies, 129–131, 129f–130f
 pharmaceuticals of, 131–134, 133f
 processing of, 131
 products, 134–150
 antibody production, 146–147, 147f
 cytokines, 136–138, 136t, 137f
 enzymes, 142–145
 hormones, 134–136
 in-home test kits, 150
 interferons, 138–141, 138f, 139t–140t
 interleukins, 141–142
 monoclonal antibodies, 147–149
 monoclonal antibody radionuclide test kits, 149–150
 therapeutic radionuclide monoclonal antibody, 149–150
 tumor necrosis factor, 142
 vaccines, 145–146, 146t
 restriction endonucleases, 124, 124f, 124t
 technology for, 123, 123f, 123t
 vector, 124–126, 125f
- Recombinant DNA (rDNA) technology
 for development of pharmaceutical proteins and peptides, 907–909, 910f
 pharmaceuticals derived from, 908t–909t, 909–913
- Recombivax, 145
 5 α -Reductase inhibitors, 852, 852f–853f
 Reductive reactions, 78–86
 aldehyde and ketone carbonyls, 80–83
 nitro and azo compounds, 83–84
- Refludan. *See* Lepirudin
 Regitine. *See* Phenolamine
 Regranex Gel. *See* Becaplermin
 Regular human insulin, recombinant, 667–668, 667f, 668t–669t, 900, 901t–902t
- Relafen. *See* Nabumetone
 Relative specificity, 885
 Relaxation, of muscle, 618–619, 619f
 Release, of virus, 333, 336
 Relistor. *See* Methylnaltrexone
 Relpax. *See* Eletriptan
 Remeron. *See* Mirtazapine
 Remicade. *See* Infliximab
 Remifentanyl, 787f, 788
 Reminyl. *See* Galantamine
 Remoxipride, 468
- Renal failure, drug metabolites and, 111
 Renal hypertension, 637
 Renal system drugs, 607–615
 ACE inhibitor prodrugs, 610–612, 611f, 612t
 aldosterone antagonists, 615, 864
 angiotensin antagonists, 612–614
 renin-angiotensin system inhibitors, 609–610, 610f
 renin inhibitors, 614–615
 Renal toxicity, of acetaminophen and phenacetin, 805–806, 806f
- Renin, 607
 Renin-angiotensin system, 607–609, 608f–609f
 Renin-angiotensin system inhibitors, 609–610, 610f
 Renin inhibitors, 614–615
 ReoPro. *See* Abciximab
 Repaglinide, 661, 672, 674, 674f–675f, 676t, 679, 679f, 681
 Replicons, 124
 Repolarization prolongators, 631, 631t, 636–637
 Repository corticotropin injection, 891, 892t
 Requip. *See* Ropinirole hydrochloride
 Receptor. *See* Delavirdine
 Rescula. *See* Unoprostone
 Reserpine, 530, 639–640, 639f
 Reserpid. *See* Reserpine
 Resorcinol, 185, 195, 533
 Restoril. *See* Temazepam
 Restriction endonucleases, 124, 124f, 124t, 909
 Retavase. *See* Reteplase
 Reteplase, 143, 143t
 Retin-A. *See* Tretinoin
 Retinoate analogs, 919, 923, 924f, 924t
 Retinoids. *See* Vitamin A

- Retinol
 chemistry of, 919–920, 919f
 sources of, 917, 919, 923
 visual cycle and, 921–922, 921f
- Retro-Michael decomposition, 360, 361f
- Retroviruses, 335
- Revatio. *See* Sildenafil citrate
- Reverse transcriptase inhibitors, 343–346
 nonnucleoside, 347–348
- Reverse transcription, 335
- Revex. *See* Nalmefene
- Rexinoids, 922
- Rexolate. *See* Sodium thiosalicylate
- Reye syndrome, 796
- RGD receptors, 628–629
- Rheumatoid arthritis, 806–807
- Rheumatrex. *See* Methotrexate
- Rhinocort. *See* Budesonide
- Rhodiol. *See* Ketoprofen
- Ribavirin, 335, 346
- Riboflavin, 938–939, 939f
- Rid-A Pain compound. *See* Salicylamide
- Ridaura. *See* Gold compounds
- Rifabutin, 219
- Rifadin. *See* Rifampin
- Rifampicin. *See* Rifampin
- Rifampin, 215, 218–219, 260t
- Rifamycins, 218–220, 335
- Rimactane. *See* Rifampin
- Rimantadine, 336
- Rimexolone, 860f, 862
- Ring equivalents, 39
- Ringworm, 192, 192t
 topical agents for, 194–196
- Riomet. *See* Metformin
- Risedronate sodium, 706, 707t, 708
- Risperdal. *See* Risperidone
- Risperidone, 466, 483t, 486, 486f
- Ritalin. *See* Methylphenidate hydrochloride
- Ritodrine, 543
- Ritonavir, 349
- Rituxan. *See* Rituximab
- Rituximab, 147–148
- Rivastigmine, 573, 576
- Rivoglitazone, 682, 682f
- Rizatriptan, 812–814, 812t, 813f
- RNA, protein production, 121–122, 122f
- RNA viruses, 331, 331t–332t, 335
- Robaxin. *See* Methocarbamol
- Robinul. *See* Glycopyrrolate
- Rocephin. *See* Ceftriaxone disodium
- Rochagan. *See* Benznidazole
- Roentgen, 416
- Rofecoxib, 798, 803
- Roferon. *See* Interferon alfa-2a, recombinant
- Rolidetracycline, 306
- Rondomycin. *See* Methacycline hydrochloride
- Ropinirole hydrochloride, 476–477
- Ropivacaine, 729
- ROS. *See* Reactive oxygen species
- Rosaniline, 189
- Rosiglitazone, 662, 681–682, 682f, 684, 684f, 684t
- Rosuvastatin, 654
- Rotatable bond count, 20
- Rotavirus vaccine, 171
- Rotigotine, 476–477
- Roundworm infections, 224–225
- Roxiam. *See* Remoxipride
- Rozerem. *See* Ramelteon
- Rubane, 248f
- Rubella vaccine, 169
- Rubidomycin. *See* Daunorubicin hydrochloride
- Rythmol. *See* Propafenone
- S
- Sabril. *See* Vigabatrin
- Safrole, metabolism of, 58
- SAHA. *See* Vorinostat
- Salbutamol, 533, 541–542
 conjugation of, 91–92
 metabolism of, 63–64, 66
- Saletto. *See* Salicylamide
- Salflex. *See* Salsalate
- Salicylamide, 45, 797f, 798
- Salicylates, 796–798, 797f
- Salicylic acid, 195
 conjugation of, 90–91, 94
- Salicylic acid derivatives, 796–798, 797f
- Salicylic acid, 797f
- Salmeterol, 541–542
- Salsalate, 797f, 798
- Salvarsan, 179
- Salvinorin A, 781, 782f
- Sanctura. *See* Trosipium chloride
- Sandostatin. *See* Somatostatin
- Sandril. *See* Reserpine
- SA node, 630
- Saquinavir, 349
- Saralasin, 612
- Sarcoptes scabiei*, 227
- Sargramostin, 138, 908t, 912
- Sarin, 572t, 577
- SARMs. *See* Selective androgen receptor modulators
- SASA. *See* Solvent-accessible surface areas
- Satraplatin, 363, 365f
- Satumomab pentetide, 149–150
- Saw palmetto, 852
- Saxagliptin, 692–693, 694f
- Scabene. *See* Lindane
- Scabicides, 227
- SCH 59884, 205
- Schizonts, 243, 243f
- Schizophrenia, 457–458, 478
- Schradan, 579–580
- Scintillation camera, 417–418, 417f
- Scopine, structure of, 582
- Scopolamine, 584–587
 structure of, 582
- Scopolamine hydrobromide, 587
- sCT. *See* Calcitonin, salmon
- Scurvy, 954–955
- Seasonale, 844
- Secobarbital, 454–455, 454t
 metabolism of, 54, 56, 59–60
- Second messengers, 562
- Secosteroids, 923
- Secretin, 903
- Sectral. *See* Acebutolol
- Sedatives. *See* Anxiolytics, sedatives and hypnotics
- Seizures
 classification of, 491–492
 description of, 491
- Selective α -adrenergic antagonists, 641
- Selective androgen receptor modulators (SARMs), 853, 853f
- Selective estrogen receptor modifiers (SERMs), 705, 832–835, 833f
- Selective estrogen receptor modulators (SERMs), 10, 10f
- Selective norepinephrine reuptake inhibitors (SNERIs), 514
- Selective progesterone receptor modulators (SPRMs), 841, 841f
- Selective serotonin reuptake inhibitors (SSRIs), 513–514
 bone formation and, 710
 5-HT_{2A} antagonists and, 514–515
- Selective toxicity, 179
- Selectivity filter, of ligand-gated sodium channels, 720
- Selegiline, 25, 475, 523
- Semilente insulin, 668, 901, 901t–902t
- Semprex. *See* Acrivastine
- Sensipar. *See* Cinacalcet
- Serax. *See* Oxazepam
- Serentil. *See* Mesoridazine besylate
- Serevent. *See* Salmeterol
- SERMIs. *See* Selective estrogen receptor modifiers; Selective estrogen receptor modulators
- Seromycin. *See* Cycloserine
- Seroquel. *See* Quetiapine
- Serotonin, 451–452
 bone formation regulation by, 710
 methylation, 102
- Serotonin 5-HT_{1B/1D} receptors, triptan binding to, 811–814
- Serotonin transport inhibitor (SERTI), 511
- Serpasil. *See* Reserpine
- Serpins, 655
- SERTI. *See* Serotonin transport inhibitor
- Sertraline, 513
- Serum, 906
- Serum-sickness syndromes, 253
- Serzone. *See* Nefazodone
- Sevoflurane, 712f, 712t, 715–716, 716f
- Sex hormones, 827–841, 828f–831f, 833f, 835f, 837f–839f, 838t, 841f
 estrogens, 827–837, 828f–831f, 833f, 835f
 progesterone receptor antagonists and SPRMs, 841, 841f
 progestins, 827, 837–841, 837f–839f, 838t
- Sibutramine, 508
- Sickling disease, malaria and, 244
- Sildenafil, 11, 11f
 as smooth muscle relaxant, 619
- Sildenafil citrate, 644
- Silvadene. *See* Silver sulfadiazine
- Silver sulfadiazine, 238
- Silymarin, 971, 971f
- Simon metabolites, 929
- Simple proteins, 881, 883t
- Simulect. *See* Basiliximab
- Simvastatin, 652–653
- Sinequan. *See* Doxepin hydrochloride
- Single photon emission computed tomography (SPECT), 418, 418f
- SIOM. *See* 7-Spiroindanyloxymorphone
- Sisomicin sulfate, 300–301
- Sitagliptin, 692, 693f–695f
- Sitagliptin phosphate, 693–694, 695f
- Sitaxsentan sodium, 638–639
- β -Sitosterol, 651–652
- Skelid. *See* Tiludronate disodium
- Skin infections, fungal, 192–193, 192t–193t
 topical agents for, 194–196
- Smallpox vaccine, 168
- Smoking, drug metabolism and, 107–108
- Smooth muscle relaxation, 618–619, 619f
- SNC-80, 780, 781f
- SNERIs. *See* Selective norepinephrine reuptake inhibitors
- Sodium 4-aminosalicylate, 217
- Sodium antimony gluconate, 224
- Sodium benzoate, 191
- Sodium caprylate, 194
- Sodium channel blockers, 627
- Sodium channels
 local anesthetic binding to, 720, 721f–722f, 722–723, 724f
 in nerve conduction, 720, 721f–722f
- Sodium iodide (¹²³I), 422
- Sodium iodide (¹³¹I), 422
- Sodium ion, in nerve conduction, 719–720
- Sodium nitrite, 620t
- Sodium nitroprusside, 643
- Sodium PAS, 217
- Sodium pertechnetate (^{99m}Tc), 423
- Sodium propionate, 191
- Sodium salicylate, 798
- Sodium stibogluconate, 224
- Sodium sulamyd. *See* Sulfacetamide sodium
- Sodium thiosalicylate, 798
- Solanaceous alkaloids and analogues, 584–588
- Solganal. *See* Gold compounds
- Solifenacin succinate, 591
- Soliris. *See* Eculizumab
- Solubility
 oral administration, 4–5
 parenteral administration, 5–6
 protein binding and, 6–7
- Solvent-accessible surface areas (SASA), 35
- Soma. *See* Carisoprodol
- Somatic nerves, 558
- Somatoliberin. *See* Growth-releasing factor
- Somatostatin, 890, 894–895
- Somatotropin. *See* Growth hormone
- Somatrem, 894
- Somatropin, rDNA origin, 894
- Somatuline Depot. *See* Lanreotide acetate
- Sombulex. *See* Hexobarbital
- Sonata. *See* Zaleplon
- Sontoquine, 248
- Sorafenib tosylate, 403, 404f, 405–406
- Sorbic acid, 191
- Sorbitrate. *See* Isosorbide dinitrate, diluted
- Sotalol, 551, 552f, 637
- South American sleeping sickness, 221
- Sparfloxacin, 208, 212–213
- Sparine. *See* Promazine

- Spasmophoric agents, 588
 SPD-421, 495, 495f
 Specificity, of enzymes, 885–886
 SPECT. *See* Single photon emission computed tomography
 Spectazole. *See* Econazole nitrate
 Spectinomycin hydrochloride, 295, 301
 Spectrobid. *See* Bacampicillin hydrochloride
 Spermatogenesis, steroid hormone regulation of, 826, 826f
 SPIO. *See* Superparamagnetic iron oxide colloids
 Spiradoline, 781, 782f
 Spirits, 182
 Spiriva. *See* Tiotropium bromide
 7-Spirodanyloxymorphone (SIOM), 780, 781f
 Spirinolactone, 615, 864, 864f
 Sporanox. *See* Itraconazole
 SPRMs. *See* Selective progesterone receptor modulators
 Sprycel. *See* Dasatinib
 Squalene epoxidase, 199–200, 200f
 SSRIs. *See* Selective serotonin reuptake inhibitors
 St. John's wort, 963, 965–967, 966f
 Stadol NS. *See* Butorphanol
 Stalevo. *See* Entacapone
 Stanozolol, 849f
 Starlix. *See* Nateglinide
 Stavudine, 345
 Stelazine. *See* Trifluoperazine hydrochloride
 STEPA. *See* Thiotepa
 Stereochemistry, of drug metabolism, 108–111
 Steric factors, 26–29, 27f–28f
 Sterilants
 classification of, 180, 181t
 evaluation of effectiveness of, 180–181
 improper use of, 181
 phenol coefficient of, 183
 Sterile capreomycin sulfate, 219–220
 Sterile corticotropin zinc hydroxide suspension, 891, 892t
 Sterilization, of recombinant protein, 131
 Steroidal estrogens, 828–829, 829f
 Steroid hormone(s), 819–865
 adrenal cortex hormones, 853–864, 854f–857f, 858t, 860f, 864f
 androgens, 847–853, 848f–849f, 848t, 851f–853f
 biosynthesis of, 819, 821f, 822
 chemical and physical properties of, 822, 822t
 chemical contraceptive agents, 841–847, 842t–844t, 846t
 gonadotropin-releasing hormone and gonadotropins, 695–701, 696f, 697t, 698f, 699t, 700f, 826–827, 826f, 890, 894
 modifications of pharmacokinetic properties of, 822–823, 823f
 neurosteroids, 864, 864f
 nomenclature, stereochemistry, and numbering of, 819, 820f–821f
 sex hormones, 827–841, 828f–831f, 833f, 835f, 837f–839f, 838t, 841f
 solubilities of, 822t
 Steroid hormone-receptor complexes, 824f, 825–826
 Steroid hormone receptors, 823–826, 824f
 Stevens-Johnson syndrome, 253
 STI-571. *See* Imatinib mesylate
 Stilbene, metabolism of, 54, 56
 Stimlate. *See* Desmopressin acetate
 Stoxil. *See* Idoxuridine
 Streptase. *See* Streptokinase
 Streptokinase, 889
 Streptomycin
 antitubercular activity of, 215
 discovery of, 294
 Streptomycin sulfate, 297
 Streptozocin, 365, 366f, 371
 Streptozotocin. *See* Streptozocin
 Styrene, metabolism of, 54
 STZ. *See* Streptozocin
 SU11248. *See* Sunitinib malate
 Subcutaneous mycoses, 193, 193t
 Suberoylanilide hydroxamic acid. *See* Vorinostat
 Sublimaze. *See* Fentanyl
 Suboxone. *See* Buprenorphine
 Substance P, 906, 967
 Subutex. *See* Buprenorphine
 Succinylcholine, 559
 Succinylcholine chloride, 605
 Sucostrin. *See* Succinylcholine chloride
 Sucralfate, 772
 Sudafed. *See* L-(+)-Pseudoephedrine
 Sufenta. *See* Sufentanil
 Sufentanil, 787f, 788
 Sular. *See* Nisoldipine
 Sulbactam, 275–276
 Sulbactam-ampicillin, 276
 Sulconazole nitrate, 202–203
 Sulfacetamide, 236–237
 Sulfacetamide sodium, 238
 Sulfachloropyridazine, 237
 Sulfadiazine, 220, 237
 Sulfadiazine sodium, 237
 Sulfadoxine, 246–247t, 253–254, 253f
 pyrimethamine and, 238
 Sulfamethazine, 236
 acetylation of, 97, 100
 Sulfamethizole, 236
 Sulfamethoxazole, 220, 235, 237, 239
 acetylation of, 97, 100
 Sulfamidochrysoidine, 228–229
 metabolism of, 84–85
 Sulfanilamide, 672f
 acetylation of, 97, 100
 antitubercular activity of, 215
 pK_a values of, 234, 235t
 Sulfapyridine, 237, 807f
 acetylation of, 97, 100
 Sulfasalazine, 239, 807f, 808
 metabolism of, 84–85
 Sulfate conjugation, 91–93, 92f
 Sulfazecin, 293–294
 Sulfimpyrazone, 810f, 811
 conjugation of, 90–91
 Sulfisoxazole, 236
 acetylation of, 97, 100
 conjugation of, 90–91
 Sulfisoxazole acetyl, 236
 Sulfisoxazole diolamine, 236, 238
 Sulfolane, 362, 364f
 Sulfonamides, 228–239
 aniline-substituted, 230
 classification of, 229
 crystalluria and pK_a, 234, 235t
 discovery and development of, 228–229
 distribution of, 234–235
 folate reductase inhibitors and, 235
 for intestinal disorders, 238–239
 ionization of, 232
 mechanism of action of, 230–232, 231f–233f
 metabolism of, 234–235
 microbial resistance to, 235
 mixed, 237–238
 nomenclature of, 230, 231f
 nonabsorbable, 238
 nonaniline, 230
 pK_a values for, 230, 232
 prodrg forms of, 230
 protein binding of, 234–235
 side effects of, 235
 spectrum of action of, 232
 structure-activity relationships, 235–236, 236t
 therapy with, 229, 229t
 topical, 238
 toxicity of, 234–235
 Sulfonates, 362
 Sulfones, 239–240
 Sulfonylurea receptor (SUR), 668–669, 670f
 Sulfonylureas, 659–661, 668–681, 670f–672f, 673t, 674f–680f, 676t
 acid-base and lipid partitioning character of, 672, 673t
 biotransformation of, 673t, 676–677, 677f–678f
 first-generation, 670, 671f
 second-generation, 670, 671f
 structure-activity relationships of, 670, 672, 673t, 674, 674f
 Sulindac, 794t, 799, 799f
 metabolism of, 7–8, 85–86
 Sulpride, 468
 Sumatriptan, 812–814, 812t, 813f
 Sunitinib malate, 404f, 406
 Superparamagnetic iron oxide colloids (SPIO), for MRI, 437
 Supprelin LA. *See* Histrelin acetate
 Suprax. *See* Cefixime
 Suprofen, 801, 801f
 SUR. *See* Sulfonylurea receptor
 Suramin sodium, 221, 224
 Surgifoam. *See* Gelatin sponge, absorbable
 Surmontil. *See* Trimipramine maleate
 Susceptibility, of contrast agent, 436–437
 Sustiva. *See* Efavirenz
 Sutent. *See* Sunitinib malate
 Sutilains, 888t, 889
 Symlin. *See* Pramlintide
 Symmetrel. *See* Amantadine
 Sympathetic ganglia, 596–597, 597f
 Sympathetic nervous system, 558
 Sympatholytics, 519, 558
 Sympathomimetic agents, 506–509, 506t, 519, 531–545
 direct-acting, 531–543
 α-adrenergic receptor agonists, 534–540
 β-adrenergic receptor agonists, 540–543
 dual α- and β-agonists/antagonists, 540
 endogenous catecholamines, 534–535
 structure-activity relationships of, 531–534, 532f, 534f
 indirect-acting, 543–544
 medical indications for, 506–507
 with mixed mechanisms of action, 544–545
 structures of, 506, 506t
 Sympathomimetics, 558
 Syn2869, 205–206
 Synarel. *See* Nafarelin acetate
 Syncria. *See* Albiglutide
 Synercid. *See* Quinupristin/dalfopristin
 Synterin. *See* Rolitetracycline
 Synthalin, 658–659
 Synthetic antibiotics, 206–220
 Synthetic conjugated estrogens, 832
 Synthetic penicillin, synthesis of, 263, 264f, 267
 Synthroid. *See* Levothyroxine sodium
 Syntocinon. *See* Oxytocin injection; Oxytocin Nasal Solution
 T
 Tabloid. *See* Thioguanine
 Tacaryl. *See* Methdilazine
 Tacaryl Hydrochloride. *See* Methdilazine hydrochloride
 Tachyphylaxis, 600
 Tacrine, 573
 Tacrine hydrochloride, 576
 Tadalafil, 11, 11f, 644
 Taft's steric parameter, 20
 Tagamet. *See* Cimetidine
 TAK-779, 351
 Taka-Diastase. *See* Diastase
 Talwin NX. *See* Pentazocine
 Tambacor. *See* Flecainide acetate
 Tamoxifen, 10, 10f, 832–833, 833f
 metabolism of, 63–64
 Tamoxifen citrate, 834
 Tamsulosin, 548
 TAN-67, 781, 781f
 Tanapraget, 838–839, 839f
 TAO. *See* Triacetyloleandomycin
 Tapazole. *See* Methimazole
 Tapeworm infections, 224–225
 Tarabine. *See* Cytarabine
 Tarceva. *See* Erlotinib hydrochloride
 Targocid. *See* Teicoplanin
 Targretin. *See* Bexarotene
 Tartrazine, metabolism of, 84–85
 Tasmar. *See* Tolcapone
 Tasopglutide, 690f, 691–692
 Tavist. *See* Clemastine fumarate
 TAX. *See* Paclitaxel
 Taxanes, 398–400, 398f–399f, 400t
 Taxol. *See* Paclitaxel
 Taxotere. *See* Docetaxel
 Tazidime. *See* Cefotaxime sodium
 Tazobactam, 276
 Tazobactam-piperacillin, 276
 TCAs. *See* Tricyclic antidepressants
 T cells, 157f, 159
 TechneScan MAG3. *See* Technetium (^{99m}Tc) mertiatide
 Technetium (^{99m}Tc) bicisate, 423
 Technetium (^{99m}Tc) disofenin, 423–424
 Technetium (^{99m}Tc) exametazime, 424–425
 Technetium (^{99m}Tc) macroaggregated albumin, 425

- Technetium (^{99m}Tc) mebrofenin, 425
 Technetium (^{99m}Tc) medronate, 425–426
 Technetium (^{99m}Tc) mertiatide, 426
 Technetium (^{99m}Tc) oxidronate injection, 426
 Technetium (^{99m}Tc) pentetate, 426–427
 Technetium (^{99m}Tc) pyrophosphate, 427
 Technetium radiopharmaceuticals, 415–416, 416f, 422–429
 Technetium (^{99m}Tc) red blood cells, 427
 Technetium (^{99m}Tc) sestamibi, 427–428
 Technetium (^{99m}Tc) succimer injection, 428
 Technetium (^{99m}Tc) sulfur colloid, 428–429
 Technetium (^{99m}Tc) tetrofosmin, 429
 Tegafur, 375, 375f
 Tegopen. *See* Cloxacillin sodium
 Tegretol. *See* Carbamazepine
 Teichomycin A₂. *See* Teicoplanin
 Teicoplanin, 316–317
 Tektuma. *See* Alikiren
 Telithromycin, 325–326
 Telmisartan, 613
 Temaril. *See* Trimeprazine tartrate
 Temazepam, 449–450
 Temovate. *See* Clobetasol propionate
 Temozolomide, 366–367, 367f–368f
 Tempra. *See* Acetaminophen
 Temsirolimus, 406–407, 407f
 Tenecteplase, 143
 Tenex. *See* Guanfacine; Guanfacine hydrochloride
 Teniposide, 390f, 391
 Tenofovir disoproxil, 345
 Tenormin. *See* Atenolol
 Tensilon. *See* Edrophonium chloride
 Tenuate. *See* Diethylpropion hydrochloride
 Tepanil. *See* Diethylpropion hydrochloride
 TEPP. *See* Tetraethylpyrophosphate
 Terazol. *See* Terconazole
 Terazosin, 547–548
 Terazosin hydrochloride, 641
 Terbinafine hydrochloride, 200
 Terbutaline, 541
 conjugation of, 91–92
 metabolism of, 63–64, 66
 methylation, 102–103
 Terconazole, 204
 Terfenadine, 753–754, 754f
 Teriflunomide, 807f
 Teriparatide injection (hPTH), 709, 904
 Terramycin. *See* Oxytetracycline hydrochloride
 Teslac. *See* Testolactone
 Teslascan. *See* Mangafodipir trisodium
 TESP. *See* Thiotepa
 Testolactone, 835f, 836–837, 848f
 Testosterone, 820f–821f, 822t, 823f, 847–848, 849f, 850
 Testosterone cyclopentylpropionate, 823f
 Testosterone cypionate, 849f, 850
 Testosterone enanthate, 849f, 850
 Testosterone propionate, 822t, 850
 Testosterone undecanoate, 850
 Testred. *See* 17 α -Methyltestosterone
 Tetracaine, 726
 2,3,7,8-Tetrachlorodibenzo-*p*-dioxin, metabolism of, 49
 Tetracyclines, 260r, 301–308, 302t, 305r
 chelates of, 303
 chemical classification of, 260
 chemistry of, 301
 mechanism of action of, 303
 microbial resistance to, 303, 308
 pharmacokinetic properties of, 304, 305r
 spectrum of activity of, 259, 303
 structure–activity relationships of, 304–305
 structures of, 301–303, 302r
 types of, 305–308
 Tetraethylammonium salts, 598
 Tetraethylpyrophosphate (TEPP), 572t, 578
 Δ^1 -Tetrahydrocannabinol, 517
 functionalization of, 44
 metabolism of, 55, 55f, 57, 78–79
 Δ^9 -Tetrahydrocannabinol. *See* Δ^1 -Tetrahydrocannabinol
 Tetrahydrofolate (THF), 374f
 Tetrahydrogestrinone (THG), 849f, 850
 Tetrahydrothiophene, 364f
 Tetrahydrozoline, 537
 Tetramethylammonium, 559–560
 Tetrazole, 352
 Tetrex. *See* Tetracyclines
 6-TG. *See* Thioguanine
 THA. *See* Tacrine hydrochloride
 Thalassemia, malaria and, 244
 Thallium radiopharmaceuticals, 429–430
 Thallous (²⁰¹Tl) chloride, 429–430
 Δ^1 -THC. *See* Δ^1 -Tetrahydrocannabinol
 Δ^9 -THC. *See* Δ^1 -Tetrahydrocannabinol
 Thelin. *See* Sitaxsentan sodium
 Theobromine, 505–506, 505t
 Theophylline, 505–506, 505t
 as smooth muscle relaxant, 619
 THF. *See* Tetrahydrofolate
 THG. *See* Tetrahydrogestrinone
 Thiabendazole, 225
 Thiamine, 935–938, 936f–937f
 Thiamine diphosphate, 935–938, 936f, 937t
 Thiamine hydrochloride, 935–938, 936f–937f
 Thiamine-responsive megaloblastic anemia (TRMA), 938
 Thiamylal, metabolism of, 59–60
 Thiazole, 683f
 Thiazolidine, 683f
 Thiazolidinedione, 662, 681–685, 682f–685f, 684t
 2,4-Thiazolidinedione, 683f
 Thienamycin, 276
 Thimerosal, 190
 Thioguanine, 378, 378f, 382
 6-Thioguanine. *See* Thioguanine
 Thionitrates, 620r
 Thiopental, metabolism of, 75, 77
 Thioperamide, 773, 774f
 Thiophos. *See* Parathion
 Thioplex. *See* Thiotepa
 Thioridazine hydrochloride, 461t, 462–463, 468, 480t, 481
 metabolism of, 75–77
 metabolites of, 111
 Thiotepa, 361–362, 364f, 369
 Thiothixene, 463, 480t, 481, 481f
 2-Thiouracil, 663–664
 Thiourea, 663–664
 Thioxanthenes, 479–481
 pharmacokinetic properties of, 479, 480f
 structure–activity relationships of, 479, 480f
 Thonzylamine hydrochloride, 746
 Thorazine. *See* Chlorpromazine hydrochloride
 Three-dimensional quantitative structure–activity relationships, 36–37, 36f
 Threohydrobupropion, 515
 Thrombin, 654–655, 655f, 906
 Thromboplastin, 654t, 655, 655f
 Thromboxane A₂, 657
 Thymidine, 376f
 Thymidylate synthase (TS), 372–373, 376f–377f
 Thymol, 184
 Thyrocalcitonin. *See* Calcitonin
 Thyrogen. *See* Thyrotropin alpha, recombinant
 Thyroglobulin, 906
 Thyroid hormones, 663
 Thyroid-stimulating hormone (TSH), 894
 Thyroliberin. *See* Thyrotropin-releasing hormone
 Thyropar. *See* Thyroid-stimulating hormone
 Thyrotropin, 894
 Thyrotropin alpha, recombinant, 136
 Thyrotropin-releasing hormone (TRH), 890
 Thyroxine, 663
 for hyperlipidemia, 650
 Tiagabine, 493, 500, 501f
 Ticar. *See* Ticarcillin disodium
 Ticarcillin-clavulanate, 275
 Ticarcillin disodium, 268, 269t, 273
 Ticlid. *See* Ticlopidine
 Ticlopidine, 628
 Tifosyl. *See* Thiotepa
 Tigecycline, 308, 324
 Tigemonam, 294
 Tikosyn. *See* Dofetilide
 Tilade. *See* Nedocromil sodium
 Tiludronate disodium, 707t, 708
 Timolol, 551, 552f
 Timoptic. *See* Timolol
 Tinactin. *See* Tolnaftate
 Tinctures, 182
 Tioconazole, 203
 Tiotropium bromide, 588
 Tipranavir, 350–351
 Tirofiban, 629
 Tissue depots, drug distribution and, 4f, 7
 Tissue plasminogen activator, recombinant, 143
 Tissue thromboplastin, 654t, 655, 655f
 Tissue tropism, 334
 Tizanidine, 538
 TMTX. *See* Trimetrexate
 TNM system, 355
 Tobramycin sulfate, 300
 TOC-039, 293
 Tocainide, metabolism of, 7
 Tocainide hydrochloride, 635
 α -Tocopherol, 927–929, 929f
 antioxidant activity of, 929–930, 930f
 β -Tocopherol, 927–929, 929f
 δ -Tocopherol, 927–929, 929f
 γ -Tocopherol, 927–929, 929f
 antioxidant activity of, 929–930, 930f
 Tocotrienols, 927–929, 929f
 Tofranil. *See* Imipramine hydrochloride
 Tolazamide, 660, 671f, 673t, 677f, 680
 Tolazoline, 546
 Tolbutamide, 659, 671f–672f, 673t, 674f, 677f, 680
 metabolism of, 55–56
 Tolbutamide sodium, 659
 Tolcapone, 477–478, 524
 Tolectin. *See* Tolmetin
 Tolinase. *See* Tolazamide
 Tolmetin, 799–800, 799f
 metabolism of, 55, 57
 Tolnaftate, 200
 Tolterodine, 594
 Tonocard. *See* Tocainide hydrochloride
 Topamax. *See* Topiramate
 Topiramate, 492, 499f, 500
 Topo. *See* Topotecan hydrochloride
 Toposar. *See* Etoposide
 Topotecan hydrochloride, 392f, 393–394
 TOPV. *See* Trivalent oral polio vaccine
 Toradol. *See* Ketorolac
 Toremifene, 832, 833f
 Toremifene citrate, 834
 Torisel. *See* Temsirolimus
 Tormalate. *See* Bitolterol
 Torsion angle, of acetylcholine, 564–565, 565f
 Toserelin acetate, 697t
 Toxic epidermal necrolysis, 253
 Toxoids, 165, 166–168, 173–174
Toxoplasma gondii, 220
 Toxoplasmosis, 220
 Tracleer. *See* Bosentan
 Tracrium. *See* Atracurium besylate
 Training set, 23
 Tramadol, 789–790
 Trandate. *See* Labetalol
 Trandolapril, 612
 Tranquilizers. *See* Antipsychotics
 Transcription, of virus, 333, 335
 Transdermal contraceptives, 843t, 845
 Transgenics, 153
 Translation, of virus, 333, 335
 Tranxene. *See* Clorazepate dipotassium
 Tranylcypromine sulfate, 510, 510t, 523
 Trastuzumab, 149
 Travase. *See* Sutilains
 Travatan. *See* Travoprost
 Travoprost, 878
 Trazodone, 514–515
 Treator SC. *See* Ethionamide
 Trelstar Depot. *See* Triptorelin pamoate
 Trelstar LA. *See* Triptorelin pamoate
 Trematode infections, 224–225
 Tremin. *See* Trihexyphenidyl hydrochloride
 Tretinoin, 407f, 409
 TRH. *See* Thyrotropin-releasing hormone
 Triacetin, 195
 Triacetyloleandomycin (TAO), 313
 Triamcinolone, 823f, 858t, 862–863
 Triamcinolone acetate, 823f, 858t, 860f, 863
 Triazolam, 449–450
 Triazolobenzodiazepines, 449–451
 Trichloroethanol, conjugation of, 89–91
 1,1,1-Trichloropropene, metabolism of, 51
 Trichomoniasis, 220
 Tricor. *See* Fenofibrate

- Tricosal. *See* Choline salicylate
 Tricyclic antidepressants (TCAs), 510–513
 Tridesiol. *See* Desonide
 Tridihexethyl chloride, 592–593
 Tri-Est. *See* Estriol
 Triethylenethiophosphoramidate. *See* Thiotepa
 Trifluoperazine hydrochloride, 480*r*, 481, 483*r*
 Triflupromazine hydrochloride, 461*r*, 462
 Trifluridine, 340
 Triglycerides, 647–648
 Trihexyphenidyl, 478
 Trihexyphenidyl hydrochloride, 592–594
 Triiodinated contrast agents, 432
 Trilafon. *See* Perphenazine
 Trileptal. *See* Oxcarbamazepine
 Trilisate. *See* Choline salicylate
 Trimegestone, 839*f*, 841
 Trimeprazine, 740*r*
 Trimeprazine tartrate, 752
 Trimethaphan, 559, 598
 Trimethaphan camphorsulfonate, 598
 Trimethaphan camsylate, 595, 599
 Trimethoprim, 110–111, 220, 235, 239
 metabolism of, 70, 72
 Trimeton. *See* Pheniramine maleate
 Trimetrexate, 380*f*, 383
 Trimipramine maleate, 512
 Trimpex. *See* Trimethoprim
 Tripelennamine, 740*r*
 conjugation of, 90–91
 Tripelennamine citrate, 745
 Tripelennamine hydrochloride, 745
 Triphasic combination contraceptive tablets,
 842*r*–843*r*, 844
 Triple sulfa, 234, 238
 Triprolidine, 740*r*
 Triprolidine hydrochloride, 750
 Triptans, 811–814, 812*r*, 813*f*
 Triptorelin pamoate, 697*r*, 698–699, 698*f*
 Trisalcid. *See* Choline salicylate
 Trisenox. *See* Arsenic trioxide
 Trisulfapyrimidines, 237. *See also* Sulfonamides
 Trivalent oral polio vaccine (TOPV), 169
 TRK-820, 781, 782*f*
 TRMA. *See* Thiamine-responsive megaloblastic anemia
 Trobicin. *See* Spectinomycin hydrochloride
 Troglitazone, 681, 682*f*
 Troleandomycin, 313
 Tropic acid, 585, 587
 Tropicamide, 16, 568, 593–594
 Tropine, structure of, 582, 584–585, 587
 Trospium chloride, 591
 Trypanosomiasis, 221, 224
 Trypsin crystallized, 888–889, 888*r*
 TS. *See* Thymidylate synthase
 TSH. *See* Thyroid-stimulating hormone
 Tuberculosis, drug therapy for, 214–220
 Tuberculosis vaccine, 172–173
 Tuberohypophyseal pathway, 472, 473*f*
d-Tubocurarine, 559, 581, 600–601
 Tubocurarine chloride, 600–601
 Tumor, 355
 Tumor necrosis factor, recombinant, 142
 Tussionex. *See* Hydrocodone
 Twilight sleep, 587
 TXT. *See* Docetaxel
 Tygacil. *See* Tigecycline
 Tykerb. *See* Lapatinib ditosylate
 Tylenol. *See* Acetaminophen
 Tylenol 3. *See* Acetaminophen
 Type 1 diabetes, 667, 900
 Type 2 diabetes, 667, 900
 Tyrocidin, 258
L-Tyrosine, 471, 472*f*
 Tyrothricin, 319–320
 Tyzine. *See* Tetrahydrozoline
- U**
 Ubiquinone, 222
 Ulcerative colitis, sulfonamides for, 238–239
 Ultiva. *See* Remifentanyl
 Ultradol. *See* Etodolac
 Ultralente insulin, 668, 901, 901*r*–902*r*
 Ultram. *See* Tramadol
 Ultrasound
 contrast agents for, 413, 440
 description of, 440, 440*f*
- UltraTag RBC Kit. *See* Technetium (^{99m}Tc) red blood cells
 Ultravist. *See* Iopromide
 Unasyn. *See* Sulbactam-ampicillin
 Uncoating, of virus, 333–335
 Uncoating acid, 194–195
 Unipen. *See* Nafcillin sodium
 Unoprostone, 878
 Uracil, 40, 40*f*
 Urecholine. *See* Bethanechol chloride
 Uric acid, 809–811, 809*f*–810*f*
 Uricosuric agents, 811
 Uridine, 376*f*
 Urinary analgesics, 214
 Urine, sulfanilamides and, 234
 Uritone. *See* Methenamine
 Urokinase, 889
 Urotropin. *See* Methenamine
 Uroxatral. *See* Alfuzosin
 Uterine bleeding, progestins for, 839
- V**
 Vaccines, 165–168
 adjuvants and, 176–177
 dosing, 167
 for human immunodeficiency virus, 347
 for malaria, 245, 255
 new antigens for, 176–177
 new technologies
 adjuvant technology, 174–177
 nucleic acid, 177–178
 pharmaceutical principles of, 167
 production of, 166–167, 167*f*
 recombinant, 145–146, 146*r*
 storage and handling of, 167–168
 types of, 167
 use of, 167–168
 viral, 168–172, 330–331, 333
 VADD. *See* Vitamin A deficiency disorders
 Vaginitis, atrophic, HRT for, 846
 Vagistat. *See* Tioconazole
 Valacyclovir hydrochloride, 341
 Valepotriate, 972, 972*f*
 Valerianic acid, 972, 972*f*
 Valerian, 972, 972*f*
 Valium. *See* Diazepam
 Valproic acid, 491–495, 495*f*
 Valroceamide, 495, 495*f*
 Valrubicin, 385, 385*f*, 389
 Valsartan, 614
 Valstar. *See* Valrubicin
 Valtrex. *See* Valacyclovir hydrochloride
 Vancenase. *See* Beclomethasone dipropionate
 Vanceril. *See* Beclomethasone dipropionate
 Vancocin. *See* Vancomycin hydrochloride
 Vancoled. *See* Vancomycin hydrochloride
 Vancomycin hydrochloride, 260*r*, 315–316
 clindamycin and, 314–315
 van der Waals forces, 26
 alcohols and, 181
 dorzolamide, 34–35, 35*f*
 van der Waals surfaces, 35, 35*f*
 Vanillylmandelic acid (VMA), 523
 Vanoxide. *See* Hydrous benzoyl peroxide
 Vanquish. *See* Acetaminophen
 Vansil. *See* Oxamniquine
 Vantas. *See* Histrelin acetate
 Vantin. *See* Cefpodoxime proxetil
 Vardenafil, 11, 11*f*
 Vardenafil hydrochloride, 644
 Variable combination contraceptive tablets, 842*r*–843*r*,
 844
 Vascor. *see* Bepridil hydrochloride
 Vascular theory, of migraines, 812
 Vasoactive intestinal peptide (VIP), 904
 Vasoconstrictors, in local anesthetics, 724–725
 Vasodilators, 617–629, 618*f*–619*f*, 620*r*, 622*f*–625*f*, 623*r*
 antihypertensive, 642–643, 643*f*
 antithrombotic agents, 627–629
 calcium antagonists, 622–627, 622*f*–625*f*, 623*r*
 metabolism of, 619–620, 620*r*
 myocardial metabolism and, 618, 618*f*
 nitrovasodilators, 618–622, 619*f*, 620*r*
 sodium channel blockers, 627
 Vasopressin, 607, 895–896, 896*r*
 Vasopressin injection, 896, 896*r*
 Vasopressin tannate, 896, 896*r*
- Vasoprost. *See* Prostaglandin E₁ cyclodextrin
 Vasotec. *See* Enalapril maleate
 Vasoxyl. *See* Methoxamine
 V-Cillin. *See* Penicillin V
 VCR. *See* Vincristine sulfate
 VDREs. *See* Vitamin D response elements
 VDRs. *See* Vitamin D receptors
 Vectors, for recombinant DNA, 124–126, 125*f*
 Vectrin. *See* Minocycline hydrochloride
 Vecuronium bromide, 602, 604
 Velban. *See* Vinblastine sulfate
 Velcade. *See* Bortezomib
 Velosef. *See* Cephadrine
 Velsar. *See* Vinblastine sulfate
 Venlafaxine, 514
 Venoms, 884–885
 Ventavis. *See* Iloprost
 Ventolin. *See* Salbutamol
 Vepesid. *See* Etoposide
 Veracillin. *See* Dicloxacillin sodium
 Veramyst. *See* Fluticasone 17*α*-furoate
 Verapamil, 31*f*
 as antiarrhythmic, 637
 as vasodilator, 623–624, 623*r*
 Verloop's multidimensional steric parameters, 20
 Verluma Kit. *See* Nofetumomab merpentan
 Vermox. *See* Mebendazole
 Verongamine, 774*f*
 Verstran. *See* Prazepam
 Very-low-density lipoprotein, 647–649, 649*r*
 Vesanoide. *See* Tretinoin
 Vesicare. *See* Solifenacin succinate
 Vesprin. *See* Triflupromazine hydrochloride
 VGCCs. *See* Voltage-gated calcium channels
 VGPCs. *See* Voltage-gated potassium channels
 VGSCs. *See* Voltage-gated sodium channels
 vHTS. *See* Virtual high-throughput screening
 Viadur. *See* Leuprolide acetate
 Viagra. *See* Sildenafil citrate
 Vibramycin. *See* Doxycycline
 Vicodin. *See* Acetaminophen; Hydrocodone
 Victoza. *See* Liraglutide
 Vidarabine. *See* Adenine arabinoside
 Videx. *See* Didanosine
 Vigabatrin, 493, 501, 501*f*
 Vildagliptin, 692–693, 694*f*
 Vinblastine, 972, 973*f*
 Vinblastine sulfate, 396–397, 396*f*
 Vinca alkaloids, 396–398, 396*f*, 972
 Vincristine, 972, 973*f*
 Vincristine sulfate, 396–398, 396*f*
 Vinorelbine ditartrate, 396, 396*f*, 398
 Vinyl chloride, metabolism of, 54, 56
 Vioform. *See* Clioquinol
 Viomycin, 219
 Vioux. *See* Rofecoxib
 VIP. *See* Vasoactive intestinal peptide
 Vira-A. *See* Adenine arabinoside
 Viracept. *See* Nelfinavir
 Viral infection
 burst size in, 330
 chemoprophylaxis, 331, 333, 336
 coreceptors in, 334
 endocytosis in, 334
 immunization for, 331, 333
 interferons and, 337–338, 338*f*–339*f*
 nucleoside antimetabolites, 339–346
 productive, 330
 stages of, 333–336, 334*f*
 Viral vaccines, 168–172
 Viramune. *See* Nevirapine
 Virion, 336
 Viroptic. *See* Trifluridine
 Virtual high-throughput screening (vHTS), 25
 Virus. *See also* Viral infection
 biochemistry of, 330
 budding of, 336
 classification of, 330–331, 331*r*–332*r*
 DNA, 331, 331*r*–332*r*, 335
 oncogenic, 335
 RNA, 331, 331*r*–332*r*, 335
 transcription and translation of, 333, 335
 uncoating of, 333–335
 vaccinations for, 330–331, 333
 Visine. *See* Tetrahydrozoline
 Visipaque. *See* Iodixanol
 Visken. *See* Pindolol

- Vistide. *See* Cidofovir
 Vistrax. *See* Oxyphencyclimine hydrochloride
 Vitamin(s), 915–956
 daily intake guidelines for, 916–917, 917t–918t
 enrichment with, 917
 fat-soluble, 917–935
 history of, 915–916
 medicinal chemistry of, 915
 overview of, 915–917
 use of, 915
 water-soluble, 916, 916t, 935–956
 Vitamin A, 917–923
 biochemistry of, 921–922, 921f
 chemistry of, 919–920
 deficiencies of, 922
 dietary intake of, 917, 917t–918t
 discovery of, 917
 hypervitaminosis, 922–923
 kinetics of, 920–921
 products, 923
 provitamins, 917, 919
 relative weights of, 920, 920t
 sources of, 917, 919, 920t
 therapeutic uses of, 922
 Vitamin A₁, 919
 Vitamin A₂, 919
 Vitamin A deficiency disorders (VADD), 922
 Vitamin B₁, 935–938
 biochemistry of, 936, 937f, 937t, 938
 chemistry of, 935–936, 936f–937f
 dietary intake of, 917t–918t, 935
 discovery of, 935
 hypervitaminosis, 938
 kinetics of, 936
 products of, 938
 sources of, 935
 therapeutic uses of, 938
 Vitamin B₂, 938–942
 biochemistry of, 938–939, 939f
 chemistry of, 938, 939f
 dietary intake of, 917t–918t, 938
 discovery of, 938
 hypervitaminosis, 939
 kinetics of, 938
 products, 939
 sources of, 938
 therapeutic uses of, 939
 Vitamin B₃, 939–942
 biochemistry of, 940–942, 941f
 chemistry of, 940, 940f
 dietary intake of, 917t–918t, 940
 discovery of, 940
 hypervitaminosis, 942
 kinetics of, 940
 products of, 942
 sources of, 940
 therapeutic uses of, 942
 Vitamin B₅, 942–944
 biochemistry of, 943–944, 943f
 chemistry of, 942–943, 942f–943f
 dietary intake of, 917t–918t, 942
 discovery of, 942
 hypervitaminosis, 944
 kinetics of, 943
 products of, 944
 sources of, 942
 therapeutic uses of, 944
 Vitamin B₆, 944–947
 biochemistry of, 944–945, 945f–946f
 chemistry of, 944, 945f
 dietary intake of, 917t–918t, 944
 discovery of, 944
 hypervitaminosis, 947
 kinetics of, 944, 945f
 products of, 947
 sources of, 944
 therapeutic uses of, 946–947
 Vitamin B₇, 947–948, 947f–948f, 947t
 Vitamin B₉, 948–951
 biochemistry of, 949, 950f, 951t
 chemistry of, 948–949, 949f
 dietary intake of, 917t–918t, 948
 discovery of, 948
 hypervitaminosis, 951
 kinetics of, 949
 products of, 951
 sources of, 948
 therapeutic uses of, 949, 951
 Vitamin B₁₂, 951–954
 biochemistry of, 953, 953f
 chemistry of, 952, 952f
 deficiencies of, 953–954
 dietary intake of, 917t–918t, 951–952
 discovery of, 951
 hypervitaminosis, 954
 kinetics of, 952
 products of, 954
 sources of, 951–952
 therapeutic use of, 953–954
 Vitamin C, 954–956
 biochemistry of, 955, 955t, 956f
 chemistry of, 954, 954f
 dietary intake of, 917t–918t, 954
 discovery of, 954
 hypervitaminosis, 955
 kinetics of, 954–955, 955f
 products of, 955–956, 956f
 sources of, 954
 therapeutic uses of, 955
 Vitamin D, 917–923
 biochemistry of, 925–926
 in bone health, 915
 bone health and, 706
 chemistry of, 923
 deficiencies of, 926
 dietary intake of, 917t–918t, 923
 discovery of, 923
 hypervitaminosis, 927
 kinetics of, 923–925
 products, 927, 927t, 928f
 sources of, 923
 therapeutic uses of, 926–927
 Vitamin D receptors (VDRs), 925–926
 Vitamin D response elements (VDREs), 925
 Vitamin E, 927–931
 biochemistry of, 929–931, 930f
 chemistry of, 928–929, 929f
 deficiencies of, 931
 dietary intake of, 917t–918t, 927
 hypervitaminosis, 931
 kinetics of, 929, 929f
 products of, 931, 932t
 sources of, 927
 therapeutic uses of, 931, 931f
 Vitamin K, 932–935
 biochemistry of, 933–934, 933f–934f
 in blood coagulation, 655–657, 656f
 in bone health, 915
 chemistry of, 932, 932f
 deficiencies of, 934
 dietary intake of, 917t–918t, 932
 discovery of, 932
 hypervitaminosis, 935
 kinetics of, 932–933
 products, 935
 sources of, 932
 therapeutic uses of, 935
 Vitamin K deficiency bleeding (VKDB), 935
 Vitamin K inhibitors, 657
 Vivactil. *See* Protriptyline hydrochloride
 Viviant. *See* Bazedoxifene
 Vivitrol. *See* Naltrexone
 VKDB. *See* Vitamin K deficiency bleeding
 VLB. *See* Vinblastine sulfate
 VM-26. *See* Teniposide
 VMA. *See* Vanillylmandelic acid
 VNB. *See* Vinorelbine ditartrate
 Voglibose, 687–688, 687f–688f
 Voltage-gated calcium channels (VGCCs),
 anticonvulsants and, 492–493
 Voltage-gated ion channels, anticonvulsants and,
 492–493
 Voltage-gated potassium channels (VGPCs),
 anticonvulsants and, 493
 Voltage-gated sodium channels (VGSCs), 720,
 721f–722f
 anticonvulsants and, 492, 492f
 local anesthetic binding to, 720, 721f–722f,
 722–723, 724f
 Voltaren. *See* Diclofenac
 Vontrol. *See* Diphenidol
 Voriconazole, 205
 Vorinostat, 407f, 408–409, 409f
 VP-16. *See* Etoposide
 VRL. *See* Vinorelbine ditartrate
 Vumon. *See* Teniposide
 Vytorin. *See* Ezetimibe
W
 Warfarin, 656f
 enantiomers of, 109
 metabolism of, 48
 R(+)-Warfarin, metabolism of, 80, 82
 Warfarin potassium, 658
 Warfarin sodium, 658
 Water-soluble contrast agents, 432
 Water-soluble vitamins, 916, 916t, 935–956
 vitamin B₁, 935–938
 vitamin B₂, 938–942
 vitamin B₃, 939–942
 vitamin B₅, 942–944
 vitamin B₆, 944–947
 vitamin B₇, 947–948
 vitamin B₉, 948–951
 vitamin B₁₂, 951–954
 vitamin C, 954–956
 WelChol. *See* Colesevelam
 Wellbutrin. *See* Bupropion
 Wernicke-Korsakoff syndrome, 938
 West African sleeping sickness, 221, 223–224
 Whitfield's ointment, 195
 Wilpowr. *See* Phentermine hydrochloride
 World Health Organization analgesic ladder, 777, 777f
 Wound healing, antiseptics and, 180–181
 Wyamycin S. *See* Erythromycin stearate
 Wycillin. *See* Penicillin G procaine
 Wydase. *See* Hyaluronidase for injection
 Wytensin. *See* Guanabenz; Guanabenz acetate
X
 Xalatan. *See* Latanoprost
 Xanax. *See* Alprazolam
 Xanthine oxidase (XO), 78, 379
 Xanthine oxidase inhibitors, 811
 Xeloda. *See* Capecitabine
 Xenobiotics, 43
 Xenon, 712t, 716
 Xenon (¹³³Xe) gas, 430
 Xenon radiopharmaceuticals, 430
 Xignis. *See* Drotrecogin alfa
 XO. *See* Xanthine oxidase
 Xopenex. *See* Levobutanol
 X-rays, 413, 417
 production of, 430, 431f
 Xylocaine. *See* Lidocaine hydrochloride
 Xylometazoline, 537
 Xyzal. *See* Levocetirizine dihydrochloride
Y
 Yocon. *See* Yohimbine
 Yodoxin. *See* Iodoquinol
 Yohimbine, 548–549
 Yomesan. *See* Niclosamide
 Yutopar. *See* Ritodrine
Z
 Zador. *See* Ketotifen fumarate ophthalmic solution
 Zalcitabine, 344–345
 Zaleplon, 451–452
 Zanaflex. *See* Tizanidine
 Zanamivir, 336–337
 Zanosar. *See* Streptozocin
 Zantac. *See* Ranitidine
 Zaronin. *See* Ethosuximide
 ZD1839. *See* Gefitinib
 Zebeta. *See* Bisoprolol
 Zefazone. *See* Cefmetazole sodium
 Zenapax. *See* Daclizumab
 Zentel. *See* Albendazole
 Zephiran. *See* Alkylbenzyltrimethylammonium
 chloride
 Zerit. *See* Stavudine
 Zestril. *See* Lisinopril
 Zetia. *See* Ezetimibe
 Zevalin. *See* Ibritumomab tiuxetan
 Zidovudine, 344
 Zinacef. *See* Cefuroxime sodium
 Zinc caprylate, 194
 Zinc propionate, 194
 Ziprasidone, 466f, 467, 483t, 487, 487f

Zithromax. *See* Azithromycin
Zocor. *See* Simvastatin
Zoladex. *See* Toserelin acetate
Zoledronic acid, 707t, 708
Zolinza. *See* Vorinostat
Zolmitriptan, 812–814, 812r, 813f
Zolof. *See* Sertraline
Zolpidem, 451

Zomepirac, 799f
Zometa. *See* Zoledronic acid
Zomig. *See* Zolmitriptan
Zomig-ZMT. *See* Zolmitriptan
Zonegran. *See* Zonisamide
Zonisamide, 499f, 500
Zopiclone, 451
Zosyn. *See* Tazobactam-piperacillin

Zovirax. *See* Acyclovir
Zuclomiphene, 833f
Zyloprim. *See* Allopurinol
Zymogen granules, 887
Zymogens, 887
Zyprexa. *See* Olanzapine
Zyrtec. *See* Cetirizine
Zyvox. *See* Linezolid